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It was in the late 1950’s after the discovery of dopamine’s wide distribution in the brain1, that 
dopamine’s function as a neurotransmitter and not as previously believed a mere precursor 
in the biosynthesis of epinephrine and norepinephrine was first recognized. Interest in 
dopamine grew after subsequent findings of its role in the pathogenesis of Parkinson’s 
disease2 and schizophrenia3.  
Today, dopamine is known as a major neurotransmitter in the CNS, where it controls a 
myriad of physiological functions, including locomotion, behavior, emotion, cognition, learning 
and motivation in addition to endocrine secretion. Dysfunctions of the dopaminergic system 
have been linked with several neurological and psychiatric disorders in addition to 
Parkinson’s disease and schizophrenia. These include depression4, Tourette’s syndrome5, 
attention-deficit hyperactivity disorder (ADHD)6 as well as drug and alcohol dependence7. 
Modulation of the dopamine transmission by targeting either the dopamine receptors or its 
transporter is hence a main strategy or central focus of research in the treatment of these 
disorders. 
The search for new ligands acting at the different dopamine receptors is for several reasons 
still of major importance.  
The lack of subtype selective ligands, especially those which are able to differentiate 
between D1 and D5 receptors, has been a major impediment in the way of clarifying the 
physiological role of the individual receptors. Most of the studies concerning the functions of 
the dopamine receptors have been carried out using genetically modified mice. Although 
valuable information has been obtained, the inconsistency of the results and the limitations of 
this strategy have proven that subtype selective ligands are indispensible as pharmacological 
tools to study both the physiological role and the possible clinical implication of the different 
dopamine receptor subtypes.  
Subtype selective ligands would also be of major value in exploring the binding site of the 
dopamine receptors. They can help determine the structural, spatial and stereochemical 
features necessary for distinguishing between the different receptor subtypes. This will in 
turn help get further insights into the binding site of the receptor subtypes.  
Dopamine receptor ligands have long been used in the therapy of neurological diseases, in 
particular of Parkinson’s disease (agonists) and schizophrenia (antagonists). Despite the 
availability of numerous dopamine antagonists, used in the therapy of schizophrenia, limited 
therapeutic efficacy and/or undesired side-effects present major obstacles for a successful 
therapy. This has been partly resolved by the development of atypical antipsychotics. 
Several hypotheses have been developed in an attempt to explain the mechanism of action 
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behind the ‘atypicality’ of these compounds. To further clarify the possible mechanism, 
dopamine ligands with different receptor profiles (e.g. lower D2, higher D1 or additional 5HT2A 
affinity) may become handy. 
Dopamine receptors 
Dopamine receptors are mainly expressed in the brain in addition to some peripheral tissues.  
Eight different dopamine-mediated pathways have been identified in the brain, the following 
are of most physiological relevance8;9: (Figure 1.1) 
 
Figure 1.1: Dopamine pathways in the brain. Ac: nucleus accumbens; Am: amygdala; C: cerebellum; Hip: 
hippocampus; Hyp: hypothalamus; P: pituitary gland; Sep: Septum; SN: substantia nigra; Str: corpus striatum; Th, 
thalamus. Figure taken from Rang & Dale’s Pharmacology9. 
• The nigrostriatal pathway: Almost 70% of the brain dopamine is localized in this 
system, which projects from the substantia nigra to the dorsal striatum (caudate 
nucleus and putamen). It is mainly involved in the control of motor function, hence the 
direct association with Parkinson’s disease, which results from the degeneration of 
the dopaminergic neurons and the consequent depletion of dopamine in this region.  
• The mesolimbic/mesocortical pathway: projecting from the ventral tegmental area 
(VTA) to respectively the limbic areas of the brain (nucleus accumbens, amygdala 
and ventral striatum) and the cortex. It has been associated with cognition, 
emotionality and motivation. Abnormalities of the dopamine transmission in this area 
have been linked with positive and negative symptoms of schizophrenia10. Drugs of 
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abuse are also believed to act via elevating the dopaminergic transmission in the 
nucleus accumbens (mesolimbic system).  
• The tuberohypophyseal pathway: connecting the hypothalamus to the pituitary gland, 
and has an inhibitory control over prolactin secretion.  
Peripherally, dopamine receptors are found in the cardiovascular system and the kidney 
where they affect vascular tone and sodium transport, respectively11.  
Further variations in the dopaminergic functions result from the action at the different 
dopamine receptor subtypes. Dopamine receptors belong to the superfamily of G-protein 
coupled receptors (GPCRs). They have been subdivided into two families, as originally 
suggested by Kebabian and Calne in 197912, based on their interaction with adenylate 
cyclase (AC) and ligand binding. The D1-like family comprises D1 and D5 receptor subtypes, 
whereas the D2-like receptors encompass the D2, D3 and D4 receptor subtypes. The two 
receptor families differ essentially in their structure, signal transduction pathways, tissue 
distribution and pharmacology. 
1.1. Receptor structure 
As already mentioned, dopamine receptors are members of the GPCRs, also known as 
seven-transmembrane domain receptors (7TM); with their characteristic structural features 
comprising an extracellular N-terminal, seven transmembrane α-helices, connected by three 
extra- and three intracellular loops and finally an intracellular C-terminal.  
The sequence identity between D1-like and D2-like receptors is only 44%, D1-like receptors 
have a shorter intracellular third loop than D2-like receptors, while their C-terminal is about 
seven times longer13. 
Both receptors of the D1-family are 80% identical in their primary sequence, D1 containing 
446 and D5 477 amino acids. Differences in the primary structure of both receptor subtypes 
are mainly observed in the third intracellular loop as well as in the external loop between the 
transmembrane domain (TM)4 and TM58. 
Within the D2-family, D2 and D3 share 75% homology, while D2 and D4 only have 53% 
conformity. The D2 receptor subtype exists in two isoforms; D2S (D2short) and D2L (D2long), the 
latter containing 29 more amino acids in the third intracellular loop8. It has been postulated 
that D2S, which is mainly localized presynaptically, functions as an autoreceptor and 
regulates dopamine neurotransmission14.   
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1.2. Tissue distribution 
The different dopamine receptor subtypes show a more or less distinct anatomical 
localization in the brain tissues. Figure 1.2 serves an illustrative overview over the relative 
distribution in the various tissues. 
The D1 receptor has the highest expression among all dopamine receptors; it is present with 
relatively high levels in all dopamine projection areas of the brain and has been mainly 
located in the putamen (dorsal striatum), nucleus accumbens (limbic area), cerebral cortex, 
hypothalamus and thalamus8;13;15. Conversely, the D5 receptor is of low abundance and more 
localized in the hippocampus, prefrontal cortex, basal ganglia, thalamus and hypothalamus16. 











Figure 1.2: Tissue distribution of the mRNA of the different dopamine receptor subtypes. Graphs from PDSP17 
database. 
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The D2 receptor subtype shows the second highest abundance in brain tissues; having a 
similar distribution as the D1 receptor, except in the substantia nigra and VTA, where only D2 
has been localized. Both D3 and D4 receptors are less abundant; D4 is the least expressed 
receptor subtype among all dopamine receptors. The D3 receptor is largely localized in the 
limbic region and not expressed in the striatum. Similarly, the D4 receptor is more expressed 
in the limbic region than in  the striatum8;13;15.  
1.3. Signal transduction 
Stimulation of dopamine receptors, as all GPCRs, does not lead to a direct alteration of the 
membrane potential of neurons. Instead, a cascade of intracellular reactions and various 
second messengers are activated through specific G-proteins and possibly other proteins. 
Consequently, the final effect of dopamine receptor stimulation does not only depend on the 
receptor subtype, but also on the signal transduction components of the affected tissues.  
The D1-like receptors (D1 and D5) couple to the stimulatory G-proteins Gs and Golf, activating 
adenylate cyclase to increase cyclic adenosine monophosphate (cAMP) levels. The signaling 
pathway includes the consequent activation of protein kinase A (PKA) and hence stimulation 
of PKA-catalyzed phosphorylation of many substrates. These substrates include two 
subtypes of the glutamate receptors, namely AMPA and NMDA receptors, in addition to 
GABA receptors. Regulation of several ion channels, including Na+, K+ and Ca2+-ion 
channels, also occurs by modulating the phosphorylation state of these channels or that of 
associated proteins18;19. Another important substrate of PKA is DARPP-32 (dopamine- and 
cAMP-regulated phosphoprotein of 32 kDa), which upon phosphorylation inhibits protein 
phosphatase 1 and thus amplifies the response to PKA and to other protein kinases18. 
D2-like receptors couple to the inhibitory G-proteins Gi and Go. They modulate many 
signaling pathways in addition to adenylate cyclase, including phospholipases, Na+, K+, Ca2+- 
ion channels as well as NMDA, AMPA and GABA receptors19.  
The transduction mechanism of dopamine receptors is more complex in vivo; dopamine 
receptors (as many GPCRs) have the potential to form homo- and heterodimers as well as 
-oligomers. Homodimers and -oligomers of D1, D2 and D3 receptors besides heterodimers of 
several dopamine receptors with other receptors have been localized. Examples of the latter 
are: D1 and adenosine A1 receptors, D2 or D3 and adenosine A2 receptors, and D1 and NMDA 
receptors. Moreover, D1, D2 and D3 receptors build D1/D2, D1/D3 and D2/D3 heterodimers. 
These heterodimers show distinct functional properties and binding profiles from the 
respective monomers20;21.  
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1.4. Functions of the dopamine receptors and their therapeutic implications 
As already mentioned, dopamine receptors are involved in the control of many physiological 
functions in the CNS as well as in the periphery. The functions of the individual receptor 
subtypes are till the present not completely discerned. This is partly owing to the lack of 
selective ligands at some of the receptor subtypes, which can be utilized as pharmacological 
tools to clarify the specific roles of each subtype. Many studies have thus been based on 
knockout (KO) mice in an attempt to elucidate these distinct functions. 
Subsequently, a brief description of the more relevant roles of the dopamine receptors will be 
given, with a focus on D1-family receptors, as they constitute the main target in this work.   
1.4.1. Control of locomotion and application in movement disorders  
Dopamine receptors are key regulators of motor functions in the CNS and consequently play 
an elemental role in the pathogenesis of several movement disorders. Most importantly is 
their role in Parkinson’s disease, where motor impairment is a direct result of the 
degeneration of the dopaminergic neurons in the striatum. Alleviation of the motor symptoms 
in Parkinson’s disease is mainly achieved by the application of dopamine agonists. 
Dopamine agonists have found therapeutic use in other movement disorders, such as 
restless leg syndrome22. On the other hand, dopamine antagonists are applied to reduce tics 
in Tourette’s syndrome23 and chorea in Huntington’s disease24. 
The most therapeutically used dopamine agonists are more or less selective for the 
receptors of the D2-family. The role of the different receptor subtypes of the D2 family is 
however not completely cleared25. While the role of the D2 receptor subtype in the control of 
motor function has been well established; it has a stimulatory role on locomotion, while its 
blockade leads to the reduction of locomotor activity, the functions of both D3 and D4 in 
locomotion are not completely clear yet.  
Within the D1 family, D1 as well as D5 receptors have been both implicated in the control of 
motor behavior. There are some indications that D5 acts synergistically with D1 in the control 
of motor functions26. Although studies on the locomotor activity of D1 KO mice showed 
conflicting results with respect to its exact role26;27, findings that D1 agonists stimulate 
locomotor activity and possess antiparkinsonial potential28;29, while antagonists show an 
inhibitory effect on locomotion, are evidence of the involvement of the D1 receptors in the 
control of motor functions30. For instance, the D1 full agonist dinapsoline (figure 1.9) has 
been found to be promising as antiparkinsonial agent28;29, with comparable efficacy to D2 
agonists and lower potential to cause dyskinsea28.  
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1.4.2. Role in reward and reward-seeking behavior and clinical implication in 
drug abuse and addictive disorders  
Brain dopamine has been identified as the central neurotransmitter in the reward system and 
has been associated with the processing of rewarding stimuli as well as reward-seeking 
behavior. Rewarding stimuli are translated into pleasurable experiences, which are liked 
desired and pursued31. Natural rewarding stimuli such as food, drink and sex in addition to 
abnormal reward-seeking behavior including gambling, excessive eating and consumption of 
drugs of abuse and alcohol, all ultimately increase the dopamine levels in the nucleus 
accumbens, though by different mechanisms32. Although the connection of the dopaminergic 
neurotransmission with reward and accordingly addiction has long been established, the 
precise role of dopamine is still not completely understood. Dopamine receptors have been 
postulated to mediate the enjoyment of rewards (pleasurable effect, for example the euphoria 
associated with psychostimulants), the learned predictions of future reward (learning) as well 
as to motivate the active seeking of rewards (wanting)33.  
Many studies have thus been concerned with investigating the role of the individual 
dopamine receptor subtypes in addiction and addictive disorders with respect to both the 
mediation of the reward-stimulating and reward-seeking effects.  
Stimulation of the D1 receptor subtype has been linked with ethanol34, food35 and 
psychostimulant reward36;37. For instance, deletion of the D1 receptor subtype in mice models 
resulted in the attenuation of the hyperactivity, commonly induced by psychostimulants, and 
in reduced alcohol consumption26. The role of the D5 receptor is still ambiguous, it is believed 
that it participates in mediating at least the locomotor stimulant effect of cocaine38. These 
findings encouraged the investigation of the applicability of D1 agonists and antagonists in 
the treatment of addiction and addictive behaviors. 
Although the characteristic locomotor stimulant effect of psychostimulants such as 
amphetamine and cocaine was reduced in D1 KO mice37, conflicting results with respect to 
the effects of D1 agonists and antagonists on the behavioral effects of cocaine were 
obtained. Some studies show that cocaine-seeking and self administration can be diminished 
by D1 agonists39;40. In opposition, others argue that D1 antagonists can lessen the incidence 
of relapse to cocaine self-administration41 besides attenuating its euphoric effects42.  
On the other hand, the ability of D1 antagonists to attenuate alcohol reward and seeking 
behavior in mice is rather well established43;44, which is coherent with findings showing that 
alcohol-seeking was significantly reduced in D1 KO mice45.  
Some D1 antagonists were inferred to be potentially useful for the treatment of addiction. For 
instance, the tetrahydroisoquinoline D1 antagonist BTS73947 (see figure 1.6) was patented 
for the use in addictive disorders, as it was found to reduce the craving for addictive 
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substances as cocaine, amphetamine, nicotine, opiates, tobacco and alcohol as well as food 
cravings46. Other D1 antagonists were also patented for the treatment of obesity and eating 
disorders47;48. Ecopipam (SCH39166, see figure 1.5) is another D1 antagonist which has 
been proven effective in the treatment of obesity and has even reached phase III trials. 
Further studies were however discontinued, as administration of ecopipam was accompanied 
by unexpected psychiatric side effects including depression, anxiety, and suicidal thoughts49. 
Another D1 antagonist which has reached phase II trials is NNC687 (currently under the 
name ADX10061, figure 1.4). It has been tested for the treatment of alcohol and nicotine 
dependence50, but the clinical trials were also discontinued.  
D2 and D3 subtypes have been connected with reward and with the various responses to 
substance of abuse. The D3 receptor has gained special attention in this respect, due to its 
concentration in the limbic area. Selective D3 antagonists, including SB277,011-A and BP897 
(Figure 1.3) were found to inhibit cocaine, alcohol and nicotine seeking behavior51;52. This 












SB277,011-A BP897  
Figure 1.3: Selective D3 antagonists SB277,011-A and BP897.  
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1.4.3. Role in psychosis and schizophrenia 
Schizophrenia is a chronic mental disorder affecting mainly the cognitive, emotional and 
behavioral state. The clinical picture of schizophrenia is characterized by the presence of 
multiple symptoms. Psychotic symptoms, manifested in the form of hallucinations and 
delusions, have been termed positive symptoms. Negative symptoms, including social 
withdrawal, apathy and anhedonia, accompanied by cognitive deficits such as disorganized 
thoughts, difficulty concentrating, difficulty completing tasks and memory problems are also 
typical for that disorder.  
Early links of dopamine to schizophrenia originate from van Rossum’s postulation that a 
hyperactivity of the dopaminergic system in some brain regions may underlie the 
development of this disorder3. This hypothesis, later known as the dopamine hypothesis of 
schizophrenia, was first supported by observations that amphetamine, which acts mainly by 
increasing dopamine levels, induces similar psychosis to schizophrenia. Later verifications 
came from studies showing that antipsychotics act as antagonists at the dopamine receptors, 
in particular at the D2 receptors53;54. However, subsequent findings showed that 
schizophrenia is not just a result of dopaminergic hyperfunction. It has been proposed that 
positive symptoms are associated with hyperdopaminergia in the mesolimbic region, 
whereas negative and cognitive deficit symptoms are a result of hypodopaminergia in the 
mesocortical region, specifically in the prefrontal cortex (PFC)10.  
D2 receptors have for a long time been the main target of action of antipsychotics, 
compounds lacking D2 affinities have no antipsychotic activity55. However, typical (first 
generation) antipsychotics, which act mainly by blocking the D2 receptors, are usually only 
effective in alleviating the positive symptoms of schizophrenia, while negative symptoms and 
cognitive deficits respond poorly and may even worsen56. Moreover, hyperprolactinemia and 
Parkinsonian-like side effects, also known as extrapyramidal symptoms (EPS), resulting from 
dopamine receptor blockade in the striatum, are quite commonly encountered with the use of 
typical antipsychotics. Consequently, the sole role of D2 receptors as therapeutic targets 
together with the notion that D2 antagonism suffices for effective antipsychotic action has 
been reevaluated. This was encouraged by the fact that atypical (second generation) 
antipsychotics, which are characterized by their ability to improve both negative and cognitive 
symptoms with lower tendency to cause the common side effects, were found to possess 
different and varying receptor binding profiles. Hence, new potential target receptors and 
mechanisms of action have been studied. 
Within the D2-family, D3 receptors are also considered as attractive targets for antipsychotics. 
Antagonists at D3 receptors are postulated to be effective against both positive and negative 
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symptoms and to have low potential to cause EPS, the latter fact is attributed to D3-receptors’ 
limited distribution and their prevalence in the mesolimbic system51. In fact the atypical 
antipsychotic amisulpride has higher D3 than D2 affinity57 and there is strong belief that mixed 
dopamine D3/D2 receptor antagonists with preferential affinity to the D3 receptor could be 
more effective as antipsychotics58. D4 receptors were also considered as possible targets for 
antipsychotics. However, findings that D4 selective antagonists are devoid of antipsychotic 
potential59 indicate that D4 antagonism does not suffice for antipsychotic action. 
The potential antipsychotic effect of D1 antagonists was also tested in patients suffering from 
schizophrenia. The results obtained were inconsistent. The D1/D5 selective antagonist 
ecopipam (SCH39166; figure 1.5), displayed no antipsychotic effect60. However, another 
study showed that NNC687 (figure 1.4), also a D1/D5 selective antagonist, possessed 
considerable antipsychotic potency, improved the negative symptoms and lacked the 
common extrapyramidal side effects (EPS)61. Its efficacy with respect to the negative 
symptoms was however disputed in other studies62. Declarative evidence of the effectiveness 
of D1 antagonists in the treatment of schizophrenia is hitherto not available. 
An opposite approach has been adopted by other studies. This has been based on results 
showing that D1 receptors are involved in the control of cognition and working memory63. 
Dopamine neurotransmission in the PFC plays a major role in cognitive function64; in 
particular D1 receptors in this region are critical in mediating cognitive and working memory 
performance65;66. This is substantiated by several findings. The D1 receptors are highly 
abundant in the PFC67;68; the D1-family are an order of magnitude more abundant in the PFC 
than the D2-family receptors. Moreover D1 antagonists were found to have an impairing effect 
on working memory and cognition69 while D1 agonists showed an enhancing effect70. This 
effect is yet not so simple; the relationship between dopamine transmission and working 
memory has been described as an “inverted U-shaped” one. A normal range of D1 
stimulation is required to maintain the integrity of working memory; excessive blockade and 
elevation of dopamine in the PFC both result in the deterioration of working memory71. 
Consequently, several studies have been advocating the potential benefits of using D1 
agonists for relieving the deficit symptoms of schizophrenia72-74. This has been based on the 
aforementioned findings, that D1 stimulation in the PFC enhances cognitive performance and 
that intermittent doses of dopamine agonists show a long lasting cognitive enhancement70. In 
fact, l-stepholidine (figure 1.8), a naturally occurring alkaloid with a unique binding profile as 
a D1 agonist and D2 antagonist, showed promising results as potential antipsychotic74;75.  
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1.5. Dopamine receptor ligands 
Dopamine receptor ligands are structurally diverse, nevertheless the majority shares some 
common structural features, which are considered necessary for binding to the receptor. 
Studies on ligand binding at catecholamine receptors in general and at modeled dopamine 
receptors (specifically D2) revealed some main structural features, essential for binding to the 
dopamine receptors and predicted key interaction sites in the receptor binding pocket. The 
binding pocket of all catecholamine receptors comprises an Asp residue at position 3.32, 
which builds a salt bridge to the protonated basic N of the ligand and is surrounded on either 
sides by two hydrophobic cavities76;77. Dopamine agonists are believed to activate the 
receptors by further interaction of their two catecholic hydroxyl groups with two Ser residues 
in TM5 by H-bond formation. Antagonists, on the other hand, only form weak interactions 
with one of the Ser residues in TM577;78. This rule is however not unequivocal; some 
dopamine agonists, such as benzergolines, lack this catecholic function79. Other crucial 
interaction sites are the hydrophobic cavities on both sides of Asp3.32, which can 
accommodate the aromatic moieties of the ligands80. This model explains why the structure 
of many receptor ligands encompasses a central basic nitrogen surrounded by two aromatic 
moieties. To serve the goal of this work, this part will mainly focus on classes of dopamine 
receptor ligands which bear this structural characteristic. 
1.5.1. Phenylbenzazepines 
This class represents one of the most important classes of D1 selective agonists and 
antagonists, which have made a major breakthrough in the pharmacology of dopamine 
receptors. (Figure 1.4)  
The prototype SCH23390 is the first discovered D1 antagonist, showing high preference for 
D1- with respect to D2-like receptors81;82. All antagonists within this class bear a halogen 
substitution at position 7 (SCH series), whereas compounds having a catecholic function, i.e. 
7,8-dihydroxy substitution, are potent D1-agonists (SKF series)83. Several structural 
modifications have been introduced into the structure of 1-phenylbenzazepines. Neumeyer et 
al. introduced minor changes into the structure of the dopamine agonists of the SKF series 
by changing the substituent at the N and at C6 of the benzazepine moiety as well as at the 
phenyl ring84. Most of the obtained compounds showed more or less high affinities for the D1-
like family. The most active were MCL203, MCL206 and MCL204, showing subnanomolar to 
nanomolar affinities for D1-like receptors, and the latter showing 100 fold D1 over D5 
selectivity. The D1/D2 selectivity was retained for all compounds, nevertheless the degree of 
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selectivity varied greatly, since the affinities for D2 receptors were also divergent, ranging 




















































Figure 1.4: Structures of 1-phenylbenzazepines and their substituted derivatives. *Values cited from PDSP17 
database; **Values cited from reference84; ***Values cited from reference85. 
Several structural modifications have also been carried out on the prototype D1 selective 
antagonist SCH23390. The phenyl ring was substituted with a benzofuran and 
dihydrobenzofuran moiety, yielding highly selective D1-like antagonists, namely NNC112, 
NNC687 and NNC756. (Figure 1.4) These were found to be potent dopamine receptor, 
similarly showing a pronounced D1/D2 selectivity85.  
Further structural variations on SCH23390 included rigidifying the structure and reducing the 
flexibility of the phenyl ring86. SCH39166 (figure 1.5), also known as ecopipam, is the most 
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though weaker compared with SCH23390, and a high selectivity over D2 receptors. Several 
interesting results were obtained from this study. Out of the four possible isomers of 
SCH39166 the (-)trans isomer (6aS, 13bR) showed the highest affinities, which proves that 
the R orientation of 1-phenylbenzazepines in general is crucial for high affinities. A further 
interesting finding was that the replacement of the Cl at position 11 with hydrogen, hydroxyl 



























Figure 1.5: Conformationally restricted benzazepines. *Values cited from reference87; **Values cited from 
reference86. 
1.5.2. Tetrahydroisoquinoline derivatives 
Tetrahydroisoquinoline ring is one of the most frequently encountered component in the 
structure of dopaminergic agents. Numerous dopamine ligands contain a 
tetrahydroisoquinoline moiety, either substituted with a benzyl/phenyl group or incorporated 
in a tetracyclic scaffold, with divergent annulation patterns. 
1.5.2.1. 1-Benzyl/1-phenyl tetrahydroisoquinolines 
A large number of both naturally occurring and synthetic 1-benzyltetrahydroisoquinolines 
have been found to exert considerable affinities for dopamine receptors, though mostly only 
in the micromolar range. Here again, different substitution patterns were accompanied by 
different affinities and selectivity profiles. Kozlik et al. patented a series of 1-
benzyltetrahydroisoquinolines substituted at the methylene bridge between the phenyl and 
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cyclohexyl rings. These compounds showed high D1/D2 selectivity with nanomolar affinities 
for D1 receptors. The most interesting compound in that series is BTS73957, which proved to 
be a potent and selective D1 antagonist88. (Figure 1.6)  
On the other hand, several 1-phenyltetrahydroisoquinolines were synthesized in analogy to 
the D1 antagonist SCH23390. They all showed antagonistic activities at the dopamine 
receptors and a marked D1/D2 selectivity. Contrary to phenylbenzazepines, the S-
enantiomers were significantly more active than the R-enantiomers. The N-methyl 
substituted 1-phenylbenzazepine displayed the highest affinity at D1-like receptors (6.6 nM) 
as well as the highest selectivity for D1 over D2 receptors. Increasing the length of the N-alkyl 




















Figure 1.6: 1-Benzyl- and 1-phenyltetrahydroisoquinolines. 
1.5.2.2. Aporphines 
The well-known dopamine agonist R(-)-apomorphine (figure 1.7), which is used in the 
treatment of Parkinson’s disease and erectile dysfunction, is the most prominent member of 
this class of dopaminergic agents. It displays high affinities for all dopamine receptors, and 
has a rather interesting binding profile; displaying the highest affinity for D4 followed by D5 
receptor, with markedly lower affinities for the D1 receptor90. Numerous structural variations 
have been introduced into the structure of apomorphine. Derivatives bearing only one 
hydroxyl substituent at position 11 were found to possess antagonistic rather than agonistic 
properties91, which is in line with the aforementioned speculations that a catecholic function is 
favored for receptor activation. Interesting was also that the nature of the N-alkyl substituent 
had a major impact on both the affinity and the selectivity of the compounds92-94; an N-propyl 





















substituent was found to be preferred by D2 receptors, while N-methyl substitution was 
favored by D1 receptors92;94. Moreover, while the R-enantiomers generally showed greater 
affinities than the S-enantiomers, the latter have been suggested to exhibit antagonistic 
rather than agonistic effects in behavioral studies95;96. For instance, S(+)-apomorphine has 
been suggested to possess dopamine antagonistic properties97.  
Similarly, the naturally occurring alkaloid S(+)-boldine, bearing an S-configuration at C6a, 
displayed dopamine antagonistic properties at the dopamine receptors. Halogenation of this 
antagonist at position 3 increased the affinities as well as the D1/D2 selectivity. The 3-iodo 
derivative showed higher D1 affinity than the 3-chloro and 3-bromo counterparts (Ki = 2 nM, 






Figure 1.7: Aporphines. *Values cited from reference93; **Values cited from reference100. 
1.5.2.3. Tetrahydroprotoberberines (THPBs) 
Several members of this class of naturally occurring alkaloids were found to act as 
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Stepholidine (figure 1.8) is a unique member of this class. Not only does it show increased 
D1 affinities, but it also possesses a rare activity profile as a dual D1 agonist and D2 
antagonist, which renders it attractive as potential antipsychotic agent74;102.  
1.5.2.4. Dihydrexidine and dinapsoline derivatives 
Dihydrexidine (figure 1.9) is the first potent D1 full agonist, showing an intrinsic efficacy 
comparable to dopamine itself83. Similar to apomorphine, dihydrexidine has a 











Figure 1.9: Structures of dihydrexidine and dinapsoline. * Values taken from reference103; **Values taken from 
reference104. 
Comparable to previously mentioned dopamine ligands, N-methyl substitution of 
dihydrexidine resulted in the loss of D1 selectivity, while in the N-propyl derivative the affinity 
for D2 was higher than for D1. Dinapsoline (figure 1.9) is another conformationally rigid 
analog of 4-phenyltetrahydroisoquinoline, which similar to dihydrexidine showed potent D1 
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1.5.3. Indolobenzazecines and Dibenzazecines 
Indolo[3,2-f][3]benzazecines and dibenz[d,g]azecines, which have been developed in our 
research group, present a structurally novel class of dopamine receptor antagonists with 
interesting pharmacological profiles. The scaffold of the prototype LE300 has been designed 
to incorporate the structures of both dopamine and serotonin in a relatively flexible backbone. 
(Figure 1.10) The more rigid pentacyclic precursor of LE300 (figure 1.10) was found to be 
devoid of activity, which indicates that a moderate amount of flexibility is crucial for the 





















Figure 1.10: LE300 encompasses the structures of dopamine and serotonin in its scaffold. 
Various modifications have been introduced into the structure of LE300 (figure 1.11), with 
the goal of drawing the SAR for this class of dopamine antagonists. The results obtained 
could be summed up as follows: 
• Removal of the indole or the benzene ring as well as substitution of the annulated 
benzene ring with a phenyl group abolished the activities106. 
• Replacement of the indole with other aromatic moieties was well tolerated; some 
dibenzazecine analogs were as active as the lead LE300106. Dibenzazecines have 
since been considered as another class of potent dopamine antagonists. These will 
be discussed later. 
• Methyl substitution of the central alicyclic N was most favored; derivatives with longer 
alkyl or aralkyl chains as well as NH unsubstituted ones all possessed significantly 
lower affinities106. 
• Methoxylation and hydroxylation of the indole ring increased the affinities for the D1-
family107. 
• Ring expansion to an 11-ring had different effects. Derivatives, where the tryptamine 
structure is maintained and the ring is elongated from the benzene side (i.e. 
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phenylpropyl moiety), possessed similar or increased affinities at some dopamine 
receptors as the lead LE300. Conversely, expanding the central ring from the indole 
side significantly attenuated the activity108. 
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Figure 1.11: Structural modifications of LE300.  
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Numerous modifications have also been carried out on the structure of the dibenzazecine 











































R = H, CH3
LE410
 
Figure 1.12: Different substitution and other structural modifications of the dibenzazecine derivatives.  
These led to the following conclusions: 
• Hydroxylated dibenzazecines mostly showed higher affinities than their methoxylated 
counterparts. With respect to the position of the hydroxyl and methoxy groups, the 
3-hydroxy and 3-methoxy derivatives were the most active ones 109. Phenolic 
dibenzazecines were generally more active than the methoxylated counterparts. 
• 2,3-Dihydroxy- and dimethoxydibenzazecines showed much lower affinities than the 
monohydroxylated ones. This is quite surprising since the dihydroxylated derivative 
shares the same substitution pattern as dopamine. Moreover both compounds were 
found to display antagonistic properties at the dopamine receptors106.  
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• The most active compound within this series was the 4-chloro-3-
hydroxydibenzazecine, which exhibited very high affinities towards the D1-like 
receptors and picomolar ones for the D5 subtype; exhibiting a 10-15 fold selectivity for 
D5 over D1109.  
• Expansion of the central azecine ring to an 11-membered ring was more or less 
tolerated, again depending on the site of ring elongation. A hydroxyphenethyl moiety 
combined with a phenylpropyl one was more favored than the combination of 
hydroxyphenylpropyl and phenethyl moieties110. 
Table 1.1: Ki values of various dopamine receptor ligands for the D1-D5 receptors. 
  Ki (nM), (Radioligand binding experiments) 
Code Structure D1 D2 D3 D4 D5 
Clozapine* 
 
189 431 646 39 235 
SCH23390* 
 




1.2 980 n.d. 80 2 
NNC75685 
 
0.17 942 n.d. n.d. n.d. 
NNC11285 
 
0.18 898 n.d. n.d. n.d. 
NNC68785 
 
5.8 >10000 n.d. n.d. n.d. 
Stepholidine* 
 





















































1.9  44.5  40.3  109  7.5 
LE-CE550107 
 
0.82 11.9 475 266 3.6 
LE-CE551107 
 
0.56 38.4 944 398 0.39 
LE404106 
 
0.39 17.5 47.5 11.3 1.5 
LE425106 
 
28.5 13 75.7 43.3 54 
LE-PM436109 
 
0.83 4.0 24.6 4.7 0.06 



































2. Aim of this work  
Partially hydrogenated indolo[3,2-f][3]benzazecines and dibenz[d,g]azecines are a novel 
class of dopamine receptor antagonists, distinguished by their nanomolar affinities as well as 
their preference for the receptors of the D1-family. The objective of the current work was to 
introduce further modifications on the structures of the lead compounds LE300 (an 
indolo[3,2-f][3]benzazecine) and LE404 (a dibenz[d,g]azecine) in order to assess the impact 
of these structural modifications on the affinities for the different dopamine receptor 
subtypes. This will help further analyze the SAR of this distinctive class of dopaminergic 
ligands. A detailed description of the work project will be discussed subsequently.  
2.1. Alteration of the annulation pattern of LE300 
Goal of this part was to prepare LE300 analogues with a modified structural skeleton in order 
to examine the effect of the scaffold structure on the affinities and the selectivities for the 
dopamine receptors. The main structural features of the lead LE300 were to be maintained, 
namely a central aza-alicycle with a benzene and an indole ring on both sides, while the 
fusion of the central aza-alicycle with respect to the indole moiety was to be varied. The first 
target compounds were LE300 analogues with the central ring fused not to the 3,2- but to the 
















Analogues fused at the 
3,3a,4-positions of the indole ring
Analogue fused at the 2,3 
positions of the indole ring
LE300
 
Figure 2.1: LE300 analogues with modified annulation patterns. 
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Here two different compounds came into question: First, the more rigid analogue, which 
encompasses a central 10-membered ring like LE300, but where the alicyclic nitrogen is 
connected to the indole ring by a methylene rather than an ethylene group. Second, the more 
flexible analogue, comprising an expanded central ring (aza-cycloundecan ring), but where 
an ethylene chain connects the alicyclic nitrogen to the indole ring, like in LE300. 
(Figure 2.1)  
A further target compound was an indolobenzazecine derivative, where the central azecine 
ring is fused at the 2,3- position of the indole ring, as opposed to the 3,2-fusion pattern of 
LE300. (Figure 2.1)  
2.2. Indole-NH  substitution 
In previous investigations, methylation of the indole-NH of LE-CE551 was found to result in a 
significant increase in the affinities for all dopamine receptor subtypes, except for D1107. Goal 
of this part was to prepare LE300 derivatives substituted at the indole-NH with a methyl 
group besides a series of other residues in order to test the effect of chain length, bulk and 























Methylation increased affinities for 
D-receptors except for D1
 
Figure 2.2: Indole-N substitution of LE300.  
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2.3. Placing substituents between the aromatic moieties 
Substituents at the indole-NH might have an impact on the conformation of the different 
azecines, which can in turn affect the activities. In order to further explore the effect of the 
substituents on the conformation of the derivatives and sequentially on the affinities, it was 
planned to prepare derivatives bearing small substituents at the methylene bridge, 
connecting both aromatic moieties. These substituents should include methyl, ethyl and 











R = Me, Et, OMe  
Figure 2.3: Substitution of LE300 at the methylene group connecting both aromatic moieties. 
2.4. LE300 substituted at the 8-position 
Starting from both α-methyltryptamine as well as L- and D-tryptophan we aimed to prepare 
the corresponding indolobenzazecine derivatives and to subsequently derivatize them. 
(Figure 2.4) Here, it was attractive to obtain the chiral target compounds in an enantiopure 
form in order to be able to assess the effect of the stereochemistry in addition to the nature of 
the substituent placed at this position. The influence of the stereochemistry of the derivatives 
on the affinities could help better explore the spatial requirements of the binding sites of the 


















L-tryptophan* R or S
 
Figure 2.4: Indolobenzazecine derivatives starting from α-methyltryptamine,  D- and L-tryptophan. 
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2.5. Dibenzazecine substituted with a methylenedioxy moiety 
LE404 is a potent dopamine receptor antagonist, displaying high affinities and a pronounced 
selectivity for the D1-like receptors. On the other hand, the 2,3-dihydroxylated and 
-dimethoxylated counterparts (figure 2.5) showed surprisingly low affinities. In case of the 
dimethoxy derivative this could be attributed to the fact that two methoxy substituents are 
spatially too bulky for the receptor binding site. Hence, we aimed to prepare an analogous 
dibenzazecine derivative, which is substituted at the 2 and 3 positions by a methylenedioxy 
group (figure 2.5), which requires less space due to its restricted rotation. This target 
derivative is postulated to show better pharmacokinetics than the phenolic dibenzazecine 
derivative LE404, which has a low oral bioavailability, most probably due to its fast 



















selective for D1 and D5
weak affinities, loss of D1-selectivity
 
Figure 2.5: Changing the substitution pattern of LE404, LE403 and LE403 into a methylenedioxy derivative. 
2.6. Antipsychotic potential of benzindoloazecines 
Since many of the previously prepared azecines have shown high in vitro affinities not only 
for the dopamine, but also for serotonin 5HT2A receptors111, it was interesting to test their in 
vivo potential as antipsychotics. For this purpose some azecine derivatives, exhibiting high 
affinities and low cytotoxicity, should be selected together with the lead compounds LE300 
and LE404 to carry out in vivo study (rat model) for antipsychotic activity as a collaborative 
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On the basis of the D1/5-selective dopamine antagonist LE 300 (1), an indolo[3,2-f]benzazecine
derivative, we changed the annulation pattern of the heterocycles. The target compounds represent
novel heterocyclic ring systems. The most constrained indolo[4,3a,3-ef ]benzazecine 2 was inactive, but
the indolo[4,3a,3-fg]benzazacycloundecene 3 showed antagonistic properties (functional Ca2þ assay)
with nanomolar affinities (radioligand binding) for all dopamine receptor subtypes, whereas the
indolo[2,3-f ]benzazecine 4 displayed a selectivity profile similar to 3 but with decreased affinities.
Introduction
Dopamine is a major neurotransmitter of the brain
involved in the control of movement, emotion, reward,
and cognition. Dysfunctions of the dopaminergic system
have been associated with several neuropsychiatric dis-
orders including Parkinson’s disease, schizophrenia, and drug
dependence. The azecine-type dopamine receptor antagonist
7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benza-
zecine (1, LE 300)2-4 represents a novel chemical structure,
possessing high affinities and a unique selectivity profile for
the D1-like receptors. Extensive SAR studies have been
carried out based on 1 (LE 300) as a lead. The objective of
the present study was to rearrange the heterocyclic skeleton
of our lead compound 1 in order to assess how different
annulation patterns would affect the affinities and selecti-
vities for the dopamine receptors. While retaining the basic
structural features of our lead, namely an indole, a benzene
ring, and a central N-methylated azacycloalkane ring, we
mainly wanted to change the annulation of the central
alicycle to the indole ring (Chart 1).
Our first targets were analogues of 1, where the aza-alicycle
is fused not to the 2,3- but to the 3,3a,4-positions of the indole.
As this annulation pattern might impart some rigidity on the
structure, we wanted to synthesize both the indolo-benzaze-
cine 2 and the more flexible indolo-benzazaundecene 3.
Compound 2 resembles the parent compound 1 in containing
a 10-membered central alicycle but differs from it in contain-
ing a methylene rather than an ethylene chain, connecting the
indole ring to the central nitrogen. Conversely, in the ring-
expanded structure of compound 3, the indole ring is con-
nected to the central nitrogen through an ethylene chain.
These target compounds, together with their pentacyclic
precursors 8 and 12, are of additional interest due to their
structural resemblance to ergolines, especially to the selective
D1 (partial)agonist (-)-4,6,6a,7,8,12b-hexahydro-7-methyl-
indolo[4,3-ab]phenanthridine CY 208-2435,6 (Chart 2). This
benzergoline derivative showed 10-fold selectivity for D5 over
D1 receptor
7 and exhibited in vivo antiparkinsonial activity.8
Our second target compoundwas the indolo-benzazecine 4,
where the 10-membered central alicycle is fused at the 2,3-
positions of the indole ring as opposed to the 3,2-fusion
pattern of 1 (Chart 1).
Chemistry
To obtain the annulated 10- and 11-membered hetero-
cycles, we had to prepare their ring-closed quinolizine-type
precursors. Previously appliedmethods for the preparation of
related quinolizines, namely by reacting the respective aralky-
lamines with 1-isochromanone4,9 or with 2(2-chloroethyl)-
benzoyl chloride,10,11 were unsuccessful. So the quinolizine 8
was prepared following a procedure described by Browne for
the preparation of analogous benzo-thieno-quinolizine.12 Re-
acting 4-aminomethylindole (5) with 2-(2-bromoethyl)benz-
aldehyde (6) in dioxane at room temperrature yielded the 3,4-
dihydroisoquinolinium salt 7. This was refluxed in 6N HCl,
and the obtained quinoliziniumsalt was alkalinized to give the
quinolizine 8. Two different procedures yielded the indolo-
benzazecine 2. First, the quinolizine 8 was quaternized with
methyl iodide and the central C-N bond of the resulting
quaternary salt 9was subsequently cleaved by treatment with
sodium in liquid ammonia. Second, the quinolizine 8 was
converted with ethylchloroformate/NaCNBH3 to the carba-
mate derivative 10, which upon reduction with lithium alu-
minum hydride also yielded the desired target compound 2.
Spectral dataof the products, obtained bybothmethods,were
identical. However, the first route proved to be more advan-
tageous with respect to the yield (Scheme 1).
Applying the procedure, previously described for the synth-
esis of the quinolizine 2, failed to produce both the homo-
quinolizine 12 and quinolizine 15. 2-(2-Bromoethyl)benz-
aldehyde (6) did not react with the respective amines 11 and 14
*To whom correspondence should be addressed. Phone: þ49 3641
949803. Fax: þ49 3641 949802. E-mail: j.lehmann@uni-jena.de.
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at room temperature. Hence, we modified the reaction condi-
tions. 4-(2-Aminoethyl)indole (11) or 2-(2-aminoethyl)indole
(14) were refluxed with 2-(2-bromoethyl)benzaldehyde (6) in
dioxane in the presence of equimolar amounts of trifluoroacetic
acid. This resulted in the direct formation of the salts of the
homoquinolizine 12 and quinolizine 15, respectively. Alkaliniza-
tion yielded the corresponding bases, which were quaternized
withmethyl iodide. Finally the obtained quaternary salts 13 and
16were cleaved using sodium in liquid ammonia to produce the
target compounds 3 and 4 (Scheme 2).
Pharmacology
All the target compounds 2, 3, and 4 together with their
pentacyclic precursors 8, 12, and 15 were screened for their
affinities for the human cloned dopamine receptor subtypes
D1, D2 L, D3, D4.4, and D5. These receptors were stably
expressed in HEK293 or CHO cells; [3H]SCH 23390 and
[3H]spiperone were used as radioligands at the D1-like and
D2-like receptors, respectively. Ki values are given in nano-
molar units (Table 1). For a detailed protocol, see Supporting
Information (SI). Additionally, the compounds were tested in
an intracellular Ca2þ assay, in order to determine their
functionality at the D1 andD2 receptors. HEK293 cells stably
expressing the respective D-receptor were loaded with a
fluorescent dye, and after preincubation with rising concen-
trations of the test compound, an agonist (SKF 38393 for D1
and quinpirole for D2) was injected and the Ca
2þ-induced
fluorescence was measured with a microplate reader. The
ability of the test compound to suppress the agonist-induced
Ca2þ influx is an indication of antagonistic or inverse agonis-
tic properties at the receptor.For adetailed description, see SI.
Results and Discussion
We synthesized three analogues of the lead compound 1,
possessing a modified annulation pattern. All of these
compounds, together with their pentacyclic precursors, are
derivatives of novel heterocyclic ring systems.
In the radioligand binding experiments, the two homo-
logues, 2 and 3, where the alicycle is fused at the 3,3a,4
positions of the indole ring, were found to possess surprisingly
different affinities: while the indolo[4,3a,3-ef ]benzazecine 2
showed no significant affinities for all dopamine receptor
subtypes (Ki > 10 μM), the ring expanded indolo[4,3a,3-fg]-
benzazacycloundecene 3 displayed nanomolar affinities, com-
parable to those of our lead 1. However, it showed almost
equal affinities for the D1-, D3-, and D5-receptor, showing a
slightly higher affinity for D5 compared to D1. A 10-fold
increase in the affinity forD2wasobserved,whencompared to
our lead1, in addition toan improvement in the affinity for the
D4-receptor. The indolo[2,3-f ]benzazecine 4 showed a nearly
similar selectivity pattern like that of compound 3 but with
noticeable decrease in the affinities for all D-receptors.
Although both compound 2 and our lead 1 contain a benzin-
dolo-azecine moiety, the structure of the former is muchmore
constrained as a consequence of its annulation. In contrast,
the ring expanded structure of compound 3 shows higher
flexibility, which is accompanied by an extreme increase in
affinities. In accordance with our previous studies,4 only
structures showing a certain degree of flexibility display
relevant affinities for the dopamine receptors.
The discrepancy in the activities between both homologues
2 and 3might be attributed to the different distances between
the pharmacophoric groups, which are the centralN and both
aromatic rings, but also to the different angles between the
aromatic rings in both structures. Another possibility may be
that analogue 2 is inactive due to the nitrogen’s lone e-pair
being buried in the center of the ring beneath the N-methyl
group. Meanwhile, the flexibility of the additional methylene
Chart 1. Rearranging the Indolo[3,2-f]benzazecine Skeleton of 1
to Analogue Indolo[4,3a,3-ef]benzazecine 2, Indolo[4,3a,3-fg]-
benzazaundecene 3 and to Indolo[2,3-f]benzazecine 4
Chart 2. SelectiveD1 (Partial)Agonist (-)-4,6,6a,7,8,12b-Hexa-
hydro-7-methylindolo[4,3-ab]phenanthridine
Scheme 1. Total Synthesis of 5-Methyl-4,5,6,7-tetrahydro-
indolo[4,3a,3-ef][3]benzazecine (2)a
aReagents and conditions: (a) dioxane, rt, 3 h; (b) 6NHCl, reflux, 4 h;
(c) aq NH4OH; (d) MeI, acetone, rt, 24 h; (e) ClCOOEt, dry THF,
-55 C, 5 h, then NaCNBH3,-55 C to rt; (f) Na0, liquid NH3,-40 C,
10 min; (g) LiAlH4, dry THF, reflux, 3 h.
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in analogue 3might permit low-energy conformations to exist
with the N lone e-pair to be directed outward. However,
studies have shown that the receptor binding site contains two
aromatic subsites around a conserved Asp3.32, whose carbox-
ylate group acts as a counterion of the protonated basic N of
the ligand.13 Accordingly, we expect our ligands to interact
with the binding sites in an N-protonated form and not with
the N lone pair of the free base.
The pentacyclic precursor compounds 8, 12, and 15 had
generally weak to no affinities. The quinolizine 8 displayed no
affinities (Ki> 10μM) for all dopamine receptors, whereas its
homologue 12 showed micromolar ones for the D1, D2, and
D5 subtypes. Similarly, the quinolizine 15 showedmicromolar
affinities for theD1 andD2 subtypes.With the exceptionof the
quinolizine 2, removal of the C-N bond of the quinolizines
and the consequent impartment of a moderate flexibility to
the central ring results in a dramatic increase in affinities. This
is in accordance with some previous observations.4
All tested compounds, displaying affinities in the radioli-
gand binding assay, were found to possess antagonistic
activities at the D1 and D2 receptors in the calcium assay.
We conclude that modifying the annulation pattern of the
parent compound 1 does not result in significant changes in
the affinities for the different dopamine receptors; equally
active (compound 3) or slightly less active (compound 4)
dopamine antagonists have been obtained. It seems, however,
that decreasing the flexibility of the structure together with
decreasing the distances between the alicyclic nitrogen and the
aromatic moieties both have a negative effect on the affinities
and can lead to a complete loss of activity.
Experimental Section
General Methods. Melting points are uncorrected and were
measured in open capillary tubes using a Gallenkamp melting
point apparatus. 1H and 13C NMR spectral data were obtained
from a Bruker Advance 250 spectrometer (250 MHz) and
Advance 400 spectrometer (400 MHz). TLC was performed
on silica gel F254 plates (Merck). MS data were determined by
GC/MS using a Hewlett-Packard GCD-Plus (G1800C) appa-
ratus (HP-5MS column; J&W Scientific). Purities of the com-
pounds were determined by elemental analysis, performed on a
Hereaus Vario EL apparatus. All values for C, H, and N were
found to be within(0.4. All compounds showed>95% purity.
Scheme 2. Total Synthesis of Benzazacycloundecene 3 and Benzazecine 4a
aReagents and conditions: (a) trifluoroacetic acid, dioxane, reflux, 20 h; (b) 2NNaOH; (c)MeI, acetone or acetonitrile, rt, 24 h; (d) Na0, liquidNH3,
-40 C, 10 min.
Table 1. Affinities (Ki, nM) for Human D1-D5 Receptors, Determined by Radioligand Binding Experiments
Ki (nM)
compd HEK D1 HEK D2 L HEK D3 CHO D4.4 HEK D5
1a 1.9 ( 0.9 44.5 ( 15.8 25.9 108 ( 39 7.5 ( 0.3
2 >10000 >10000 >10000 >10000 >10000
3 4.2 ( 0.5b 4.0 ( 0.5c 42.9 ( 8.5c 39.1 ( 9.6b 2.5 ( 0.7c
4 28.5 ( 7.2b 55.1 ( 15.4c 513 ( 217b 225 ( 50c 10.3 ( 1.5c
8 >10000 >10000 >10000 >10000 >10000
12 1836 ( 658b 4458 ( 1192c >10000 >10000 1525 ( 206c
15 2101 ( 703b 1476 ( 28.5c >10000 >10000 >10000
aValues cited from ref 10, CHO cell lines were used for D2 L, D3, and D4.4; HEK cell lines for D1 and D5.
bKi values are the means of three experiments;
performed in triplicate ( SEM. cKi values are the means of two; experiments; performed in triplicate ( SEM.
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2,8,9,13b-Tetrahydro-6H-isoquino[2,1-b]pyrrolo[4,3,2-de]-
isoquinoline (8). To a stirred solution of 4-aminomethylindole14
(1.16 g, 8 mmol) in 30 mL dioxane was added dropwise a
solution of 2-(2-bromoethyl)benzaldehyde15 (3.4 g, 16 mmol)
in 10mLdioxane. Stirring was continued for 3 h, whereupon the
intermediate isoquinolinium salt separated as a brownish sticky
substance. The mixture was then allowed to settle, the super-
natant was decanted, the sediment washed twice with dioxane
and then twice with diethyl ether, and finally dried under
vacuum. The obtained isoquinolinium salt 7 was subsequently,
without further purification, dissolved in 30mL6NHCl and the
solution was refluxed for 4 h. The formed quinolizinium salt,
which separated as white solid, was filtered off, washed several
times with cold water, and dried. It was then alkalinized with
aqueous ammonia and the formed quinolizine base 8 was
extracted with a mixture of dichloromethane/isopropanol
(3:1). Finally, the extract was dried over Na2SO4 and the
solvents removed under reduced pressure to give 0.86 g
(41.1%) of a white solid. This was recrystallized from chloro-
form/ethanol giving cream-white crystals; mp: 185-188 C. 1H
NMR: 250 MHz (DMSO-d6): δ 2.64-3.01 (m, 4H, 8, 9),
3.93-3.99 (d, J = 15.85, 1H, 6), 4.31-4.37 (d, J = 15.85, 1H,
6), 5.33 (s, 1H, 13b), 6.73-6.76 (m, 2H,Ar-H), 6.98-7.04 (t, 1H,
J=7.4, Ar-H) 7.16-7.27 (m, 4H, Ar-H), 7.41-7.44 (d, J=7.1,
1H, 5), 10.66 (s, 1H, indole-NH). 13CNMR: 250MHz (DMSO-
d6): δ 29.43 (9), 46.48 (8), 55.34 (6), 57.8 (13b), 109.48 (3), 113.53
(13c), 113.92 (1), 120.19 (5), 122.51 (11), 124.83 (5b), 126.03 (12),
126.54 (4), 127.24 (13), 128.13 (5a), 129.35 (10), 133.93 (9a),
134.03 (2a), 137.77 (13a). Anal. (C18H16N2 3 0.25EtOH): C,H,N.
General Procedure for the Preparation of Homoquinolizine 12
and Quinolizine 15. A solution of 4-(2-aminoethyl)-16 or 2-(2-
aminoethyl)indole17 (7.5 mmol), 2-(2-bromoethyl) benzalde-
hyde (9.4 mmol), and trifluoroacetic acid (7.5 mmol) in dioxane
was refluxed under nitrogen for 20 h, whereupon a solid formed.
The precipitated salts were filtered off, washedwith dioxane and
then with diethyl ether, and subsequently dissolved in hot water,
filtered, and the filtrate rendered alkaline with 1 N NaOH.
Finally, the formed bases were extracted with chloroform and
the extracts dried over Na2SO4.
2,6,7,9,10,14b-Hexahydroindolo[30,40:3,4,5]azepino[2,1-a]-
isoquinoline (12). Evaporation of the solvent yielded a brown
solid that was crystallized from isopropanol/ether and then
recrystallized from chloroform to give cream colored crystals;
crude yield 89%; mp: 188-190 C. 1H NMR for the base:
250 MHz (CDCl3): δ 2.75-3.63 (m, 8H, 6, 7, 9, 10), 5.42 (s,
1H, 14b), 6.55 (s, 1H, 1), 6.91-6.94 (d, J = 6.9, 1H, 11),
7.09-7.27 (m, 6H, 3, 4, 5, 12, 13, 14), 8.04 (s, 1H, indole-NH).
13CNMRforHCl salt: 400MHz (MeOD-d4): δ 25.60 (10), 28.09
(6), 57.82 (7), 59.39 (9), 66.74 (14b), 109.54 (14c), 110.02 (3),
118.57 (1), 122.64 (4), 125.36 (5b), 126.36 (5), 126.67 (12), 128.16
(14), 128.56 (13), 128.89 (11), 130.58 (5a), 131.19 (14a), 131.94
(10a), 136. (2a). Anal. (C19H18N2 3 0.5CHCl3): C, H, N.
5,6,8,9,10,14c-Hexahydroindolo[30,20:3,4,]pyrido[2,1-a]isoquinoline
(15). Evaporation of the solvent yielded an orange-brown solid,
which was purified by column chromatography (EtOAc-MeOH,
15:1); yield 21%; mp: 197-200 C (analytical data see SI).
General Procedure for the Preparation of the Quaternary
Salts. To a stirred solution of the respective quinolizine or
homoquinolizine in acetone (or acetonitrile for compound 15)
was added a 10-fold molar excess of methyl iodide. Stirring was
continued for a period ranging from 24 to 48 h, and the formed
quaternary salts were isolated (analytical data, see SI).
General Procedure for the Ring-Opening. Ammonia was con-
densed in a three-necked 100mL flask, whichwas equippedwith
a balloon and a stopper and cooled in a liquid nitrogen bath.
After filling 3/4 of the flask’s volume, the cooling bath was
removed and ammonia was allowed to liquefy. The respective
quaternary salts were then added to the stirred liquid ammonia.
This was followed by gradual addition of small pieces of sodium
metal until the blue color remained for 10 min. A few drops of
saturated ammonium chloride solution were added to terminate
the reaction, and themixturewas stirred under nitrogen until the
liquid ammonia completely evaporated. To the residue was
added 10 mL water, and the mixture was then extracted with
30 mL diethyl ether. The organic phase was dried over Na2SO4,
and the solvent was removed under reduced pressure to yield the
crude products, which (except for compound 2) were sufficiently
pure and did not require further purification.
5-Methyl-4,5,6,7-tetrahydroindolo[4,3a,3-ef][3]benzazecine (2).
Evaporation of the solvent yielded a cream-colored solid, which
was crystallized from chloroform; yield 24%; mp: 257-260 C.
1H NMR: 250 MHz (CDCl3): δ 1.55 (mc, 2H, 6), 2.12 (s, 3H,
N-Me), 2.78 (mc, 2H, 7), 3.15 (mc, 2H, 4), 4.58 (s, br, 2H, 12),
6.73-6.76 (d, J= 7.1, 1H, Ar-H), 6.97-7.26 (m, 7H, Ar-H), 8.00
(s, 1H, indole-NH). HRMS 276.1621 (calcd for C19H20N2:
276.1626). Anal. (C19H20N2): C, H, N.
6-Methyl-5,6,7,8,13,15-hexahydro-4H-indolo[4,3a,3-fg][3]benz-
azacycloundecene (3).Evaporationof the solventyieldedayellowish
solid; yield 62%;mp: 157-159 C. 1HNMR: 250MHz (CDCl3): δ
2.49 (s, 3H, N-Me), 2.88 (mc, 4H, 4, 8), 3.07 (mc, 4H, 5, 7), 4.42 (s,
2H, 13), 6.79-6.82 (d, J = 7.1, 1H, Ar-H), 7.02-7.27 (m, 7H,
Ar-H), 8.39 (s, 1H, indole-NH). 13C NMR: (CDCl3): δ 28.96 (4),
29.03 (8), 44,64 (N-Me), 56.72 (7), 57.66 (5), 109.63 (1), 115.15 (13),
121.24 (3), 124.68 (2), 124.68 (10), 125.61 (3b), 126.04 (14), 126.14
(12), 129.33 (11), 130.34 (9), 133.39 (3a), 137.58 (8a), 140.11 (14a)
140.89 (12a). Anal. (C20H22N2 3 0.67H2O): C, H, N.
7-Methyl-6,7,8,9,10,15-hexahydroindolo[2,3-f ][3]benzazecine (4).
Evaporation of the solvent yielded a beige solid; yield 65%; mp:
139-141 C (analytical data see SI).
Ethyl 4,5,6,7-Tetrahydroindolo[4,3a,3-ef ][3]benzazecine-5-car-
boxylate (10). A stirred solution of the quinolizine 8 (0.56 g,
2.2 mmol) in 200mL of dry THFwas cooled in methanol/dry ice
at -55 C. While keeping the reaction mixture under nitrogen,
ethyl chloroformate (1.26 g, 11.6 mmol) was added and stirring
was continued for 5 h. Then a solution of sodium cyanoboro-
hydride (0.46 g; 7.3 mmol) in 10 mL dry THF was added at
-55 C and the reaction mixture was stirred overnight while
allowing it to reach room temperature. It was subsequently
treated with 120mLof 2NNaOH, the THF layer was separated,
washed with brine, and finally the organic layer was evaporated
under reduced pressure (analytical data, see SI).
Reduction of the Carbamate. A solution of compound 10
(200 mg, 0.6 mmol) in 10 mL of THF was slowly added to an
ice-cooled, stirred suspension of lithium aluminum hydride
(100 mg, 2.6 mmol) in 15 mL of dry THF while keeping the
reaction under nitrogen. After the addition was completed, the
reaction mixture was heated under reflux for 3 h. It was then
cooled in an ice bath, and the excess of unreacted lithium
aluminum hydride was quenched by careful addition of satu-
rated potassium sodium tartarate solution until no H2 evolved.
The resulting suspension was then filtered off and the filtrate
evaporated under reduced pressure to yield compound 2, which
was crystallized from chloroform yielding white crystals; yield
40%; mp: 257-260 C. 1H NMR: 250 MHz (CDCl3): δ 1.56
(mc, 2H, 7), 2.13 (s, 3H, N-Me), 2.79 (mc, 2H, 6), (mc, 2H, 4), (s,
br, 2H, 12), 6.73-6.76 (d, J = 7, 1H, Ar-H), 7.00-7.26 (m, 7H,
Ar-H), 8.00 (s, 1H, NH).
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I. Experimental synthetic procedures: 
General methods: Melting points are uncorrected and were measured in open capillary tubes, using a 
Gallenkamp melting point apparatus. 1H- and 13C-NMR spectral data were obtained from a Bruker 
Advance 250 spectrometer (250 MHz) and Advance 400 spectrometer (400 MHz). Elemental analyses 
were performed on a Hereaus Vario EL apparatus. TLC was performed on silica gel F254 plates 
(Merck). MS data were determined by GC/MS, using a Hewlett Packard GCD-Plus (G1800C) apparatus 
(HP-5MS column; J&W Scientific).  
7-Methyl-6,7,8,9,10,15-hexahydroindolo[2,3-f][3]benzazecine (4): 
1H-NMR: 400 MHz (CDCl3): δ 2.31 (s, 3H, N-Me), 2.65 - 2.67 (t, J = 6, 2H, 9), 2.73 - 2.77 (m, 4H, 6, 
8), 2.88 - 2.91 (t, J = 6, 2H, 5), 4.32 (s, 2H, 15), 7.08 - 7.16 (m, 4H, Ar-H), 7.27 (dd, 1H, Ar-H), 7.43 
(dd, 1H, Ar-H), 7.67 - 7.70 (dt, 2H, Ar-H). 13C-NMR: 400 MHz (CDCl3): δ 27.19 (9), 29.38 (5), 34.39 
(15), 45.84 (N-Me), 57.98 (6), 58.65 (8), 110.17 (11), 112.59 (14b), 118.57 (14), 119.14 (13), 121.02 
(12), 126.07 (3), 126.20 (1), 129.42 (14a), 130.27 (2), 130.78 (4), 135.02 (10a), 135.12 (4a), 140.22(9a), 
140.28(15a). GC-MS: m/z: 290 (1%), 230 (3%), 218 (11%), 143 (9%), 130 (5%), 115 (7%), 104 (5%), 
89 (4%), 79 (8%), 71 (9%), 57 (32%), 42 (100%). Anal. (C20H22N2 x 0.25 H2O): C, H, N 
 
4-Aminomethylindole (5):  Prepared by reduction of 4-cyanoindole using LiAlH4  according to Lit.
2: 
A solution of 4-cyanoindole (5.68 g, 40 mmol) in 50 ml dry THF was added slowly to a stirred 
suspension of LiAlH4 in 200 ml dry THF, at 0 °C under nitrogen. The reaction mixture was heated under 
reflux for 90 minutes, and then cooled, and the excess unreacted LiAlH4 was destroyed by careful 
addition of a saturated potassium sodium tartarate solution. It was then filtered, and the filtrate dried 
over Na2SO4. The dried solution was finally evaporated under reduced pressure, yielding 5.55 g (yield 
95.7 %) of a white solid.  Mp.: 134 - 136°C, reported 124 - 125 °C; 1H-NMR: 250 MHz (CDCl3): δ: 
1.65 (s, 2H), 4.17 (s, 2H), 6.63 - 6.65 (mc, 1H),  7.07 - 7.10 (d, 1H), 7.19 - 7.26 (m, 2H), 7.31 - 7.34 (d, 
1H), 8.44 (s, br, 1H). 
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2-(2-Bromoethyl)-benzaldehyde (6): The same procedure described in Lit.3 was applied, but 
dichlormethane was used as a solvent instead of carbontetrachloride. The crude product was used 
without purification for further syntheses. 
2-(Indol-4-ylmethyl)-3,4-dihydroisoquinolinium bromide (7): A brownish sticky substance was 
obtained. Samples for analytical analyses were crystallized from isopropanol/ether, giving greenish-
yellow crystals. Mp.: 179-180˚C. 1H-NMR: 400 MHz (DMSO d6): 3.11 - 3.16 (t, 2H, J = 8, 3), 3.90 - 
3.94 (t, 2H, J = 8, 4), 5.51 (s, 2H, N+-CH2), 6.69 (mc, 1H, Ar-H), 7.17 - 7.21 (t, 1H, J = 8, Ar-H), 7.25 - 
7.27 (d, 1H, J = 7, Ar-H), 7.46 - 7.48 (t, J = 3, 2H, Ar-H), 7.52 - 7.54 (d, 1H, J =8, Ar-H), 7.57 - 7.59 (d, 
1H, J = 8, Ar-H), 7.79 - 7.83 (dt, 1H, J = 1, 8, Ar-H), 7.94 - 7.96 (d, 1H, J = 8, Ar-H), 9.67 (s, 1H, 
N+=CH), 11.43 (s, 1H, indole-NH). 
 
7-Methyl-2,8,9,13b-tetrahydro-6H-isoquino[2,1-b]pyrrolo[4,3,2-de]isoquinolin-7-ium iodide (9):  
Creamy-white solid, Yield 91%. Samples for analysis were crystallized from a mixture of water / 
ethanol (4:1). Mp.: chars without melting at 263°C. 1H-NMR: 400 MHz (DMSO d6): δ 3.26 (s, 3H, N-
CH3), 3.26 – 3.37, 3.63 and 3.81 (mc, 4H, 8, 9), 5.00 – 5.04 (d, 1H, J = 14.9, 6), 5.13 – 5.16 (d, 1H, J = 
14.9, 6), 6.28 (s, 1H, 13b), 7.03 – 7.04 (d, 1H, J = 7, Ar-H), 7.14 (s, 1H, Ar-H), 7.21 – 7.26 (t, 1H, J = 
7.6, Ar-H), 7.38 – 7.43 (m, 5H, Ar-H), 11.25 (s, 1H, indole-NH); 13C-NMR: 400 MHz (DMSO d6) at 
343 K: 23.84 (9), 49.54 (N+-Me), 55.12 (8) (weak signal), 62.82 (6) (weak signal), 68.91 (13b), 107.87 
(13c), 112.29 (3), 116.40 (2), 119.68 (5a), 120.92 (13a), 123.81 (5), 124.19 (11), 127.70 (4), 128.07 
(13), 128.97 (12), 129.21 (13d), 129.72 (10), 131.00 (9a), 134.02 (2a). Anal. (C19H19IN2) C, H, N 
Ethyl 4,5,6,7-tetrahydroindolo[4,3a,3-ef][3]benzazecine-5-carboxylate (10):   Purified by column 
chromatography (hexane - EtOAc, 3:1). White solid. Yield 27 %. Mp.: 168-170 °C . 1H-NMR: 250 MHz 
(CDCl3): δ 1.06 (s, br, 3H, OCH2CH3), 3.11 (mc, 2H, 7), 3.57 (mc, 2H, 6), 4.03 - 4.05 (d, 2H, 4), 4.63 
(s, br, 2H, OCH2CH3), 7.06 - 7.34 (m, 8H, Ar-H), 8.21 (s, 1H, indole-NH). 
13C-NMR 250 MHz 
(CDCl3): δ 14.38 (OCH2CH3), 29.61 (7), 33.04 (12), 48.5 (6), 50.85 (4), 61.11 (OCH2CH3), 110.87 (1), 
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115.98 (9), 121.73 (3), 122.97 (12a), 124.15 (11), 125.93 (3a), 126.3 (2), 129.88 (10), 130.25 (8), 
130.58 (3b), 137.01 (7a), 137.79 (14a), 142 (11a), 156.8 (C=O). GC-MS: m/z: 334 (24%), 261 (12%), 
245 (19%), 232 (50%), 218 (100%), 202 (11%), 189 (5%), 130 (21%), 115 (30%), 103 (12%), 89 
(17%), 77 (28%), 63 (16%). Anal. (C21H22N2O2 x 0.67 EtOAc): C, H, N 
4-(2-Aminoethyl)indole (11): This was prepared according to the procedure described in Lit.4. Indole-
4-carbonitrile was converted to indole-4-carboxaldehyde using sodium hypophosphite/Raney nickel.  
Condensation of the obtained carboxaldehyde derivative with nitromethane gave 4-(2-nitrovinyl)indole, 
which was reduced by LiAlH4 to the desired amine. The crude amine, was used for subsequent 
syntheses. 1H-NMR: 250 MHz (DMSO d6): 2.81 - 2.93 (m, 6H), 6.47 (s, 1H), 6.76 - 6.79 (d, 1H), 6.95 - 
7.01 (t, 1H), 7.20 - 7.29 (m, 2H), 11.04 (s, 1H). 
8-Methyl-2,6,7,9,10,14b-hexahydroindolo[3’,4’:3,4,5]azepino[2,1-a]isoquinolin-8-ium iodide 
(13): Evaporating the solvent yielded a brownish solid, which was washed with diethylether, dried and 
finally crystallized from water to give yellow crystals. Yield 71%. Mp.: 224-227°C. 1H-NMR: 250 MHz 
(MeOD d4): δ 3.09 – 4.18 (m, 8H, 6, 7, 9, 10 and N-CH3), 6.52 (s, 2H, 1, 14b), 6.91 - 6.93 (d, J = 7.1, 
1H, Ar-H), 7.07 – 7.43 (m, 7H, Ar-H). Anal. (C20H21IN2 x 0.25 H2O): C, H, N 
2-(2-Aminoethyl)indole (14): According to Lit.5: Ethyl indole-2-carboxylate was reduced using 
LiAlH4 to indol-2-ylmethanol, which was oxidized by activated MnO2 to indole-2-carboxaldehyde. 
Condensation of the latter with nitromethane afforded 4-(2-nitrovinyl)indole, which was finally reduced 
by LiAlH4 to the desired amine. The crude amine was used for subsequent syntheses. 
1H-NMR: 250 
MHz (CDCl3): 1.77 (s, br, 2H), 2.82 - 2.87 (t, J = 6.1, 2H), 3.02 - 3.07 (t, J = 6.1, 2H), 6.27 (s, 1H), 7.09 
- 7.15 (m, 2H), 7.67 - 7.32 (t, J = 6.9, 1H), 7.55 - 7.59 (dd, J = 6.7, 1H), 9.11 (s, 1H).  
7-Methyl-5,6,8,9,10,14c-hexahydroindolo[3’,2’:3,4,]pyrido[2,1-a]isoquinolin-7-ium iodide (16): 
Evaporating the solvent yielded a yellowish-brown solid, that did not crystallize. Yield 69%. Mp.: 248-
251°C. 1H-NMR: 250 MHz (MeOD d4): δ 3.23 – 4.14 (m, 11 H, 5, 6, 8, 9 and N-CH3), 6.11 (s, 1H, 
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14c), 7.08 – 7.48 (m, 8H, Ar-H). 13C-NMR : 250 MHz (MeOD d4): δ 19.04 (9), 23.70 (5), 48.58 (N
+-
Me), 53.51 (8), 60.45 (6), 67.22 (14c), 104.43 (14b), 11.17 (11), 117.64 (14), 119.88 (13), 122.07 (12), 
126.52 (14d), 127.18 (2), 128.01 (14a), 128.06 (3), 128.32 (1), 128.67 (4), 130.02 (9a), 132.13 (4a), 
137.04 (10a).  Anal. (C20H21IN2 x H2O): C, H, N 
5,6,8,9,10,14c-Hexahydroindolo[3’,2’:3,4,]pyrido[2,1-a]isoquinoline (15): 
1H-NMR: 250 MHz (CDCl3): δ 2.61 - 3.63 (m, 8H, 5, 6, 8, 9), 5.34 (s, 1H, 14c), 7.04 - 7.28 (m, 5H, 
Ar-H), 7.23 - 7.28 (m, 1H, Ar-H), 7.45 - 7.48 (d, J = 7.45, 1H, Ar-H), 7.58 - 7.65 (m, 1H, Ar-H), 8.33 
(s, 1H, indole-NH). 13C-NMR: 250 MHz (CDCl3): δ 23.54 (9), 24.13 (5), 44.07 (6), 50.84 (8), 55.84 
(14c), 110.71 (11), 111.88 (14b), 118.73 (14), 119.52 (13), 120.99 (12), 126.24 (2), 126.4 (3), 127.92 
(14a), 128.3 (1), 128.65 (4), 132.71 (9a), 133.35 (4a), 136.15 (14d), 138.04 (10a). Anal. (C19H18N2 x 0.4 
EtOAc): C, H, N 
 
II.  Experimental Procedures for the Pharmacological  assays 
Dopamine Receptor Affinity 
i) Cell culture 
D1, D2L, D3, and D5 were expressed in human embryonic kidney (HEK) cells and D4.4 receptors were 
expressed in Chinese hamster ovary (CHO) cells. Cells were grown at 37oC under an atmosphere of 5% 
CO2: 95% air in HAM/F12-medium (Sigma-Aldrich) for CHO cells and Dulbecco’s modified Eagles 
Medium Nutrient mixture F-12 Ham for HEK293 cells, both supplemented with 10% fetal bovine 
serum, 1 mM L-glutamine and 0.2 g/ml of G 418 (all from Sigma-Aldrich).ii) Preparation of Whole-
Cell-Suspension
6 
Human D1, D2L, D3, D4 and D5 receptor cell lines were grown on T 175 culture dishes (Greiner bio-one, 
Frickenhausen) to 85% confluence. The medium was removed and the cells were incubated with 3 ml 
trypsine-EDTA-solution (Sigma-Aldrich), to remove the cells from the culture dish. After incubation, 
cells were suspended in 6 ml medium, in order to stop the effect of trypsine-EDTA-solution. The 
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resulting suspension was centrifuged (483 RCF, 4oC, 4 min.). The pellet was re-suspended in 20 ml ice-
cooled PBS (Phosphate-buffered saline: 137 mM NaCl, 2.7 mM, 8.1 mM Na2HPO4 and 1.4 mM 
KH2PO4) and centrifuged again. This procedure was repeated, the obtained pellet was suspended in 12 
ml buffer (5 mM magnesium chloride, 50 mM TRIS-HCl, pH=7.4) and the resulting suspension was 
directly used for the radioligand binding assay.  
1.1.1.1. iii) Radioligand Binding Assay 
The binding studies were performed following the protocol previously described but in 96- well format.7 
The assays, using the whole-cell-suspension, were carried out in triplicate in a volume of 550 l (final 
concentration): TRIS-Mg2+-buffer (345 l), [3H]-ligand (50 l), whole-cell-suspension (100 l) and 
appropriate drugs (55 l). Non-specific binding was determined using fluphenazine (100 M) for D1 and 
D5 tests and haloperidol (10 M) for D2, D3 and D4 tests. The incubation was initiated by addition of the 
radioligand and was carried out in 96 deep well plates (Greiner bio-one, Frickenhausen) using a 
thermocycler (Thermocycler comfort®, Eppendorf, Wessling) at 27oC. The incubation was terminated 
after 90 min by rapid filtration with a PerkinElmer Mach III HarvesterTM using a PerkinElmer Filtermat 
A, previously treated with a 0.25% polyethyleneimine-solution (Sigma-Aldrich) and washed with water. 
The filtermat was dried for 3 min at 400 watt using a microwave oven (MW 21, Clatronic, Kempen). 
The dry filtermat was placed on a filter plate (Omni filter platesTM, PerkinElmer Life Sciences) and each 
field of the filtermat was moistened with 50 µl Microscint 20TM scintillation cocktail. The radioactivity 
retained on the filters was counted using a Top Count NXTTM microplate scintillation counter (Packard, 
Ct., USA). For the determination of the Ki values at least two independent experiments each in triplicate 
were performed. 
The competition binding data were analyzed with GraphPad PrismTM software using nonlinear 
regression with sigmoidal dose response equation. Microsoft ExcelTM was used to calculate the mean 
and the standard error of the mean. Ki values were calculated from IC50 values applying the equation of 
Cheng and Prusoff.8 
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Functional assay: Measuring intracellular Ca
2+
 with a fluorescence microplate reader
7;9 
i) Cell Culture 
Human D1 and D2L receptors were stably expressed in human embryonic kidney cells (HEK293) and 
cultured as mentioned above. 
ii) Preparation of Whole-Cell-Suspension 
Human D1 and D2L receptor cell lines were grown on T 175 culture dishes (Greiner bio-one, 
Frickenhausen) to 85-90% confluence. The medium was removed via a suction apparatus and the cells 
were rinsed twice with 6 ml Krebs-HEPES buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 
mM KH2PO4, 4.2 mM NaHCO3, 11.7 mM D-Glucose, 1.3 mM CaCl2, 10 mM HEPES, pH 7.4). After 
these two washes, cells were loaded with 3 l of a 0.5 M Oregon Green TM 488 BAPTA-1/AM-solution 
(Molecular Probes, Eugene, OR) (in DMSO) in 6 ml Krebs-HEPES buffer containing 3 µl of a 20% 
Pluronic F-127-solution (Sigma Aldrich) (in DMSO) for 45 min at 37oC. After 35 min incubation, the 
culture dish was rapped slightly in order to remove all cells from the dish for further incubation. To this 
cell suspension 5ml Krebs-HEPES buffer were added again to rinse all cells from the plate. The 
resulting suspension was portioned into ten 1.5 ml Eppendorf caps and centrifuged at 10640 RCF for 10 
seconds. The supernatant buffer was removed and the resulting ten pellets were divided into two 
portions à 5 pellets, each portion was suspended in 1 ml Krebs-HEPES buffer. The two suspensions 
were centrifuged again for 10 sec. After removing the buffer, the two pellets were combined and re-
suspended in 1 ml buffer, diluted with 17 ml Krebs-HEPES buffer and plated into 96-well plates 
(OptiPlate HTRF-96TM, Packard, Meriden, CT; Cellstar, Tissue Culture Plate, 96W, Greiner bio-one, 
Frickenhausen). The microplates were kept at 37oC under an atmosphere containing 5% CO2 for 30 min 






Screening for agonistic and antagonistic activity was performed using a NOVOstar microplate readerTM 
(BMG LabTechnologies) with a pipettor system. Agonistic activities were tested by injecting 20 µl 
buffer alone as negative control, standard agonist in buffer as positive control, and rising concentrations 
of the test compounds in buffer, each into separate wells. Fluorescence measurement started 
simultaneously with the automatic injection. SKF 38393 was used as standard agonist for D1 receptors 
and quinpirole for D2 receptors (final concentration: 1 µM). 
Screening for antagonistic activities was performed by pre-incubating the cells with 20 µL of the test 
compound dilutions (final concentrations: 100 µM, 50 µM, 10 µM, 5 µM, 1 µM, 500 nM, 100 nM, 50 
nM, 10 nM, 1 nM, 0,1 nM) at 37oC 30 min prior to injection of 20µL standard agonist per well. As 
standard agonists we used as described for the agonist screening SKF38393 for D1 and quinpirole for D2 
receptors, respectively. Fluorescence measurement also started simultaneously with the automatic 
injection. At least two independent experiments, each carried out in four or six replications, were 
performed. 
Fluorescence intensity was measured at 520 nm (bandwidth 25nm) for 30 s at 0.4 s intervals. Excitation 
wavelength was 485 nm (bandwidth 20 nm). Agonistic or antagonistic activities were assessed by a dose 
response curve, obtained by determination of the maximum fluorescence intensity of each data set and 
nonlinear regression with sigmoidal dose III. Table of elemental analysis for key compounds 
Compound  C H N 
2
 found 82.37 7.35 10.03 
 calc. for 
C19H20N2 
82.57 7.29 10.14 
3 found 79.50 7.92 8.83 
 calc. for 
C20H22N2x 0.67 
H2O 
79.43 7.78 9.26 
4 found 81.40 7.57 9.38 
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 C20H22N2 x ¼ 
H2O 
81.45 7.69 9.50 
8
 found 81.48 6.13 10.59 
 calc. for 
C18H16N2 x ¼ 
C2H5OH 
81.74 6.49 10.30 
9 found 56.71 4.65 6.88 
 calc. for 
C19H19IN2 
56.73 4.76 6.96 
10* found 72.10 6.64 7.58 
 calc. for 
C21H22N2O2 x 
0.67 EtOAc 
72.30 7.01 7.13 
12 found 70.50 5.85 8.30 
 calc. for 
C19H18N2 x ½ 
CHCl3 
70.11 5.58 8.39 
13 found 57.04 5.25 6.46 
 calc. for 
C20H21IN2 x ¼ 
H2O 
57.08 5.15 6.66 
15 found 79.60 6.53 9.25 
 calc. for 
C19H18N2 x 0.4  
EtOAc 
79.92 6.90 9.05 
16 found 55.42 5.27 6.30 
 calc. for 
C20H21IN2 x 
H2O 
55.31 5.34 6.45 
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To further investigate SAR in the class of azecine-type dopamine receptor antagonists, we synthesized
a series of derivatives, substituted at the indole-NH of the lead compound LE300 by different alkyl
chains in addition to phenylpropyl, allyl, propargyl, and acetyl residues. The affinities of the target
compounds for all human dopamine receptors (D1–D5) were investigated by radioligand binding assay
and their functionality by a calcium assay. Both the affinities and selectivities for the dopamine
receptors were found to be affected by the nature of the substituent. The N14-methylated derivative
displayed the highest affinities for all D-receptors. In general, the affinities decreased with increasing
chain length of the N-alkyl. Different substituents, partly led to altered affinity, and selectivity profile
when compared with our lead LE300.
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Introduction
Dopamine is a key neurotransmitter in the brain, playing a
regulatory role in locomotion, cognition, emotion and event
prediction. Dysfunctions of the dopaminergic system have
been linked to several neuropsychiatric diseases; hence
dopamine receptors have long served as attractive targets
for drug development [1]. Dopamine receptor antagonists,
for instance, have been implemented as antipsychotics.
The azecine-type dopamine receptor antagonists, based on
the lead compound 1 (LE 300), represent a novel class of
dopamine receptor ligands [2–4]. They were found to
possess high affinities for dopamine receptors and a unique
selectivity profile for the D1-like receptors.
Some previous studies have shown that substitution of the
indole-NH might be advantageous; indole-NH-methylation of
the methoxylated derivative (2) led to increased affinities for
all dopamine receptors except for D1 [5]. The N14-methylated
derivative of 1 was subsequently synthesized and as expected
showed similar promising affinities. Hence, we synthesized a
series of derivatives of 1, substituted at the indole-NH with
different alkyl chains, in order to study the effect of the
substituent’s length and bulk on the affinities. Moreover,
N-allyl-, propargyl-, and acyl derivatives were prepared, which
possess different electronic as well as steric properties com-
pared with the alkyl groups. Finally, 1 was substituted with a
phenylpropyl group, to examine the effect of both an
additional aromatic group and a bulky moiety. The affinities
of the prepared compounds for the human dopamine recep-
tors (D1–D5) were investigated by radioligand binding exper-
iments, and their functionality as agonists or antagonists was
determined by a functional Calcium assay at the D1-, D2-,
and D5-receptors.
Chemistry
For the synthesis of the quinolizine 3, we simplified previous
methods to a one-step reaction, which we already adopted for
Correspondence: Christoph Enzensperger, Institut für Pharmazie,
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the synthesis of analogous quinolizines [6]. Tryptamine was
refluxed with 2-(2-bromoethyl)benzaldehyde in dioxane in
the presence of an equimolar amount of trifluoroacetic acid.
This one-pot Pictet-Spengler procedure, showed obvious
advantages over the previously applied one, where trypt-
amine was first reacted with 1-isochromanone and the
resulting amide cyclised (Bischler-Napieralski) using POCl3
followed by NaBH4 reduction [4, 7]. The obtained quinolizine
was then quaternized with methyl iodide, and the quater-
nary salt was treated under Birch conditions with sodium
in liquid ammonia to afford the indolobenzazecine 1.
Substitution of the indole-NH was achieved by the reaction
of 1 with the corresponding halide derivative after deproto-
nation with sodium hydride in DMF. For this purpose a
twofold excess of NaH and only an equimolar amount of
the halide derivative were used, to ensure that no quaterni-
zation took place at the basic, central alicylic N. The N7,N14-
dimethylated compound 5 was obtained by treating the
quinolizine with excess of methyl iodide in the presence
of sodium hydride, which led to the simultaneous N14-alky-
lation and N7-quaternisation. The formed quaternary salt 4
was then cleaved under Birch conditions (Scheme 1).
However, when trying to synthesize the propargyl deriva-
tive 11, three different products were obtained. The GC-MS
spectrum showed 3 peaks of the same mass (m/z 328), beside
the peak of the starting material. Even when the reaction
temperature was decreased to 08C and the reaction time was
reduced from 24 h to 2 h, a mixture of the three products in
addition to the starting material was obtained. We assume
that the excess of NaH led to a base-catalyzed alkyne/allene
rearrangement (Fig. 1), which has been described for acety-
lenes [8]. A mixture of the 2-propynyl, 1-propynyl, and allenyl
derivatives was obtained, but could not be separated. The 13C-
NMR spectrum also showed characteristic peaks for the three
predicted products. Therefore, only an equimolar amount of
NaH was used. This did not affect a complete reaction, hence
accounting for the low yield. However it led to the propargyl
derivative as a sole product.
Pharmacology
All the target compounds were screened for their affinities
for the human cloned dopamine receptor subtypes D1, D2L,
D3, D4.4, and D5. These receptors were stably expressed in
Scheme 1. Synthesis of N14-alkylated
LE300. Reagents and conditions: (a) Dioxane,
TFA, reflux, 18 h; (b) NaOH; (c) NaH, THF, xss
methyl iodide, 08C–r.t., 24 h; (d) Na0, liq. NH3,
S408C, 10 min; (e) Methyl iodide, acetone, r.t.,
4 h; (f) NaH, DMF, RX, 08C–r.t., 24 h (warm to
408C with acetyl chloride).
Figure 1. Alkyne/allene rearrangement of compound 11.
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HEK293 or CHO cells; [3H]SCH 23390 and [3H]spiperone
were used as radioligands at the D1-like and D2-like receptors,
respectively. Ki values are given in nanomolar units (Tab. 1).
The detailed protocol has been previously described [9].
The functionality at the D1-, D2-, and D5-receptors was
tested in an intracellular calcium fluorescence assay [10],
where all prepared compounds were found to possess
antagonistic properties.
As some of the prepared compounds displayed interestingly
high affinities for the dopamine receptors, the cytotoxicity
of some selected compounds was investigated, in order to test
out their applicability in an in-vivo assay as antipsychotics.
Moreover, it was of interest to study the effect of the different
substituents on the cytotoxicity of the compounds. This was
tested in anMTT cell proliferation assay, the protocol has been
described [11]. (Cc50-values are given in Table 1).
Results and discussion
With regard to the binding profile (Table 1), all N14-alkylated
derivatives showed a higher affinity for the D1-like receptors.
The N14-methylated derivative 5 displayed the highest affin-
ities among all prepared derivatives. Compared with the lead
1, compound 5 showed a 5–15 fold increase in affinities for all
D-receptor subtypes, except for D1. The ethylated derivative 6
displayed lower affinities than the methylated one (5), but
they were nearly equal to those of 1. It is quite evident, that
the affinities decreased with increasing alkyl chain length.
This was most pronounced in the N14-octyl derivative 15,
which showed the lowest affinities among all tested com-
pounds. The only exception was the pentyl derivative 14,
which displayed lower affinities for D5 than 15; in fact it
showed the highest D1/D5-selectivity (1:10).
Modification of the alkyl chains did not lead to significant
alterations in the affinities for the different D-receptor. The
fluoroethylated derivative 7 exhibited affinities similar to the
ethylated one. The cyclopropylmethyl derivative 9 generally
showed affinities similar to the N14-propyl derivative 8,
except at D5, where they were much lower.
Compared with 1, the affinities of the N-acetylated com-
pound 12 for the D1- andD3-receptors were lower, those for D4
and D5 almost equal, while a slight enhancement in the
affinity for D2 could be observed.
The allylated derivative 10 displayed an unexpected
selectivity profile; showing the highest affinity for D4-subtype
among all synthesized compounds. A similar effect was
not noticed in compound 11, where the indole-NH is
substituted with a propargyl group. In spite of its bulk,
the propargyl derivative exhibited rather high affinities for
the D1- and the D5-receptor. This might be explained in
different ways: Either thep-bonds enable further interactions
with the receptors (like stacking) or the terminal alkyne-H
serves as H-donor. Moreover, compared with the other 3-
carbon chains (N-allyl- (10) and N-propyl- (8)), the N-prop-
argyl-derivative 11 has a straight shape and less confor-
mational flexibility.
The derivative substituted with a phenylpropyl group (13)
also showed significantly reduced affinities to all subtypes.
The longer alkyl chains like pentyl- (14) and octyl- (15)
showed an interesting effect on the binding to the D1-family:
For the D1-receptor the pentyl derivative (14) has a clearly
higher affinity than the octyl-derivative (15). This is in line
with all other receptor subtypes except the D5 receptor,
where the affinity of octyl-derivative (15) is higher than that
of the pentyl-derivative 14. The phenylpropyl-derivative (13),
whichmight display similar space filling like 15, has a higher
affinity for the D5-receptor than the much smaller pentyl-
derivative (14).
The fact that substitution of indole-NH with small groups
(Me and Et) did not decrease the affinities, proves that the
indole-NH does not play a role as H donor in the interaction
with the receptor. We assume that the enhancing effect of
methyl substitution on the affinities is rather caused by steric
effects.
It is apparent that increased alkyl chain length goes along
with increased cytotoxicity. The methylated derivative 5
exhibited a low cytotoxicity, whereas the octyl derivative
15 displayed a sixfold increase in cytotoxicity. The high
affinities together with the low cytotoxicity of the methyl-
ated derivative, rendered it suitable further in-vivo studies,
the results are reported in a separate paper.
In conclusion: To elucidate the effect of indole-NH substi-
tution, eleven new N14-substituted benzindoloazecines were
synthesized and their affinities for all dopamine receptors
were determined by radioligand binding experiments.
The affinities and even selectivity were seriously affected
by the nature and bulk of the substituent. Interesting is also
that many N14-substituted derivatives showed an increase
in the affinity for D4. All in all, a clear correlation (Fig. 2) can
be seen between the chain length and the affinities; an
optimal binding affinity was obtained with a methyl group.
Longer alkyl chains and bulky substituents were unfavorable.
However, against this trend, longer alkyl chains seem to
influence the binding to the D1- and the D5-receptor in
opposing directions. The pentyl-derivative (14) has the
lowest D5-affinity and longer chains seem to be better toler-
ated at the D5-receptor than at the D1-receptor. This effect
can be further exploited in order to gain D1- or D5-selective
compounds, which might be valuable tools but are not yet
available [12].
Furthermore, the cytotoxicity of the synthesized deriva-
tives increased with increasing chain length. On the whole,
the N14-methylated derivative showed the most interesting
affinities together with lowest cytotoxicity, which rendered it
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Table 1. Affinities (Ki, nM) for human D1–D5-receptors, determined by radioligand binding experiments and cytotoxicity (Cc50, mM)
Compounds Ki, [nM] Cytotoxicity
Cc50, [mM]
c








































10 27 (15) b 28.9 ( 9.3) b 99.3 (15) b 9.1 (3.6) a 5.5 (2) a 85.5 (8.2)
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Melting points are uncorrected and were measured in open
capillary tubes, using a Gallenkamp melting point apparatus.
1H- and 13C-NMR spectral data were obtained from a Bruker
Advance 250 spectrometer (250 MHz) and Advance 400 spec-
trometer (400 MHz). TLC was performed on silica gel F254 plates
(Merck). MS data were determined by GC/MS, using a Hewlett
Packard GCD-Plus (G1800C) apparatus (HP-5MS column; J&W
Scientific). Purities of the compounds were determined by
elemental analysis, performed on a Hereaus Vario EL apparatus.
All values for C, H, and N were found to be within 0.4. All
compounds showed >95% purity.
Table 1. (continued )
Compounds Ki, [nM] Cytotoxicity
Cc50, [mM]
c

























15 184 (60) a 3383(694) b 1760 (532) a 1414 (531) a 77.3 (3) b 24.6 (5.0)
 Values taken from [3]
 Values taken from [5]
a Ki-values are the means of three experiments; performed in triplicate, SEM is given in parantheses
b Ki-values are the means of two; experiments; performed in triplicate  SEM
c Cc50 values are means of three experiments, standard deviation is given in parentheses
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5,6,8,9,14,14b-Hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]-
isoquinoline (3)
A solution of tryptamine (4.2 g, 26.45 mmol), 2-(2-bromoethyl)-
benzaldehyde (6.9 g, 32.4 mmol), and trifluoroacetic acid
(2.99 g, 26.25 mmol) in 150 mL dioxane, kept under nitrogen,
was refluxed and stirred vigorously for 18 h. The separated
yellow solid was filtered off, washed with dioxane and then
repeatedly with diethyl ether. The obtained solid was then alkali-
nized using 1 N NaOH, and the formed base was extracted with
dichloromethane. Finally, the organic phase was dried over
Na2SO4, and evaporated under reduced pressure leaving a beige
solid. (4 g, yield 55.6%). M.p.: 117–1198C, (Lit. 167–1688C [7], 95–
988C and 125–1278C [13]). 1H-NMR 400 MHz (CDCl3): d 2.69–2.81,
2.85–3.14, 3.42–3.55 (m, 8H, 5, 6, 8, 9), 5.39 (s, 1H, 14b), 7.11–7.18
(m, 2H, 11, 12), 7.22–7.23 (d, J ¼ 7, 1H, 4), 7.27–7.31 (m, 2H, 2, 13),
7.34–7.37 (t, J ¼ 7, 1H, 3), 7.41–7.42 (d, J ¼ 7, 1H, 10), 7.52–7.54 (d,
J ¼ 7, 1H, 1) 7.74 (s, 1H, NH). GC-MS: m/z: 273 (10%), 245 (6%), 230




Evaporation of the solvent yielded a creamy white powder,
which was crystallized from methanol, giving white cubic
crystals. Yield 69%. M.p. 90–928C (Lit. 56–588C [4]). 1H-NMR
250 MHz (CDCl3): d 2.28 (s, 3H, N-Me), 2.61–2.90 (m, 8H, 5, 6,
8, 9), 4.35 (s, 2H, 15), 7.07–7.36 (m, 7H, Ar), 7.46–7.49 (d, J ¼ 7,
1H, Ar), 7.82 (s, 1H, NH). GC-MS: m/z: 290 (21%), 245 (22%), 230
(49%), 217 (100%), 204 (10%), 189 (15%), 177 (12%), 154 (16%),




Yellow powder. Yield 82%. M.p. 254–2558C. 1H-NMR 250 MHz
(DMSO-d6): d 3.25 (s, 3H, N
þ-Me), 3.78 (s, 3H, indole N-Me),
3.10–4.23 (m, 8H, 5, 6, 8, 9), 6.34 (s, 1H, 14b), 6.79–6.82 (d, J ¼ 7,
1H, Ar), 7.10–7.16 (t, J ¼ 7, 1H, Ar), 7.23–7.61 (m, 6H, Ar). 13C-NMR
250 MHz (DMSO-d6): d 17.7 (9), 24.3 (5), 31.1 (indole N-Me), 49.3
(Nþ-Me), 53.4 (8), 62.4 (6), 64.4 (14b), 104.0 (13), 110.7 (9a), 119.3
(1a), 120.2 (11), 123.0 (12), 125.7 (14c), 127.5 (2), 128.2 (3), 129.0
(9b), 129.3 (4), 129.4 (1), 131.4 (14a), 132.2 (4a), 138.3 (13a).
7,14-Dimethyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]-
benzazecine (5)
Purified by column chromatography (EtOAc). Yellow powder.
Yield 20%. M.p. 103–1058C. 1H-NMR 400 MHz (CDCl3): d 2.35 (s,
3H, N-Me), 2.45–2.48 (t, J ¼ 6, 2H, 5), 2.70–2.73 (t, J ¼ 6, 2H, 9),
2.76–2.81 (m, 4H, 6, 8), 3.56 (s, 3H, indole N-Me), 4.54 (s, 2H, 15),
7.04–7.08 (ddd, J ¼ 5/2/0.6, 1H, Ar), 7.10–7.12 (dd, J ¼ 7/1, 1H,
Ar), 7.16–7.21 (m, 3H, Ar), 7.24–7.26 (d, J ¼ 8, 1H, Ar), 7.32–7.33
(dd, J ¼ 8/3, 1H, Ar), 7.50–7.52 (d, J ¼ 8, 1H, Ar). GC-MS: m/z: 304
(21%), 260 (9%), 246 (53%), 232 (100%), 217 (63%), 200 (17%), 168
(10%), 157 (47%), 144 (55%), 128 (38%), 115 (88%), 104 (61%), 91
(41%), 77 (78%), 63 (34%). Anal. calcd. for C21H24N2  0.2 EtOAc:




Evaporation of the solvent gave a yellow powder. Crystallized
from ethanol/H2O giving yellow crystals. Yield 56%. M.p. 103–
1048C. 1H-NMR 250 MHz (CDCl3): d 1.01–1.07 (t, J ¼ 7, 3H, 2’), 2.37
(s, 3H, N-Me), 2.43–2.48 (t, J ¼ 6, 2H, 5), 2.71–2.77 (m, 6H, 6, 8, 9),
4.02–4.11 (q, J ¼ 7, 2H, 1’), 4.58 (s, 2H, 15), 7.02–7.33 (m, 7H, Ar),
7.50–7.53 (d, J ¼ 7, 1H, Ar). 13C-NMR 250 MHz (CDCl3): 14.8 (2’),
23.3 (9), 32.8 (15), 33.23 (5), 38.2 (1’), 45.4 (N-Me), 59.0 (8), 59.4 (6),
108.8 (13), 112.8 (9a), 117.9 (10), 118.6 (11), 121.5 (12), 126.3 (3),
126.7 (2), 127.9 (9b), 131.0 (4), 131.7 (1), 134.9 (13a), 135.7 (14a),
138.1 (4a), 142.2 (15a). GC-MS: m/z: 318 (32%), 274 (9%), 260 (38%),
246 (98%), 230 (100%), 217 (76%), 202 (21%), 171 (19%), 158 (39%),
143 (44%), 130 (37%), 115 (68%), 104 (28%), 91 (33%), 77 (49%), 65
Figure 2. The effect of the substituent on the affinities for the different D-receptors.
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(22%). Anal. calcd. for C22H26N2: C, 82.97%; H, 8.23%; N, 8.80%.
Found: C, 83.05%; H, 8.44%; N, 8.70%.
14-(2-Fluoroethyl)-7-methyl-6,7,8,9,14,15-hexahydro-5H-
indolo[3,2-f][3]benzazecine (7)
Crystallized from Methanol then recrystallized from hexane
giving white crystals. Yield 38%. M.p. 107–1088C. 1H-NMR
250 MHz (CDCl3): 2.34 (s, 3H, N-Me), 2.38–2.42 (t, J ¼ 6, 2H, 5),
2.67–2.72 (m, 6H, 6, 8, 9), 4.21 (dd, 10/4, 2H, 1’), 4.35 (dd, J ¼ 6/4,
2H, 2’), 4.61 (s, 2H, 15), 7.03–7.33 (m, 7H, Ar), 7.52 (d, J ¼ 8, 1H,
Ar). 13C-NMR 250 MHz (CDCl3): 23.4 (9), 32.9 (15), 33.3 (5), 43.7 (d
(23.3Hz)) (1’), 45.3 (N-Me), 58.8 (8), 59.6 (6), 82.2 (d (171.7 Hz)) (2’),
108.8 (13), 113.6 (9a), 118.90 (10), 119.1 (11), 121.1 (12), 126.4 (3),
126.9 (2), 128.0 (9b), 131.2 (4), 131.9 (1), 135.3 (13a), 136.5 (14a),
137.8 (4a), 142.3 (15a). GC-MS: m/z: 336 (15%), 316 (9%), 278 (24%),
264 (51%), 230 (56%), 217 (36%), 156 (30%), 143 (33%), 128 (37%),
115 (100%), 104 (84%), 91 (44%), 78 (100%), 65 (47%). Anal. calcd.




Evaporation of the solvent gave a yellow solid. Crystallized from
isopropanol/H2O giving yellow crystals. Yield 56%. M.p. 73–748C.
1H-NMR 250 MHz (CDCl3): d 0.75–0.81 (t, J ¼ 7, 3H, 3’), 1.43–1.52
(sextet, J ¼ 7, 2H, 2’), 2.34 (s, 3H, N-Me), 2.42–2.47 (t, J ¼ 6, 2H, 5),
2.69–2.73 (m, 6H, 6, 8, 9), 3.93–3.97 (t, J ¼ 7, 2H, 1’), 4.55 (s, 2H,
15), 7.02–7.37 (m, 7H, Ar), 7.51–7.53 (d, J ¼ 8, 1H, Ar). GC-MS: m/z:
332 (37%), 274 (23%), 260 (64%), 244 (35%), 230 (100%), 217 (67%),
202 (16%), 154 (15%), 143 (21%), 130 (24%), 115 (30%), 103 (17%),
91 (22%), 71 (30%). Anal. calcd. for C23H28N2: C, 83.09%; H, 8.49%;
N, 8.43%. Found: C, 83.09%; H, 8.62%; N, 8.34%.
14-(Cyclopropylmethyl)-7-methyl-6,7,8,9,14,15-
hexahydro-5H-indolo[3,2-f][3]benzazecine (9)
Purified by column chromatography (DCM/MeOH, 9:1), yielding a
creamy white oil. Yield 63%. 1H-NMR 250 MHz (CDCl3): d 0.18–
0.24 (m, 2H, 3’), 0.40–0.47 (m, 2H, 4’), 0.84–1.08 (m, 1H, 2’), 2.36 (s,
3H, N-Me), 2.48–2.53 (t, J ¼ 6, 2H, 5), 2.71–2.78 (m, 6H, 6, 8, 9),
3.91–3.94 (d, J ¼ 6, 2H, 1’), 4.55 (s, 2H, 15), 7.03–7.31 (m, 7H, Ar),
7.47–7.50 (d, J ¼ 7, 1H, Ar). GC-MS: m/z: 344 (27%), 286 (13%), 272
(27%), 239 (45%), 230 (100%), 217 (60%), 202 (19%), 160 (30%), 144
(324%), 130 (44%), 115 (72%), 103 (22%), 91 (29%), 71 (34%). Anal.
calcd. for C24H28N2  0.25 H2O: C, 82.60%; H, 8.23%; N, 8.03%.
Found: C, 82.48%; H, 8.32%; N, 7.91%.
14-Allyl-7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f]-
[3]benzazecine (10)
Purified by column chromatography (EtOAc/MeOH, 2:1), yielding
a colorless oil, which solidifies to a waxy white solid on standing.
Yield 25%. M.p. 78–808C. 1H-NMR 250 MHz (CDCl3): d 2.27 (s, 3H,
N-Me), 2.45–2.50 (t, J ¼ 6, 2H, 5), 2.72–2.77 (m, 6H, 6, 8, 9), 4.50 (s,
2H, 15), 4.60–4.62 (m, 2H, 1’), 4.75–4.82 (dd, J ¼ 17/1, 1H, 3’),
4.99–5.04 (dd, J ¼ 10/1, 1H, 3’), 5.62–5.77 (m, 1H, 2’), 7.03–7.30
(m, 7H, Ar), 7.50–7.53 (dd, J ¼ 8/1, 1H, Ar). 13C-NMR 250 MHz
(CDCl3): 23.1 (9), 32.5 (5), 33.1 (15), 45.3 (N-Me), 45.7 (1’), 58.8 (8),
59.0 (6), 109.1 (13), 113.0 (9a), 115.9 (2’), 117.8 (10), 118.8 (11),
120.8 (12), 126.3 (3), 126.7 (2), 127.8 (9b), 131.1 (4), 131.7 (1), 133.3
(3’), 135.3 (13a), 136.4 (14a), 137.8 (4a), 141.8 (15a). GC-MS: m/z:
330 (13%), 272 (22%), 258 (37%), 244 (39%), 230 (100%), 217 (60%),
202 (14%), 182 (13%), 167 (35%), 156 (17%), 144 (19%), 130 (29%),
115 (82%), 103 (34%), 91 (43%), 77 (67%), 63 (30%). Anal. calcd.
for C23H26N2  0.25EtOAc: C, 81.78%; H, 8.01%; N, 7.95%. Found:
C, 81.44%; H, 8.26%; N, 8.01%.
7-Methyl-14-prop-2-ynyl-6,7,8,9,14,15-hexahydro-5H-
indolo[3,2-f][3]benzazecine hydrochloride (11)
The base was purified by column chromatography (DCM/MeOH,
20:1), to separate the product from the unreacted starting
material. The obtained product was converted to the HCl salt,
and crystallized twice from methanol/ether yielding a white
solid. Yield 11%. M.p. 171–1748C. 1H-NMR 250 MHz (MeOD): d
2.58–2.60 (t, 1H, 3’), 2.89 (s, 3H, N-Me), 2.91–2.98 (t, J ¼ 8, 2H, 5),
3.30–3.35 and 3.54–3.65 (m, 6H, 6, 8, 9), 4.52 (s, 2H, 1’), 4.86 (s, 2H,
15, under MeOD), 7.03–7.30 (m, 7H, Ar), 7.50–7.53 (dd, J ¼ 8/1,
1H, Ar). 13C-NMR 250 MHz (MeOD): 18.3 (9), 28.1 (5), 30.1 (15), 32.2
(1’), 43.6 (N-Me), 52.8 (8), 56.5 (6), 72.2 (3’), 77.8 (2’), 109.2 (13),
109.6 (9a), 117.7 (10), 119.8(11), 122.0 (12), 126.9 (3), 127.6 (2),
127.9 (9b), 131.8 (4), 131.4 (1), 133.4 (13a), 135.4 (14a), 135.8 (4a),
136.8 (15a). Anal. calcd. for C23H24N2  HCl  0.25 H2O: C, 74.78%;




Purified by column chromatography (EtOAc/MeOH, 16:5), yield-
ing a brown oil, which solidifies to a yellowish brown solid on
standing. Yield 63%. M.p. 99–1008C. 1H-NMR 250 MHz (CDCl3): d
2.28 (s, 3H, N-Me), 2.40–2.44 (t, J ¼ 6, 2H, 5), 2.62–2.73 (m, 9H, 6, 8,
9, COMe), 4.75 (s, 2H, 15), 7.00–7.46 (m, 7H, Ar), 7.78–7.81 (dd,
J ¼ 8/2, 1H, Ar). 13C-NMR 250 MHz (CDCl3): 23.9 (9), 27.6 (COMe)
33.6 (5), 33.7 (15), 45.8 (N-Me), 58.3 (8), 60.5 (6), 114.3 (13), 118.3
(10), 121.2 (9a), 122.6 (11), 123.8 (12), 126.1 (3), 126.5 (2), 130.3
(9b), 131.1 (4), 131.7 (1), 135.9 (13a), 136.9 (14a), 138.1 (4a), 141.4
(15a), 170.5 (CO). GC-MS: m/z: 332 (12%), 289 (11%), 246 (39%), 230
(199%), 217 (91%), 202 (14%), 170 (16%), 160 (74%), 144 (31%), 130
(42%), 115 (56%), 103 (21%), 91 (24%), 77 (41%), 63(22%). Anal.
calcd. for C22H24N2O  0.25 EtOAc: C, 77.93%; H, 7.39%; N, 7.90%.
Found: C, 77.98%; H, 7.49%; N, 7.95%.
7-Methyl-14-(3-phenylpropyl)-6,7,8,9,14,15-hexahydro-
5H-indolo[3,2-f][3]benzazecine (13)
The base was converted to the HCl salt, and the aqueous solution
was washed twice with EtOAc. The aqueous solution was then
alkalinized, and the formed base was extracted with chloroform.
Evaporation of the solvent gave a brown oil that did not crystal-
lize. Yield 57%. 1H-NMR 250 MHz (CDCl3): d 1.70–1.81 (q, J ¼ 8,
2H, indole N-CH2 CH2CH2Ph), 2.35 (s, 3H, N-Me), 2.38–2.52 (m, 4H,
5, indole N-CH2CH2 CH2Ph), 2.68–2.76 (m, 6H, 6, 8, 9), 3.95–4.02 (t,
J ¼ 8, 2H, indole N-CH2CH2CH2Ph), 4.53 (s, 2H, 15), 7.03–7.32 (m,
12H, Ar), 7.50–7.53 (d, J ¼ 7, 1H, Ar). GC-MS: m/z: 408 (3%), 244
(4%) 230 (8%), 217 (6%), 143 (9%), 128 (7%), 117 (17%), 104 (13%), 91
(100%), 77 (23%), 65 (22%). Anal. calcd. for C29H32N2  0.75 H2O):




Purified by column chromatography (DCM/MeOH, 9.5:0.5), yield-
ing creamy white oil. Yield 41%. 1H-NMR 250 MHz (CDCl3): d
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0.81–0.87 (t, J ¼ 7, 3H, 5’), 1.41–1.49 (m, 6H, 2’– 4’), 2.37 (s, 3H, N-
Me), 2.44–2.48 (t, J ¼ 6, 2H, 5), 2.72–2.77 (m, 6H, 6, 8, 9), 3.92–3.99
(t, J ¼ 8, 2H, 1’), 4.56 (s, 2H, 15), 7.03–7.33 (m, 7H, Ar), 7.50–7.53
(d, J ¼ 8, 1H, Ar). 13C-NMR 250 MHz (CDCl3): 13.9 (5’), 22.4 (4’),
23.2 (9), 29.1 (3’), 29.6 (2’), 32.8 (5), 33.1 (15), 43.8 (1’), 45.2 (N-
Me), 58.9 (8), 59.6 (6), 109.0 (13), 112.7 (9a), 117.8 (10), 118.5
(11), 120.6 (12), 126.3 (3), 126.7 (2), 127.7 (9b), 131.0 (4), 131.7
(1), 135.1 (13a), 136.1 (14a), 138.0 (4a), 142.0 (15a). GC-MS: m/z:
360 (13%), 302 (10%), 288 (22%), 255 (50%), 244 (32%), 230
(100%), 217 (69%), 202 (19%), 160 (22%), 144 (48%), 130
(63%), 115 (90%), 105 (40%), 91 (47%), 71 (47%). Anal. calcd.
for C25H32N2  HCl  0.75 H2O: C, 73.15%; H, 8.47%; N, 6.82%.
Found: C, 72.90%; H, 8.74%; N, 6.64%.
7-Methyl-14-octyl-6,7,8,9,14,15-hexahydro-5H-indolo-
[3,2-f][3]benzazecine (15)
Evaporation of the solvent gave a white oily substance, which
did not crystallize. Yield 81%. 1H-NMR 400 MHz (CDCl3): d 0.90–
0.94 (t, J ¼ 7, 3H, 8’), 1.20–1.45 (m, 12 H, 2’–7’), 2.40 (s, 3H, N-Me),
2.45–2.48 (t, J ¼ 6, 2H, 5), 2.70–2.73 (t, J ¼ 6, 2H, 9), 2.76–2.81
(m, 4H, 6, 8), 3.56 (s, 2H, 1’), 4.58 (s, 2H, 15), 7.05–7.21 (m, 5H, Ar),
7.26–7.28 (d, J ¼ 8, 1H, Ar), 7.31–7.33 (dd, J ¼ 8/2, 1H, Ar), 7.51–
7.53 (d, J ¼ 8, 1H, Ar). 13C-NMR 400 MHz (CDCl3): 14.1 (8’), 22.6
(7’), 23.4 (9), 27.0 (3’), 29.2 (5’), 29.3 (2’), 30.0 (4’), 31.8 (6’), 32.9 (5),
33.4 (15), 43.8 (1’), 45.3 (N-Me), 59.1 (8), 59.6 (6), 109.0 (13), 112.7
(9a), 117.8 (10), 118.5 (11), 120.6 (12), 126.3 (3), 126.7 (2), 127.8
(9b), 131.0 (4), 131.7 (1), 135.2 (13a), 136.1 (14a), 138.1 (4a), 142.3
(15a). GC-MS: m/z: 402 (23%), 344 (14%), 297 (28%), 260 (9%), 246
(38%), 230 (73%), 217 (37%), 200 (6%), 171 (7%), 158 (26%), 144
(33%), 129 (30%), 115 (64%), 104 (41%), 91 (32%), 77 (100%). Anal.
calcd. for C28H38N2: C, 83.53%, H, 9.51%, N, 6.96%. Found: C,
83.38%, H, 9.18%, N, 6.46%.
Pharmacology
Radioligand binding assay
The binding studies were performed following the protocol
previously described but in 96-well format [3]. The assays,
using the whole-cell-suspension, were carried out in tripli-
cate in a volume of 550 mL (final concentration): TRIS-Mg2þ-
buffer (345 mL), [3H]-ligand (50 mL), whole-cell-suspension
(100 mL) and appropriate drugs (55 mL). Non-specific binding
was determined using fluphenazine (100 mM) for D1- and
D5-tests and haloperidol (10 mM) for D2-, D3-, and D4-tests.
The incubation was initiated by addition of the
radioligand and was carried out in 96 deep well plates
(Greiner bio-one, Frickenhausen) using a thermocycler
(Thermocycler comfort1, Eppendorf, Wessling) at 278C.
The incubation was terminated after 90 min by rapid filtra-
tion with a PerkinElmer Mach III HarvesterTM using a
PerkinElmer Filtermat A, previously treated with a 0.25%
polyethyleneimine-solution (Sigma-Aldrich) and washed
with water. The filtermat was dried for 3 min at 400 W
using a microwave oven (MW 21, Clatronic, Kempen). The
dry filtermat was placed on a filter plate (Omni filter
platesTM, PerkinElmer Life Sciences) and each field of the
filtermat was moistened with 50 mL Microscint 20TM scin-
tillation cocktail. The radioactivity retained on the filters
was counted using a Top Count NXTTM microplate scintil-
lation counter (Packard, Ct., USA). For the determination of
the Ki-values at least two independent experiments each in
triplicate were performed.
The competition binding data were analyzed with
GraphPad PrismTM software using nonlinear regression with
sigmoidal dose response equation. Microsoft ExcelTM was
used to calculate the mean and the standard error of the
mean. Ki-values were calculated from IC50-values applying the
equation of Cheng and Prusoff [14].
Functional assay
Measuring intracellular Ca2þ with a fluorescence microplate
reader [3, 10]. Human D1- and D2L-receptors were stably
expressed in human embryonic kidney cells (HEK293) and
cultured as mentioned above. Human D1- and D2L-receptor
cell lines were grown on T 175-culture dishes (Greiner bio-
one, Frickenhausen) to 85–90% confluence. The medium was
removed via a suction apparatus and the cells were rinsed
twice with 6 mL Krebs-HEPES buffer (118 mM NaCl, 4.7 mM
KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 4.2 mM NaHCO3,
11.7 mM D-Glucose, 1.3 mM CaCl2, 10 mM HEPES, pH 7.4).
After these two washes, cells were loaded with 3 mL of a 0.5 M
Oregon GreenTM 488 BAPTA-1/AM-solution (Molecular
Probes, Eugene, OR) (in DMSO) in 6 mL Krebs-HEPES buffer
containing 3 mL of a 20% pluronic F-127-solution (Sigma
Aldrich) (in DMSO) for 45 min at 378C. After 35 min
incubation, the culture dish was rapped slightly in order
to remove all cells from the dish for further incubation.
To this cell suspension 5 mL Krebs-HEPES buffer were
added again to rinse all cells from the plate. The resulting
suspension was portioned into ten 1.5 mL Eppendorf
caps and centrifuged at 10640 RCF for 10 s. The supernatant
buffer was removed and the resulting ten pellets were
divided into two portions à 5 pellets, each portion was
suspended in 1 mL Krebs-HEPES buffer. The two suspensions
were centrifuged again for 10 s. After removing the
buffer, the two pellets were combined and re-suspended
in 1 mL buffer, diluted with 17 mL Krebs-HEPES buffer
and plated into 96-well plates (OptiPlate HTRF-96TM,
Packard, Meriden, CT; Cellstar, Tissue Culture Plate, 96W,
Greiner bio-one, Frickenhausen). The microplates were kept
at 378C under an atmosphere containing 5% CO2 for 30 min
before they were used for the assay.
Screening for agonistic and antagonistic activity was
performed using a NOVOstar microplate readerTM (BMG
LabTechnologies) with a pipettor system. Agonistic
activities were tested by injecting 20 mL buffer alone as
negative control, standard agonist in buffer as positive
control, and rising concentrations of the test compounds
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in buffer, each into separate wells. Fluorescence measure-
ment started simultaneously with the automatic injection.
SKF 38393 was used as standard agonist for D1-receptors
and quinpirole for D2-receptors (final concentration: 1 mM).
Screening for antagonistic activities was performed by
pre-incubating the cells with 20 mL of the test compound
dilutions (final concentrations: 100 mM, 50 mM, 10 mM, 5 mM,
1 mM, 500 nM, 100 nM, 50 nM, 10 nM, 1 nM, 0,1 nM) at 378C
30 min prior to injection of 20 mL standard agonist per well.
As standard agonists, we used as described for the agonist
screening SKF38393 for D1- and quinpirole for D2-receptors,
respectively. Fluorescence measurement also started simul-
taneously with the automatic injection. At least two inde-
pendent experiments, each carried out in four or six
replications, were performed.
MTT-test
U87-MG glia cells (ATCC HTB-14) were cultured at 378C, and
5% CO2 in DMEM (PAA, E15-883) þ 10% FCS (Thermo
Scientific HyClone). In 96-well plates 15 000 cells were dis-
persed in 200 mL into each well. After 24 h the medium was
replaced by DMEM þ FCS containing the test compound
dissolved in finally 0.25% DMSO. To minimize edge-effects
as mentioned by Rasmussen [15] each concentration of the
compound was measured in 6 wells distributed across the 96-
well plate and only the inner 6  10 wells of the plate were
analyzed. The outer wells were filled with 200 mL PBS-buffer.
As positive control, 6 wells with cells andmedium containing
0.25% DMSO were analyzed. After 24 h of incubation, the
medium was removed and 100 mL MTT (Fluka), dissolved in
phenol red-free DMEM (without FCS) at 0.5 mg/mL, were
added to each well. The plates were incubated for 4 h.
Cells were killed and formazan crystals were solubilized by
addition of 100 mL of 20% sodium dodecylsulfate (SDS)
in H2O followed by incubation overnight at 378C. Optical
density was measured at 544 nM using a microplate reader
(Galaxy FluoStar, BMG Labtechnologies) with background
substraction (compounds in the same preparation without
cells). Cytotoxicity values were calculated as percentage of
positive control (¼ 100%). Cc50-values were calculated with
Graph Pad Prism TM 3.0. All experiments were repeated at
least three times.
We thank Bärbel Schmalwasser, Petra Wiecha, and Heidi Traber for skillful
technical assistance in performing the pharmacological assays. Dina
Robaa thanks the Egyptian Cultural Affairs and Mission Section for her
stipend. Furthermore we would like to thank the DFG for the financial
support of the project (EN 875/1-1). Robert Kretschmer thanks the Hans-
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Abstract. Serotonin and dopamine play an important role in the aetiology of schizophrenia. Combination of the 
structural scaffolds of both neurotransmitters in a single molecule led to aromatic annelated [d,g]azecines, which 
showed to be nanomolar to subnanomolar dopamine D1-D5 receptor antagonists. In this work the potential 
antipsychotic activity of some azecine derivatives was characterized by radioligand binding experiments and 
conclusively confirmed in vivo (rats) by applying a conditioned avoidance model. Furthermore, the compounds 
were tested in vivo for the development of catalepsy, which is considered to be improved by 5-HT2A antagonism 
and which is a predictive parameter for extra-pyramidal side-effects caused by many antipsychotics. The 
investigated azecines displayed low cytotoxicity and affinities at human dopamine D1-D5 and serotonin 5-HT2A 
receptors in a nanomolar range. Their antipsychotic activities in the rat model were comparable with those of 
haloperidol and risperidone, but revealed a two to five times better therapeutic range with regard to catalepsy. 
Preliminary tests for oral bioavailability also revealed promising results for this new class of potential antipsychotic 
compounds. In conclusion, aromatic annelated [d,g]azecines represent a novel class of substances with 
interesting qualities as potential atypical antipsychotics. 
1. Introduction   
Due to a lack of efficacy and severe side-effects of 
the commonly used drugs, the treatment of 
schizophrenia is still a problem. In the last decades, 
the focus of scientific research on antipsychotic drugs 
moved step by step towards the use of non-selective 
compounds with both dopamine and serotonin 
receptor affinities. Classical antipsychotics are 
predominantly dopamine D2 receptor antagonists. 
They are very potent in treating positive symptoms, 
which are mainly caused by dopamine hyperfunction 
in the mesolimbic system. On the other hand, these 
drugs are not very useful to treat the negative 
symptoms and often produce intolerable extra-
pyramidal side-effects, which are both, at least 
partially, caused by a dopamine hypofunction in some 
brain regions (Knable et al., 1997; Abi-Dargham and 
Laruelle, 2005). With the development of atypical 
antipsychotics, the hypotheses of an influence of 
serotonin on schizophrenia arose (Moller, 1999). It is 
not clarified yet, what influence serotonin has on the 
symptoms. One main hypothesis is an indirect 
connection of serotonin 2A receptor (5-HT2A) 
antagonism on dopamine release in the mesocortex, 
which acts beneficially on the negative symptoms but 
may also affect extra-pyramidal side-effects caused 
by dopamine D2 antagonists (Ichikawa and Meltzer, 
1999).  
This hypothesis is encouraged by the benefit of 5-
HT2A antagonists in in vivo studies (Meltzer et al., 
1989; Kehne et al., 1996; Kleven et al., 1996; 
Prinssen et al., 2002).  
 
Figure 1 Lead structure development starting from the structural scaffolds of dopamine and serotonin. 
We have been interested to combine the basic 
structures of both neurotransmitters into a single 
molecule, hopefully achieving simultaneously high 
affinities for both, dopamine and serotonin receptors 
and thus go for new potential antipsychotic drugs with 
better therapeutic indices concerning positive 
symptoms and extra-pyramidal side-effects. 
Furthermore a beneficial influence on negative 
symptoms was supposed to be achieved.  
LE300 (compound 1), a benzindoloazecine (Figure 
1), has been previously  identified by us as a highly 
active dopamine receptor antagonist (nanomolar to 
subnanomolar Ki-values), whereas compounds 2 and 
3 showed no affinities for dopamine receptors up to 
10µM (Witt et al., 2000). Lead structure optimization 
of aromatic annelated azecines revealed as most 
favourable structural features an indole or 3-
substituted benzene as one of the aromatic moieties 
and a methyl function at the basic nitrogen (Witt et al., 
2000; Kassack et al., 2002; Mohr et al., 2006). Based 
on this we selected four azecine derivatives for further 
investigations (Figure 2). 
 
Figure 2 Compounds used in this study for in vivo 
investigations.  
In this present study we determined the affinities of 
the selected azecines not only for the dopamine D1-
D5 but also for the for serotonin 5-HT2A receptors and, 
with regard to in vivo application, tested their toxicity 
on cultured human glia cells. Based on the in vitro 
results we performed in vivo tests using rats with the 
above mentioned compounds LE300, LE300ME, 
LE404 and LE425 (Figure 2). It was examined, 
whether the high in vitro binding affinities of the 
azecines at the different dopamine and serotonin 
receptors result in high potencies in an animal model 
for positive symptoms. For this purpose, inhibition of 
conditioned avoidance response (CAR) was used, 
which is considered a reliable test system for the 
identification of potential neuroleptics (Arnt, 1982; 
Wadenberg and Hicks, 1999). Catalepsy tests in rats 
were performed in order to measure the influence of 
the in vitro determined 5-HT2A receptor affinities on 
extra-pyramidal side-effects in vivo, caused by 
dopamine D2 antagonism. In general, we wanted to 
estimate in vivo, whether the molecular combination 
of dopamine and serotonin scaffolds might yield in 
new and more advantageous antipsychotic drugs.  
2. Materials and methods 
2.1.  Substances 
Haloperidol (Sigma-Aldrich, Germany), Risperidone 
(Promochem, Germany), LE404 (7-methyl-
5,6,7,8,9,14-hexahydrodibenzo[d,g]azecine-3-ol) 
(Hoefgen et al., 2006), LE425 (3-methoxy-7-methyl-
5,6,7,8,9,14-hexahydrodibenzo[d,g]azecine) (Hoefgen 
et al., 2006), LE300 (7-methyl-6,7,8,9,14,15-
hexahydro-5H-indolo[3,2-f][3]benz-azecine) (Witt et 
al., 2000) were available in the lab from previous 
work.  
LE300ME (7,14-Dimethyl-6,7,8,9,14,15-hexahydro-
5H-indolo[3,2-f][3]benzazecine) is a new compound, 
prepared from 5,6,8,9,14,14b-hexahydroindolo-
[2’,3’,3,4]pyrido[2,1-a]isoquinoline (Robaa et al., 
2011). Chemical characterisation of this new 
substance is given in the supporting information.  
2.2. In vitro tests 
2.2.1. Radioligand binding and functional 
calcium assay 
Radioligand binding experiments and a functional 
calcium assay were performed as described 
previously (Schulze et al., 2009). In addition to the 
human dopamine receptor subtypes D1, D2L, D3, D4.4 
and D5 we established a radioligand binding assay for 
human cloned 5-HT2A receptors. Human 5-HT2A, D1, 
D2L, D3, and D5 receptors were stably expressed in 
human embryonic kidney cells (HEK293) and D4.4 
receptors in chinese hamster ovary cells (CHO), 
respectively. A serotonin 5-HT2A expressing cell line 
(HEK293) was kindly provided by M. U. Kassack 
(University of Düsseldorf, Germany). 
Cell culture 
Cells were grown at 37°C under an atmosphere of 5% 
CO2: 95% air in HAM/F12-medium (Sigma-Aldrich, 
Germany) for CHO cells and Dulbecco’s Modified 
Eagles Medium Nutrient Mixture F-12 Ham (Sigma-
Aldrich, Germany) for HEK293 cells, each 
supplemented with 10% foetal bovine serum, 1mM L-
glutamine and 0.2 µg/mL of G 418 (all from Sigma-
Aldrich, Germany). 
Radioligand binding experiments 
Radioligand binding studies were performed using a 
whole cell suspension in tris-HCl buffer (pH 7.4). 
[3H]SCH23390 (Amersham, UK), was used as 
radioligand for the D1 and D5 receptor binding 
experiments, and [3H]spiperone (Amersham, UK) for 
5-HT2A, D2L, D3 and D4.4 receptors. Non-specific 
binding was determined using fluphenazine (Sigma-
Aldrich, Germany) (100 µM) for D1, D5 and 5-HT2A 
receptors and haloperidol (Sigma-Aldrich, Germany) 
(10 µM) for D2L, D3, and D4.4 experiments. The test 
compound (dilutions for final concentrations between 
100 µM and 1 pM) and the radioligand were added to 
the cell suspension and the mixture was incubated at 
27 °C for 90 min using a thermocycler (Thermocycler 
comfort®, Eppendorf, Germany). Experiments were 
carried out in 96 well format (Greiner bio-one, 
Germany) in a final volume of 550 µL per well. For 
determining the Ki values, at least two independent 
experiments each in triplicate were performed. The 
competition binding data were analyzed with Graph 
Pad PrismTM 3.0 software using nonlinear regression 
with sigmoidal dose response equation. Ki values 
were calculated applying the equation of Cheng and 
Prusoff (1973). 
Functional calcium assay 
Screening for agonistic and antagonist activity was 
performed in an intracellular calcium assay using a 
NOVOstar microplate readerTM (BMG Lab 
Technologies, Germany) with a pipettor system. 
Agonistic activities were tested by injecting 20 µL 
buffer alone as negative control, standard agonist in 
buffer as positive control (final concentration: 1 µM), 
and test compounds in buffer in rising concentrations, 
respectively, each into separate wells. Screening for 
antagonist activities was performed by pre-incubating 
the cells with 20 µL of the test compound dilutions 
(final concentrations: 100 µM, 50 µM, 10 µM, 5 µM, 1 
µM, 500 nM, 100 nM, 50 nM, 10 nM, 1 nM, 0.1 nM) at 
37°C 30 min prior to injection of 20 µL standard 
agonist per well. Fluorescence measurement started 
simultaneously to the automatic injection. SKF38393 
(Sigma-Aldrich, Germany) was used as standard 
agonist for D1 and D5 receptors and quinpirole 
(Sigma-Aldrich, Germany) for D2L receptors. At least 
two independent experiments, each in four or six 
replications, were performed. Fluorescence intensity 
was measured at 520 nM (bandwidth 25 nM) for 30 s 
at 0.4 s intervals. Excitation wavelength was 485 nM 
(bandwidth 20 nM). Agonistic or antagonist activities 
were assessed by a dose response curve, obtained 
by determination of the maximum fluorescence 
intensity of each data set and nonlinear regression 
with sigmoidal dose response equation using Graph 
Pad Prism TM 3.0. 
2.2.2. Cytotoxicity - MTT-test 
U87-MG glia cells (HTB-14; ATCC, USA) were 
cultured at 37 °C, and 5% CO2 in Dulbecco’s Modified 
Eagles Medium (DMEM) (PAA, Austria) + 10% Foetal 
calf serum (FCS) (Thermo Scientific HyClone, UK). In 
96 well plates 15,000 cells were dispersed in 200 µL 
into each well. After 24 hours the medium was 
replaced by DMEM + FCS containing the test 
compound solved in 0.25% DMSO (final 
concentration). To minimize edge-effects as 
mentioned by Rasmussen (2002), each concentration 
of each compound was measured in 6 wells 
distributed across the 96 well plate and only the inner 
6x10 wells of the plate were analyzed. The outer 
wells were filled with 200 µL PBS-buffer. As positive 
control, 6 wells with cells and medium containing 
0.25% DMSO were analyzed. After 24 hours of 
incubation, the medium was removed and 100 µL 
MTT (Fluka, Germany), dissolved in phenol red-free 
DMEM (without FCS) at 0.5 mg/mL, were added to 
each well. The plates were incubated for 4 hours. By 
addition of 100 µL of 20% sodium dodecyl 
sulphate (SDS), followed by incubation overnight at 
37°C, all cells were killed and formazan crystals were 
solubilised. Optical density was measured at 544 nM 
using a microplate reader (Galaxy FluoStar, BMG Lab 
technologies) with background subtraction 
(compounds in the same preparation without cells). 
Cytotoxicity values were calculated as percentage of 
positive control (= 100%). CC50 values (EC50 
equivalents of cytotoxicity) were determined with 
Graph Pad Prism TM 3.0. All experiments were 
repeated at least three times independently. 
2.3. In vivo tests 
2.3.1. Animals 
Female Han-Wistar rats, aged 8 weeks and weighing 
between 120 and 160 g at the beginning of the 
experiments, were used for the pole jump 
experiments and the locomotor activity tests. For the 
catalepsy test rats aged 4-8 months were used, 
weighing between 200 and 280 g. Animals were kept 
under controlled laboratory conditions (dark-light 
cycle 12:12 h, temperature 23±2°C, air humidity 55-
60%). They were housed in groups of four animals 
with free access to commercial food (Altromin 1326®, 
Altromin Lage, Germany) and tap water. The 
permission of the animal protection commission of the 
State of Thuringia was given. 
2.3.2. Administration of Substances 
Haloperidol, LE404, LE425, LE300 and LE300ME 
were converted into hydrochlorides and dissolved in 
isotonic saline solution. Risperidone was used as 
free base, dissolved in isotonic saline solution with 
two drops of Tween 80. The pH was adjusted to 5 - 7.  
In all experiments, except the oral bioavailability tests, 
1 mL/100 g-1 body weight was injected intra-
peritoneally. Pre-treatment time for haloperidol and 
the new test compounds LE400, LE425, LE300 and 
LE300ME was 30 min. According to literature pre-
treatment time for risperidone was 60 min for the 
pole jump experiment (Becker and Grecksch, 2008). 
The control groups received saline solution only.  
For oral bioavailability, examined in the pole jump 
test, LE404 and LE300ME were administered by oral 
gavage. Four rats were treated with 2.5 mg/kg body 
weight of the substances, dissolved in saline solution 
(0.5 mL/200 g body weight). Further investigations on 
LE404 were performed on 13 animals (5 mg/kg on 8 
rats, 20 mg/kg on 5 rats).  
2.3.3. Testing 
After a short handling period in which the rats were in 
close contact with the laboratory staff, at an age of 30 
days, all rats were habituated to the experimental 
equipment and the operator 10 min per day over 10 
days. Trainings and experiments were performed 
between 7:00 a.m. and 3:00 p.m.  
2.3.3.1. Locomotor activity 
Horizontal and vertical movements of the rats (n=8 
per dose) were observed in an open field box (50 cm 
x 50 cm x 50 cm) over 5 min. The bottom of the box 
was divided into 25 equal quarters. Rats were placed 
in the middle of the box. Line crossing, rearing on the 
edge /in the middle, grooming and defecation was 
counted individually over the whole time. The 
illumination in the test room was stable at 30 lx. The 
open field box was cleaned with Descosept AF 
(Schumacher, Melsungen, Germany) and wiped after 
each test. Dose response curves were generated with 
Graph Pad PrismTM 3.0. 
2.3.3.2. Catalepsy 
Catalepsy was measured in two different test 
systems: the cross-leg-position test (CLP) and the bar 
test (Kleven et al., 1996) with 7 rats per dose. In the 
bar test, 30 and 90 min after drug administration, 
animals were placed with their forepaws on a wooden 
bar, which was 10 cm high. The time was measured, 
during which the rat remained in this position. 
Immediately after the bar test, the rats were exposed 
to the CLP test, where one of the hind limbs was 
placed over the forepaw and time was measured 
during which the rat remained immobile. Rats, which 
stayed in the awkward position longer than 90 s were 
estimated as cataleptic. Dose response curves and 
ED50 values could be obtained by plotting the amount 
of cataleptic rats against the individual dose by Graph 
Pad PrismTM 3.0.  
2.3.3.3. Pole Jump 
Rats were entrained daily to jump onto a pole when a 
white noise signal (1000 Hz, 50 dB, conditioned 
stimulus, CS) was presented, in order to avoid an 
electric foot–shock (0.2 mA, unconditioned stimulus, 
UCS), which was given additionally to the noise after 
4 s. Maximum trial duration was 20 s. Animals were 
exposed to 10 trials every day until they showed 
stable conditioned avoidance response (CAR). Stable 
CAR was defined by at least eight out of ten jumps 
within 4s after presentation of the white noise. Only 
rats with at least 6 days of training and a stable CAR 
over the last two days were used for the experiments. 
Rats were applied to the experiment with different 
concentrations of one substance in randomized order. 
Between the experiments each rat had a seven day 
wash out period including training every day. 
Drug tests consisted of three steps according to 
literature (Becker and Grecksch, 2008). First, the 
stable CAR of each rat was verified within 5 trials with 
conditioned and unconditioned stimulus as described 
above. Only rats which jumped in four out of five trials 
within 4 s (stable CAR) were used for the further 
experiment.  
After administration of the test compounds and 
keeping the pre-treatment time, the animals were 
exposed to the pole jump apparatus again. Within 10 
trials only the CS, but not the electric foot-shock 
(UCS) was presented and the time was measured 
until the rat jumped onto the pole. Each trial was 
stopped after 20 s. A predefined interval of 30 to 90 s 
(mean intertrial interval 60 s) was kept between each 
trial. A reduced CAR in this experiment is considered 
as antipsychotic activity of the administered drug. 
Reaction times were integrated over time. 
Determination of the area under the curve (AUC) 
values was performed by Graph Pad PrismTM 3.0. Out 
of these AUC values for each rat, a dose response 
curve could be obtained and ED50 values determined.  
Immediately after the 10 trials only with CS, five trials 
were performed where the CS-UCS combination was 
used again. Time was measured until the rats jumped 
onto the pole. This step should differentiate between 
the inhibition of CAR as known for antipsychotic drugs 
and unspecific motor impairments caused by the 
administered drugs. Based on reaction times the 
percentage of conditioned avoidance reaction, 
avoidance reaction and non–reaction was 
determined. 
2.4. Statistics 
All in vitro experiments were at least performed twice 
independently. The outlined results are mean values 
± SEM (SD for MTT test), calculated by Microsoft 
Office Excel® 2007. In vivo results were analysed by 
SPSS Statistics® 17.0. Locomotor activity 
measurements were subjected to ANOVA followed by 
post hoc analyses using the Bonferroni test. 
Catalepsy was analysed based on the times the rats 
remained in the awkward position by ANOVA. CAR 
times in the pole jump test could not be examined by 
ANOVA, since the test was stopped at 20 s and there 
was no normal distribution between the measured 
times. Hence, nonparametric tests were performed. 
The significance over all experiments was determined 
by a Kruskal-Wallis-H test and the differences 
between the different doses to saline solution were 
examined by Mann-Whitney-U tests, followed by 
Bonferroni-Holm correction. Significance between 
occurrences of non-reactions at different doses was 
calculated by χ2- and two-sided Fisher test. 
Correlations were calculated according to Pearson 
with two-sided significance. All values were converted 
into mol units, calculated for the free base. 
Significance was set at p<0.05. 
3. Results 
3.1. In vitro tests 
Affinities (Ki values) of the azecines LE404, LE435, 
LE300 and LE300ME for dopamine and 5-HT2A 
receptors obtained by radioligand binding 
experiments are presented in Table 1. For all test 
compounds Ki values were in the nanomolar or 
subnanomolar range. Conduction of a functional 
calcium assay revealed, that all compounds act as 
antagonists at D1, D2 and D5 receptors. 
In general, cytotoxicity of test compounds was 
examined by using an MTT-test on the human glia 
cell line U87. Incubation of compounds LE404, LE425 
and LE300 with U87 cells did not reveal any 
cytotoxicity up to 250 µM (Table 2). For compound 
LE300ME a weak cytotoxicity was determined 
(CC50=140 µM). Hence, an efficacy/ safety ratio of 
1000 was given for all drugs used in the in vivo 
experiments.  
Table 1 Affinities for dopamine D1 – D5 and serotonin 5-HT2A receptors in radioligand binding experiments  
 Ki [nM] ± SEM 
Substance D1 D2 D3 D4 D5 5-HT2A 
LE425 28.5±5.2a 13.0±9.0a 75.7±7.3b 43.4±13.3a 54±20.5d 4.42±1.27 
LE300 1.9±0.5c 44.7±15.8c 40.4±14.5d 74.9±50d 7.5±0.4c 0.13±0.01 
LE404 0.39±0.16a 17.5±1.5a 47.5±16b 7.6±3.7a 1.5±0.5a 0.67±0.04 
LE300ME 2.0±0.5 8.2±5.8 7.2±2.8 13.2±2.9 0.5±0.1 0.36 
Risperidone 104±43e 4.8±1.3e 13.6±0.47e 12.1±5.0e 563e 0.18±0.02e 
Haloperidol 3.4±1.8 0.28±0.26 0.18±0.03 3.5±0.89 4.2±0.3 103±21 
adata taken from Hoefgen et al. (2006); bdata taken from Mohr et al. (2006); cdata taken from Kassack et al. (2002); ddata 
taken from Enzensberger et al. (2007); edata from  PDSP database (National_Institute_of_Mental_Health, 2010)  
 
Table 2 Cell viability ± SD after drug administration (100 µM) 
and calculated CC50 values (EC50 equivalent of cytotoxicity) 
tested on the human glia cell line U87 
substance Viability at 100 µM [%] CC50 [µM] 
LE425 118.7±4.8 >250µM 
LE300 128.0±7.3 >250µM 
LE404 120.7±0.5 >250µM 
LE300ME 74.0±17.6 139.6±22.7 
3.2. In vivo tests 
3.2.1. Locomotor activity 
Rats were exposed to an open field box 30 and 90 
min after drug administration in order to observe 
changes in behaviour as a result of drug action. Line 
crossing (horizontal movement), rearing, grooming 
and defecation were analyzed separately. Grooming 
and defecation did not change significantly after drug 
administration. Horizontal and vertical movements 
revealed parallel dose response curves. Therefore, 
locomotor activities were measured as sum of both, 
crossing lines and rearing. Comparing the 
observations 30 and 90 min after drug administration, 
haloperidol (0.1, 0.2, 0.4 mg/kg), risperidone 
(0.125, 0.4, 0.5 mg/kg), LE425 (2.0, 5.0, 10.0 mg/kg), 
LE300 (1.0, 2.0, 5.0 mg/kg) and LE300ME (1.0, 2.0, 
5.0 mg/kg) revealed no significant difference between 
both measurements (p>0.05). For LE404 (0.5, 1.0, 
2.0 mg/kg), the effects on locomotor activity seen 30 
min after drug administration were significantly 
reduced for all doses (p<0.005) after 90 min. 
Haloperidol (F3,28=29.21, p<0.001), risperidone 
(F3,28=17.96, p<0.001), LE425 (F3,28=31.81, p<0.001), 
LE300 (F3,28=22.21, p<0.001), LE404 (F3,28=49.43, 
p<0.001) caused reduced locomotor activity at all 
investigated doses compared to the control group. 
LE300ME caused a significant decrease in locomotor 
activity at doses above 1 mg/kg (F2,21=40.05, 
p<0.001). ED50 values and 95% confidence intervals 
are outlined in Table 3. A figure containing the results 
of the test after 30 min is provided in the supporting 
information. 
3.2.2. Pole Jump 
Prior to drug testing, all rats were examined 
on stable conditioned avoidance response (CAR). 
Only rats which jumped onto the pole within 4 s in 
four out of five times were used for testing. There 
were no significant differences in reaction times 
(p>0.05) between the animals used in the 
experiments. The results for both parts of the 
experiment (without and with current) are presented 
graphically for each drug in the supporting 
information. ED50 values and 95% confidence 
intervals are outlined in Table 4. For easier 
understanding, the part without electric foot-shock will 
in the following be termed as “part A”, and the one 
with foot-shock will be named “part B”.  
Haloperidol 
Haloperidol was investigated over five doses in a 
range from 0.05 to 0.4 mg/kg body weight. The 
Kruskal-Wallis-H test revealed a significant inhibition 
of CAR (p<0.001) of the haloperidol treated animals 
compared to the saline injected group. Undertaking a 
Mann-Whitney-U test, followed by a Bonferroni-Holm 
correction for each dose, we identified 0.1, 0.15, 0.2 
and 0.4 mg/kg as effective doses (p<0.005), whereas 
0.05 mg/kg had no effect (p>0.05).  
Table 3 ED50 values and 95% confidence intervals (CI) of 
locomotor activity (vertical and horizontal movement)  
Substance 
Locomotor activity 
ED50 [mg/kg] 95% CI 
Risperidone 0.30 0.24 – 0.38 
Haloperidol 0.10 0.04 – 0.25 
LE425 2.09 1.21 – 3.61 
LE404 0.41 0.34 – 0.64 
LE300 0.74 0.58 – 0.93 
LE300ME 1.72 1.22 – 2.41 
Part B was conducted in order to investigate an 
unspecific impairment of the rats to undertake CAR. 
At 0.05, 0.1 and 0.15 mg/kg there was no increase of 
escape failures (p>0.05) whereas at doses of 0.2 and 
0.4 mg/kg the impairment was significantly higher 
than in the control group (p<0.01). The dose-
dependent decrease in CAR as well as the 
appearance of non-reactions at doses of 0.2 and 0.4 
mg/kg is shown in Figure 3 for all test compounds.  
Table 4 ED50 values and 95% confidence intervals (CI) of 
CAR in the pole jump experiment  
Substance 
CAR ED50 
[mg/kg] 95% CI 
Risperidone 0.61 0.48 – 0.76 
Haloperidol 0.20 0.16 – 0.24 
LE425 2.51 1.91 – 3.31 
LE404 0.32 0.22 – 0.46 
LE300 0.94 0.78 – 1.14 
LE300ME 0.71 0.60 – 0.85 
Risperidone 
Risperidone was examined in four different doses 
(0.25 – 0.75 mg/kg) and caused a dose dependent 
significant inhibition of CAR (p<0.001). The 
investigated doses 0.25, 0.4, 0.5 and 0.75 mg/kg 
reduced CAR significantly compared to the saline 
treated animals (p<0.05). 
In Part B, CAR-inhibition was significantly increased 
at 0.4, 0.5, and 0.75, but not at 0.25 mg/kg. No 
significant impairment on escape behaviour was 
detected at any investigated dose (p>0.05). 
LE404 
LE404 significantly increased CAR inhibition over all 
doses (range 0.1 – 2.0 mg/kg) shown by a Kruskal-
Wallis-H test (p<0.005). Whereas 0.1 mg/kg revealed 
no difference compared to the control group (Mann-
Whitney-U, p>0.05), a significant enhancement of 
reaction time compared to the control group was 
measured for 0.3, 0.5, 1.0 and 2.0 mg/kg (p<0.001).  
In part B significant CAR-inhibition could be observed 
for 0.3 – 2.0 mg/kg. An impairment of escape 
behaviour was only significant for 0.5, 1.0 and 2.0 
mg/kg (p<0.05), but not below 0.5 mg/kg (p>0.05). 
LE300ME 
Administration of LE300ME enhanced the reaction 
times at all investigated doses (p<0.01): 0.5 – 2 
mg/kg. In part B, CAR-inhibition could not be 
observed at a dose of 0.5 mg/kg (p>0.05). All other 
investigated doses, produced a significant reduction 
of CAR (p<0.001). Increase of non-reaction was 
observed at doses equal to or higher than 1.0 mg/kg 
(p<0.001). 
LE425 
In a range from 0.5 to 5.0 mg/kg of LE425, a dose 
dependent increase in reaction time was observed 
(p<0.001). For 0.5 mg/kg neither an increase in 
reaction time in part A (p>0.05), nor a significant 
inhibition of CAR in part B (p>0.05) was observed 
compared to the control group. For all other doses 
investigated, starting with 1 mg/kg, enhancement of 
reaction time and inhibition of CAR were significant 
(p<0.01). A significant non-reaction occurred only at 3 
and 5 mg/kg (p<0.05).  
 
Figure 3 Effects of test compounds in the pole jump task 
with current after 4 s: percentage of jumps within 4 s (CAR), 
after 4 s (avoidance) and no jump within 20 s (non-reaction). 
LE300 
LE300 was investigated in five different doses 
ranging from 0.3 to 2.0 mg/kg body weight and 
showed a dose dependent increase in reaction time 
over all doses in the Kruskal-Wallis-H test (p<0.001). 
At a dose of 0.3 mg/kg body weight no significant 
difference compared to the control group was 
observed (p>0.5), whereas all doses between 0.5 and 
2.0 mg/kg caused a significant enhancement of 
reaction time compared to the animals treated with 
saline solution (p<0.05). In part B, all doses 
influenced CAR significantly (p<0.05). An impairment 
of the escape behaviour occurred above 2.0 mg/kg 
(p<0.001).  
3.2.3. Catalepsy 
Results of bar and cross-leg tests 30 min after drug 
administration are shown in Figure 4. All investigated 
compounds, including the standards haloperidol and 
risperidone, caused catalepsy, stably expressed 
between 30 and 90 min after drug administration. 
However, these effects occurred at much higher 
doses compared to effects on CAR. ED50 values (and 
95% confidence intervals) [mg/kg] were as follows: 
bar test: haloperidol 0.73 (0.68 – 0.79), risperidone 
0.90 (0.76 – 1.05), LE425 13.92 (12.91 – 15.01), 
L404 6.54 (5.76 – 7.42), LE300 8.84 (7.64 – 10.24), 
LE300ME 8.68 (8.27 – 9.09); cross-leg test: 
haloperidol 0.78 (0.70 – 0.87), risperidone 0.97 
(0.87 – 1.08), LE425 12.25 (11.57 – 12.97), LE404 
6.12 (6.11 – 6.12), LE300 7.17 (6.18 – 8.31), 
LE300ME 6.16 (4.22 – 8.97). Obviously, the adverse 
side-effect catalepsy needed much higher dosages 
for the new potential LE-type-neurolepics than for the 
established reference neuroleptics haloperidol and 
risperidone. 
 
Figure 4 Dose-dependence of bar test and cross-leg test 30 
min after drug administration. Rats (n = 7 per dose) which 
remained ≥ 90 s in an  awkward position were counted as 
cataleptic. 
3.2.4. Oral bioavailability 
In order to examine the oral bioavailability of the 
investigated azecines, 2.5 mg/kg of LE404 and 
LE300ME were administered per os to four rats each 
and the treated animals were exposed to the pole 
jump test 45 min (LE404) or 60 min (LE300ME) after 
drug administration. At this dose LE300ME revealed 
a 74.5±19.2% CAR-Inhibition. All rats were 
significantly influenced by the peroral administered 
drug (p=0.004, data not shown). Compound LE404 
could only induce a CAR-inhibition of 30.1±2.1% in 
two out of four rats at this dose, not enhanced by 
variation of the pre-treatment time (30 to 90 min). 
Further dose-increase of LE404 to 5 mg/kg body 
weight (n=8 rats) led to similar results (Figure 5). Only 
three out of 8 rats were affected at this higher dose, 
with an enhanced CAR-inhibition rate of 80.9±8.8%. 
At a dose of 20 mg/kg (n=5), all investigated animals 
showed CAR-inhibition of 94.1±4.5%. Three out of 
five rats displayed catalepsy at this dose (bar test). 
 
Figure 5 Oral bioavailability of LE404 at different doses 
measured in the pole jump test as percentage of CAR-
inhibition (each bar represents one rat). 
4. Discussion 
Dopamine receptor antagonists, in first line those with 
prevalence for the D2 subtype, are known as potent 
drugs against the positive symptoms of 
schizophrenia, but often cause therapy limiting side-
effects. Parkinson like symptoms, often induced by 
these drugs, are considered to be reduced by 
serotonin 2A receptor antagonism. The azecines 
described in this study were structurally designed to 
combine both, potency against positive symptoms by 
dopamine antagonism and reduced side-effects by 
serotonin antagonism in one drug. This class of new 
substances has brought up some nanomolar 
antagonists at human dopamine (D1 – D5) receptors 
with prevalence to the D1 family. In the current work, 
we investigated in vitro some of these potential 
antipsychotics also at the human 5-HT2A receptor, 
measured their cytotoxic effects and conclusively their 
efficacy in vivo.  
Based on the results of in vitro testing, we selected 
the four azecine derivatives LE300, LE300ME, LE404 
and LE425 for in vivo investigations. Besides the high 
affinities for dopamine and 5-HT2A receptors, a low 
general cytotoxicity of the compounds was a basic 
requirement for the selection. Fortunately, all 
investigated compounds showed nanomolar affinities 
to D1 – D5 and 5-HT2A receptors and CC50 values on 
human glia cells in cytotoxicity assays above 100 µM.  
Previous studies have shown that all clinical relevant 
neuroleptics inhibit selective conditioned avoidance 
response (CAR) at doses that do not influence the 
natural escape behaviour (Wadenberg and Hicks, 
1999). The suppression of CAR in rats has a high 
predictive validity for antipsychotic potency (Kuribara 
and Tadokoro, 1981). Therefore we studied the 
neuroleptic like potency of our four test compounds 
by a one-way active avoidance task in the pole jump 
model. 
In our experiments, haloperidol and LE404 were 
equally potent in CAR inhibition and LE300ME was 
as potent to reduce CAR as risperidone. LE300 and 
LE425 showed the same effects, but only at higher 
doses. All tested azecines inhibited CAR potently at 
doses, at which the escape behaviour was not 
restrained. From these results we conclude that the 
tested azecines have a high likelihood of neuroleptic 
potency to treat positive symptoms of schizophrenia.  
It might be argued, that the effect of CAR is only a 
consequence of reduced locomotor activity. So we 
measured locomotor activity and indeed found it to be 
decreased by all test compounds. However, the 
calculated ED50 values of the locomotor activity 
inhibition do only correlate moderately with the 
suppression of CAR (r2=0.65, p=0.05). Some mild 
correlation is reasonable, due to the fact that both, 
locomotor activity and antipsychotic efficacy are at 
least partially caused by the same mechanism – 
dopamine antagonism. Nevertheless, there are 
published examples of antipsychotics, where CAR 
inhibition occurs at doses, at which the locomotor 
activity is not influenced (Becker and Grecksch, 
2008). In the present study, LE300ME showed 
significantly less reduction in locomotor activity than 
effects on CAR.  
Next to the improvement of symptoms, a high 
therapeutic range regarding side-effects is a main 
demand on new neuroleptics. Extra-pyramidal 
movement disorders are some of the most common 
adverse side-effects of antipsychotics and are often 
therapy limiting. Therefore we examined the induction 
of catalepsy, a reliable animal model for these 
Parkinson like symptoms, for all test substances. 
Haloperidol showed catalepsy at very low doses (<1 
mg/kg), while the ED50 values of the investigated 
azecines ranged between 6 and 16 mg/kg body 
weight. LE404 even had a 5-fold broader therapeutic 
range regarding catalepsy than the investigated 
standard compounds (compare Table 5). LE300 and 
LE300ME revealed mild advantages compared to 
haloperidol and risperidone in the catalepsy-
potency-ratio. It is remarkable, that the azecine 
derivatives but not risperidone, an often prescribed 
atypical antipsychotic, show advantages over 
haloperidol in this model. Nevertheless, risperidone 
itself is mainly used because of its equally effect on 
negative and positive symptoms. The occurrence of 
extra-pyramidal side-effects (EPS) in patients at 
higher doses of risperidone is well known. In several 
studies clinical titrated doses of haloperidol and 
risperidone showed no significant difference in the 
occurrence of EPS (Ceskova and Svestka, 1993; 
Chouinard et al., 1993). The standard compounds 
haloperidol and risperidone are accepted and 
commonly used drugs in the treatment of 
schizophrenia. Regarding the receptor binding profile, 
the typical antipsychotic haloperidol displayed high 
binding affinities to all dopamine receptors, but 
prevalence for the D2 and D3 receptors. It showed 
only very low affinity for the 5-HT2A receptor. 
Risperidone as an example for atypical 
antipsychotics showed selectivity to the D2, D3, D4 
receptors, but also high affinities for the 5-HT2A 
receptor in a subnanomolar range. LE300, LE300ME, 
LE404 and LE425 revealed affinities for the 5-HT2A 
receptor comparable with those of risperidone, but 
much higher affinities for D1 and D5. The different 
subreceptor affinities and selectivities of the test 
compounds should enable us to investigate the 
influence of the different dopamine receptor subtypes 
and the 5-HT2A receptor on potency against positive 
symptoms and induction of catalepsy. Using the 
results from open field tests (locomotor activity), pole 
jump tests (CAR-inhibition, antipsychotic potency) 
and bar tests (catalepsy), we tried to correlate the 
data of the in vitro receptor binding studies with the 
ones obtained in animal models in vivo. A distinct 
correlation between the affinities for a single receptor 
subtype to the ED50 values of the different animal 
tests could not be found (p>0.05). Best results, but 
with no significance were observed for D2/locomotor 
activity (r2=0.71, p=0.22), D4/CAR-inhibition (r2=0.63, 
p=0.59) and D2/catalepsy (r2=0.64, p=0.16). 
Surprisingly there was a strong and significant 
correlation between the CAT(C-L)/CAR ratio and D1 
(r2=0.95, p=0.03) or D5 receptors (r2=0.96, p=0.03), 
which could imply an advantage of high affinities to 
the D1 receptor family, displayed by almost all 
hexahydrodibenz- and hexahydrobenzindoloazecines. 
Some formerly postulated correlation between 5-HT2A 
receptor affinities and catalepsy (Balsara et al., 1979) 
or CAT/CAR-ratio, respectively, could not be found for 
the tested compounds (p>0.5). This missing 
correlation as well as the results for risperidone 
indicate that the 5-HT2A receptor affinity might not be 
responsible for less extra-pyramidal side-effects as 
also discussed by Kapur et al. (Kapur, 1996). Further 
investigations on azecines should therefore 
concentrate on the influence of the additional 5-HT2A 
affinities on negative symptoms. 
Dopamine hypofunction in the prefrontal cortex, 
postulated as crucial for negative symptoms, might be 
reduced due to the possible dopamine release into 
this brain region by 5-HT2A receptor blockade (Davis 
et al., 1991).  
  
Table 5 ED50 values of the in vivo tests and determination of the CAT/CAR-inhibition ratio 
CAT (bar) –catalepsy (bar test); CAT (CLP) – catalepsy (cross-leg-position test); CAR – conditioned avoidance reaction 
Beside the therapeutic effect itself and few side-
effects, oral bioavailability is a basic requirement for 
antipsychotic drugs. We investigated one example of 
both scaffolds (dibenz- and benzindolo[d,g]azecines) 
by oral administration in the pole jump test. The 
benzindoloazecine LE300ME showed constantly 
good results at the investigated dose of 2.5 mg/kg 
(79.6% CAR-inhibition). All rats were influenced at 
this dose (n=4). Results for the dibenzazecine LE404 
were more difficult to interpret. Some rats showed 
distinct inhibition of CAR at 2.5 and catalepsy at 20 
mg/kg, whereas other rats showed CAR-inhibition 
only at 20 mg/kg with no effect on escape behaviour 
or catalepsy. Hence, we assume that the oral 
bioavailability of LE404 may be inter-individually 
different. Though we cannot explain this observation 
so far, an influence of the phenolic hydroxy function of 
this substance on oral bioavailability is conceivable.  
5. Conclusion 
Aromatic annelated [d,g]azecines represent a novel 
and advantageous type of potential neuroleptics. 
They were investigated with respect to serotonin 
receptor affinity, cytotoxicity, in vivo antipsychotic 
potency (pole jump test, CAR), extra-pyramidal side-
effects (catalepsy) and oral bioavailability. Four 
examples of this substance class, each with different 
selectivity profile to dopamine receptors, were 
selected for the experiments. All of them showed to 
be potent in an animal model for antipsychotic 
activity. LE404 and LE300ME revealed activities 
against positive symptoms comparable to the 
standard compounds haloperidol and risperidone. 
LE300 and LE425 showed the same effects on CAR 
albeit at higher doses. By these observations, we 
could prove for the first time the ability of the 
investigated azecines to pass the blood-brain-barrier. 
The tested azecines caused catalepsy only at 
significantly higher doses than haloperidol and 
risperidone. Hence, three of four substances 
revealed a beneficial therapeutic range compared to 
the standard compounds regarding extra-pyramidal 
side-effects. LE404, the best compound in this study, 
was about 5 times better than haloperidol or 
risperidone. Analysing the CAT/CAR-ratio for all 
tested compounds, their possible clinical value based 
on the animal experiments can be ranged as follows: 
LE404 > LE300ME ≥ LE300 > LE425 ≥ haloperidol 
≥ risperidone. Nevertheless, this should be only 
seen as tendency and is maybe not transferable to 
the effects in humans. In addition we investigated the 
effects on CAR of the two most promising compounds 
after oral administration. LE404 displayed a 
heterogeneous result when administered orally, most 
probably due to the phenolic function. Only some of 
the animals behaved as expected, while others 
needed a much higher dose for the same outcome. 
However, compound LE300ME showed constant 
CAR-inhibition already at low doses after oral 
administration. We conclude that the investigated 
azecines represent a class of substances with 
interesting characteristics of potential neuroleptics. 
Beside the high dopamine and serotonin receptor 
affinities and low cytotoxicity, these compounds 
showed high potency against positive symptoms in 
vivo, less extra-pyramidal side-effects than 
risperidone and probably acceptable oral 
bioavailability. 
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Abstract: LE300 derivatives substituted at position 8 with three different residues, 
namely methyl, hydroxymethyl and carboxylic acid, were prepared. The 8-methyl and 
8-hydroxymethyl derivatives were obtained as the separated R- and S- enantiomer as 
well as the racemic mixture, while the amino acid derivative could only be obtained in a 
racemized form. The separate enantiomers showed significantly different affinities; the 
8S-methyl and 8R-hyroxymethyl derivatives, where the substituent points behind the 
plane, were markedly more active than their enantiomeric counterparts. The racemized 
derivative substituted with a carboxylic acid group, though it could not be in an 



































Contribution: Synthesis and characterization of all target and intermediary 
compounds, separation of the racemate by preparative chiral HPLC, determination of 
Ki values of some derivatives by radioligand binding assay, development of SAR and 




Synthesis and Dopamine Receptor Affinities of Racemic and 
Enantiopure Indolo[3,2-f][3]benzazecine Derivatives 
Dina Robaaa, Christoph Enzensperger a, Shams ElDin Abulazmb, Mohamed M. Hefnawyc, Hussein I. El-
Subbagh c and Jochen Lehmann a, c 
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b Department of Medicinal Chemistry, Faculty of Pharmacy, University of Alexandria, Egypt   
c Department of Pharmaceutical Chemistry, College of Pharmacy,  King Saud University, Saudi Arabia 
Racemic and enantiopure 8-substituted derivatives of the lead dopamine receptor antagonist LE 300 (1) were 
prepared and their affinities for dopamine receptors (D1-D5) were tested. The separate enantiomers showed 
significantly different affinities; 8S-methyl and 8R-hyroxymethyl derivatives where the substituents point 
behind the plane, were markedly more active than their enantiomeric counterparts. The racemized derivative 
substituted with a carboxylic acid group was selective for the D5-receptor.  
INTRODUCTION  
Dopamine is known as a major neurotransmitter in the CNS, where it controls numerous physiological 
functions, including locomotion, behaviour, emotion, cognition, learning and motivation. Dysfunctions of the 
dopaminergic system have been linked with several neurological and psychiatric disorders mainly Parkinson’s 
disease1;2 and schizophrenia.3;4 Dysregulations of the dopamine system have also been associated with 
depression5, attention-deficit hyperactivity disorder6 and alcohol dependence.7  
Partially hydrogenated indolo[3,2-f][3]benzazecines,8;9 represent a structurally novel class of dopamine 
receptor antagonists, distinguished by  nanomolar affinities as well as their preference for the receptors of the 
D1 family. Their structure is typically made up of a tetracyclic ring system; with two aromatic moieties 
surrounding a central azecine ring. Since the discovery of 7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-
f][3]benzazecines (1, LE300),9 the lead benzindoloazecine derivative, extensive research has been devoted to 
the search for derivatives showing either improved affinities and/or  subtype selectivity. Considerable work has 
been accomplished in developing SAR of this class of compounds.8;10;11 This revealed that the backbone 
scaffold is optimally made up of a two aromatic ring system (indole and benzene, or two benzene rings) 
surrounding a central azecine moiety. Both aromatic rings should be separated by a methylene group. Further 
studies showed that small substituents at some positions of the benzindoloazecine scaffold, e.g. at the indole 
nitrogen, are well tolerated or may even result in increased affinities.12  
Aim of this work was to prepare the first indolo[3,2-f][3]benzazecine derivatives (benzindoloazecines) 
substituted at a C-atom of the azecine ring besides the methyl group at the azecine nitrogen. We selected 





selectivities of the compounds. Since this type of substitution results in the formation of a chiral centre, we 
wanted to obtain not only the racemic but also the enantiopure derivatives in order to additionally assess the 
effect of the stereochemistry.  
Enantiomeric pairs commonly show different activities, pharmacokinetics or even toxicity. Diverse 
dopamine receptor ligands are chiral in nature, their chirality originating mostly at the central ring, mainly 
affecting the spatial conformation of the scaffold as a whole. (cf. apomorphines,13 phenylbenzazepines14 and 
dihydrexidine15). Our notion was that an additional substituent at the 8-position of the benzindoloazecine 
molecule might similarly affect the conformation of the whole scaffold, depending on the configuration of the 
substituent (R- or S-).   
































Our primary targets were racemic and enantiopure benzindoloazecine derivatives substituted at position 8 
with a small residue such as a methyl group. Based on the obtained results, the nature of the substituent was to 
be modified by introduction of a functional group such as a carboxyl or hydroxyl group. 
CHEMISTRY 
To obtain the R- and S-enantiomers of the target 8-methylated benzinodoloazecines (6 and 7) racemic -
methyltryptamine (2) was first converted to the quinolizine derivative 4 by reaction with 2-(2-
bromoethyl)benzaldehyde following a previously established procedure for the synthesis of analogous 
quinolizines.16 Subsequent quaternization with methyl iodide and reduction of the obtained quaternary salts 
under Birch conditions yielded the target azecine as a racemate 5.  
Resolution of the racemate to attain the enantiomers 6 and 7 was achieved by means of preparative chiral 
HPLC on a cellulose-based chiral stationary phase. Several attempts to crystallize the obtained enantiopure 
derivatives to obtain an X-ray structure and in turn assign the respective configuration were not successful.  
The quinolizine derivatives 10 and 11, obtained from the enantiomerically pure methyl esters of D- and L-
tryptophan (8 and 9), served as starting materials for the preparation of further 8-substituted LE300 derivatives. 
Conversion of the quinolizines 10 and 11 to the corresponding azecines however failed at the last step, namely 












































a Reagents and conditions: (a) TFA, dioxane, reflux, 6h; (b) MeI, acetone, 24 h; (c) Na0, liq. NH3, -40°C, 10 
min. 



















































* R and S
 
 a Reagents and conditions: (a) TFA, dioxane, reflux, 3h; (b) MeI, acetone, 35 °C,  24 h; (c) Na0, liq. NH3, -
40°C, 10 min; (d) 1N NaOH, MeOH, 0°C, 2 h; (e) LiAlH4, dry THF, reflux, 5 h. 
As an alternative route, the ester function of the quaternary salts 12 and 13 were first hydrolyzed in 1N 
sodium hydroxide at 0 °C, and the resulting products 14 and 15 were reduced under Birch conditions yielding 





give the hydroxymethyl derivatives 18 and 19. (Scheme 2) However, investigations of the enantiomeric purity 
of the obtained derivatives 18 and 19 by means of chiral HPLC as well as measurement of their optical rotation 
revealed that these derivatives were obtained in an almost completely racemized form. It can be presumed that 
this racemisation occurred due to the basic conditions used for the hydrolysis of the ester function of the 
quaternary salts 12 and 13 to the corresponding carboxylic acid derivatives 14 and 15, despite the mild 
conditions applied namely at 0 °C for 2 h.  
In a further trial to obtain enantiopure derivatives, the hydrolysis step was circumvented, and the ester 
function of the quinolizines 10 and 11 was first reduced using lithium aluminium hydride. The resulting 
hydroxymethylquinolizines 20 and 21 were subsequently quaternized, and the quaternary salts 22 and 23 were 
finally reduced with sodium in liquid ammonia to give the target azecines 24 and 25. (Scheme 3)  
Scheme 3a. Synthetic route B: 8-Hydroxymethyl-quinolizine as starting material for enantiopure 8-









































* R and S
(R)
 
a Reagents and conditions: (a) LiAlH4, dry THF, rt, 90 min; (b) MeI, acetone, 24 h; (c) Na°, liq. NH3, -40°C, 
10 min; (d) MsCl, TEA, DCM, 12 h, rt; (e) LiAlH4, dry THF, reflux, 2h. 
The enantiopurity of the obtained azecines was ascertained by measuring their specific rotation (  =  
-158.4° and 161°, respectively) and by chiral HPLC. These findings substantiate our earlier speculations that in 
the previously adopted synthetic procedure racemisation took place at a step prior to the synthesis of the 
hydroxymethyl derivatives 18 and 19, and that it most probably occurred during hydrolysis. It could also be 
concluded that the amino acid derivatives 16 and 17 are not enantiomerically pure and that they are racemized 
to the same extent as the hydroxymethyl derivatives 18 and 19. In order to identify the configuration of the 
aforementioned separated S- and R-enantiomers of 8-methyl benzindoloazecine (6 and 7; scheme 1), we 
adapted an alternative route for the synthesis of the (8S)-enantiomer (6) starting from an enantiomerically pure 
precursory substance, namely the 8R-hydroxymethyl quinolizine 20. This was first converted to the 
corresponding R-mesylate, which was directly reduced with lithium aluminium hydride to give the (8S)-methyl 
5 
 
quinolizine 26. Reduction with sodium in liquid ammonia finally yielded the corresponding (8S)-azecine 
derivative 6. (Scheme 3)  Comparison of the respective specific rotation of the herein obtained azecine with the 
previously obtained ones (scheme 1; 6 and 7) enabled us to assign the respective configuration.  
PHARMACOLOGY 
All the target enantiopure compounds (6, 7, 24 and 25) together with their racemic forms (5 and 18) as well 
as the racemized amino acid derivative 16 and 17 were screened for their affinities for the human cloned 
dopamine receptor subtypes D1, D2L, D3, D4.4 and D5. These receptors were stably expressed in HEK293 or 
CHO cells; [3H]SCH 23390 and [3H]spiperone were used as radioligands at the D1-like and D2-like receptors, 
respectively. Ki values are given in nanomolar units (Table 1). A detailed protocol has been elsewhere 
described.16 Additionally, the compounds were tested in an intracellular Ca2+ assay, in order to determine their 
functionality at the D1 and D2 receptors. HEK293 cells stably expressing the respective D-receptor were loaded 
with a fluorescent dye (Oregon green), and after preincubation with rising concentrations of the test compound, 
an agonist (SKF 38393 for D1 and quinpirole for D2) was added and the Ca
2+-induced fluorescence was 
measured with NOVOSTAR® microplate reader. The ability of the test compound to suppress the agonist-
induced Ca2+ influx is an indication of antagonistic or inverse agonistic properties at the receptor. 
RESULTS and DISCUSSION 
Benzindoloazecine derivatives substituted at position 8 with three different residues, namely methyl, 
hydroxymethyl and carboxylic acid, were prepared. The 8-methyl and 8-hydroxymethyl derivatives were 
obtained as the separated R- and S- enantiomer (6, 7 and 24, 25, respectively) as well as the racemic (5) or 
racemized (18, 19) mixture, while the amino acid derivative could only be obtained in a racemized form 
(16+17). 
All racemates showed decreased affinities for the dopamine receptors compared with the lead 
benzindoloazecine 1; the most pronounced decrease was observed with the amino acid derivative 16. This was 
however  interesting, since compound 16 displayed practically no affinities for all dopamine receptors (Ki > 
10000 nM), except for the D5 receptor, where it showed submicromolar one (ca. 657 nM). This apparent 
selectivity for D5 against D1 is seldom encountered, which renders the compound highly attractive as a potential 
D5-selective pharmacological tool. To attest this D5/D1 selectivity a competitive binding experiment at the D1 
receptor (determination of Ki value) was carried out, not to only rely on the results of the screening. Separation 
of the enantiomers of compound 16 could not be accomplished, but it would be of great value, as the separate 
enantiomers could show higher affinities or more pronounced selectivity.  
While the racemic (8RS)-methyl benzindoloazecine 5 showed significantly decreased affinities (radioligand 
binding experiment), the separated R- and S- enantiomers displayed a high discrepancy in their affinities. The 
S-enantiomer 6 (bond pointing below the plane) was almost as active as the lead benzindoloazecine 1. The 





micromolar affinities for D1-like receptors (D1 and D5) and was practically devoid of activity for D2-like 
receptors (D2, D3 and D4).  
Table 1: Affinities (Ki, nM) for human D1-D5 receptors, determined by radioligand binding experiments 
Compounds 
Ki, (nM) 
D1 D2 D3 D4 D5 
1* 
 
1.9 ± 0.9 44.5 ±15.8 40.3 ± 4.4 108 ± 39 7.5 ± 0.3 
5 
 
32.4 ± 13.3b 526 ± 69b 385 ± 3.5b  16.9 ± 6.5b 
6 
 
6.1 ± 2.2a 85.3 ± 15.2b 304 ± 1b 64.1 ± 19.3b 4.4 ± 2.5b 
7 
 
640 ± 119b >10000 >10000 >10000 389 ± 0.8b 
16 
 
>10000 >10000 >10000 >10000 657 ± 163a 
18 
 
44.8 ± 29.6b 200.7 ± 89.4a >10000 512 ± 274b 93.2 
24 
 
10.3 ± 1.4b 268 ± 56a 681 ± 68a 408 ± 31b 11.4 ± 2.3b 
25 
 
114 ± 9b 2923 ± 442a 4676 ± 1593b 4861 ± 803b 91.4 ± 8.5b 
*Values taken from ref. 10. CHO cell lines were used for D4.4; HEK cell lines for D1, D2L, D3, and D5. 
aKi values are the means 
of three experiments; performed in triplicate ± SEM. bKi values are the means of two; experiments; performed in triplicate ± SEM.  
A similar but less pronounced difference was observed between the R- and S- enantiomers of 8-hydroxymethyl 
benzindoloazecine, the R-enantiomer 24 (bond also pointing below the plane) was more active than the S-










































hydroxymethyl benzindoloazecine was relatively less active than its 8-methylated counterpart (the S-
enantiomer; in both compounds the bond points below the plane), the (8S)-hydroxymethyl derivative was more 
active than the (8R)-methylated one. 
 
EXPERIMENTAL SECTION 
General methods: Melting points are uncorrected and were measured in open capillary tubes using a 
Gallenkamp melting point apparatus. 1H and 13C NMR spectral data were obtained from a Bruker Advance 250 
spectrometer (250 MHz) and Advance 400 spectrometer (400 MHz). TLC was performed on silica gel F254 
plates (Merck). MS data were determined by GC/MS using a Hewlett-Packard GCD-Plus (G1800C) apparatus 
(HP-5MS column; J&W Scientific). Purities of the compounds were determined by elemental analysis, 
performed on a Hereaus Vario EL apparatus, or by HPLC. All values for C, H, and N were found to be within 
(±0.4). All compounds showed > 95% purity. 
General Procedure for the preparation of the quinolizines 3, 10 and 11 starting from the respective 
amines: A solution of the respective arylethylamine (-methyltryptamine, methyl D- or L-tryptophante) (1 
mmol), 2-(2-bromoethyl)benzaldehyde (1.2 mmol) and trifluoroacetic acid (1 mmol) in dioxane was refluxed 
under nitrogen for three to six hours (with -methyltryptamine). The solvent was then evaporated under reduced 
pressure, the remaining residue basified with 2N NaOH and the resulting quinolizine base was extracted with 
dichloromethane.  
(8RS,14bRS)-8-Methyl-5,6,8,9,14,14b-hexahydroindolo[2',3':3,4]pyrido[2,1-a]isoquinoline (3). The 
obtained product was crystallized from isopropanol/hexane giving pale yellow needle-shaped crystals; yield 
69.5%; mp: 75-77 °C. 1H-NMR: 250 MHz (CDCl3): 1.41-1.48 (2d, J=7, 3H, CH3), 2.50-3.25 (m, 6H, 
aliphatic), 3.46-3.67 (m, 1H, H-8), 5.24 and 5.41 (2s, 1H, H-14b), 7.07-7.51 (m, 8H, aromatic), 7.66 and 7.72 
(2s, 1H, indole-NH). GC-MS: two peaks of the same molecular weight were detected,  which correspond to the 
two diastereomers formed during the reaction: m/z: 288 (53%), 273 (23%), 245 (63%), 230 (99%), 217 (74%), 
202 (14%), 156 (22%), 143 (16%), 130 (100%), 115 (96%), 103 (40%), 89 (29%), 77 (83%), 63 (33%). And 
m/z: 288 (%), 273 (23%), 245 (63%), 230 (99%), 217 (74%), 202 (14%), 156 (22%), 143 (16%), 130 (100%), 
115 (96%), 103 (40%), 89 (29%), 77 (83%), 63 (33%). And m/z: 288 (53%), 273 (23%), 245 (63%), 230 
(99%), 217 (74%), 202 (14%), 156 (22%), 143 (16%), 130 (100%), 115 (96%), 103 (40%), 89 (29%), 77 
(83%), 63 (33%). And m/z: 288 (44%), 273 (19%), 245 (51%), 230 (83%), 217 (70%), 202 (19%), 156 (20%), 
143 (11%), 130 (100%), 115 (92%), 103 (40%), 91 (34%), 77 (86%), 63 (31%).  
Methyl (8R)-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinoline-8-carboxylate (10). 
Purified by column chromatography, dichloromethane/methanol (100:1). Yield 55.2%; m.p. 84-87 °C 
(analytical data see SI).  
Methyl (8S)-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinoline-8-carboxylate (11). 
Purified by column chromatography, dichloromethane/methanol (100:1). Yield 59.1%; m.p. 84-86 °C 





General Procedure for the Preparation of the Quaternary Salts 4, 12, 13, 22 and 23. To a stirred 
solution of the respective quinolizine in acetone was added a 10-fold molar excess of methyl iodide. Stirring 
was continued for 24 h, the precipitated solid was filtered off and the filtrate treated with excess diethyl ether to 
precipitate the rest of the quaternary salt. Both precipitates were collected, washed with diethylether and dried. 
(8RS)-7,8-Dimethyl-5,6,8,9,14,14b-hexahydroindolo[2',3':3,4]pyrido[2,1-a]isoquinolin-7-ium iodide (4). 
Yellow solid. Yield 86.4%; m.p. 274-275 °C. 1H NMR: 250 MHz (DMSO-d6): δ 1.53-1.57 and 1.63-1.65 (2d, 
J= 6, 3H, CH3), 2.85-3.27 (m, 4H, aliphatic), 3.10 and 3.16 (2s, 3H, N-CH3), 3.50-3.69 (m, 1H, aliphatic), 4.03 
and 4.26-4.20 (2m, 2H, aliphatic), 6.12 and 6.22 (2s, 1H, H-14b), 7.00-7.21 (m, 2H, aromatic), 7.36-7.65 (m, 
6H, aromatic), 10.20 and 11.48 (2s, 1H, indole-NH).  
(8R)-(Methoxycarbonyl)-7-methyl-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinolin-
7-ium iodide (12). Yellow solid. Yield 88%; m.p. 217-218 °C (analytical data see SI). 
(8S)-(Methoxycarbonyl)-7-methyl-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinolin-7-
ium iodide (13). Yellow solid. Yield 85%; m.p. 215-216 °C (analytical data see SI). 
(8R)-8-(Hydroxymethyl)-7-methyl-5,6,8,9,14,14b-hexahydroindolo[2',3':3,4]pyrido[2,1-a]iso-quinolin-
7-ium iodide (22). Yellow solid. Yield 99.1%; m.p. >300 °C Used without further purification for subsequent 
syntheses (analytical data see SI). 
(8S)-8-(Hydroxymethyl)-7-methyl-5,6,8,9,14,14b-hexahydroindolo[2',3':3,4]pyrido[2,1-a]iso-quinolin-
7-ium iodide (23). Yellow solid. Yield 95.0 %; m.p. > 300 °C. Used without further purification for subsequent 
syntheses.  
General Procedure for the Ring-Opening. Ammonia was condensed in a three-necked 100 mL flask, 
which was equipped with a balloon and a stopper and cooled in a liquid nitrogen bath. After filling 3/4 of the 
flask’s volume, the cooling bath was removed and ammonia was allowed to liquefy. The respective quaternary 
salts were then added to the stirred liquid ammonia. This was followed by gradual addition of small pieces of 
sodium metal until the blue colour remained for 10 min. A few drops of saturated ammonium chloride solution 
were added to terminate the reaction, and the mixture was stirred under nitrogen until the liquid ammonia 
completely evaporated. To the residue was added 10 mL water, and the mixture was then extracted with 30 mL 
diethyl ether. The organic phase was dried over Na2SO4, and the solvent was removed under reduced pressure. 
(8RS)-7,8-Dimethyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine (5) and its separated R- 
and S-enantiomers 6 and 7. Creamy white solid. Yield 89.7%; m.p. 82-84 °C. 1H NMR: 400 MHz (CDCl3): δ 
1.09-1.11 (d, J=7, 3H, CH3), 2.31 (s, 3H, N-CH3), 2.57-2.62 (m, 2H, aliphatic), 2.75-2.82 (m, 2H, aliphatic),  
2.85-2.93 (m, 3H, aliphatic), 4.23-4.27 (d, J=15, 1H, H-15), 4.39-4.43 (d, J=15, 1H, H-15), 7.10-7.33 (m, 5H, 
aromatic), 7.29-7.33 (m, 2H, aromatic), 7.49-7.51 (d, J=7, 1H, aromatic), 7.92 (s, 1H, indole-NH). 13C NMR: 
400 MHz (CDCl3): δ 14.88 (CH3), 31.15 (5), 32.29 (9), 35.24 (15), 41.74 (N-CH3), 53.26 (6), 59.72 (8), 110.30 
(13), 111.27 (9a), 118.09 (10), 119.03 (11), 120.97 (12), 126.49 (3), 126.76 (1), 129.57 (9b), 130.28 (2), 130.64 
(4), 135.10 (14a), 135.25 (13a),  137.91 (4a), 141.07 (15a). HPLC retention time: 11.64 min (48.7%) and 22.10 
min (48.99%) (column: Chiralcel OD; eluant: n-hexane/ ethanol 9:1; flow rate: 1.3 mL/min; UV detector λ= 
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220 nm). Anal. calcd. for C20H20N2 x1H2O: C 78.40%, H 7.24%, N 9.14%; found C 78.00%, H 7.26%, N 
9.06%. 
The enantiomers were separated using a preparative Chiracel® OD column (Cellulose tris (3,5-
dimethylphenylcarbamate). Eluent: hexane/ethanol 9:1; flow rate: 194 mL/min; temp.: 25 °C; UV-Detector λ= 
220 nm. The isolation was accomplished by 1 mL injection of a solution of 5 (75 mg in 1 mL n-hexane/ethanol 
1:1). Specific rotation of the first eluted enantiomer was  = 132° (c 1, CHCl3), and for the second 
 = -128°(c 1, CHCl3). Comparison of the specific rotation obtained for both enantiomers with that 
obtained for (8S)-7,8-dimethyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine (6) prepared by 
alternative synthetic route (Scheme 3) = 136° (c 1, CHCl3), revealed that the first eluted enantiomer 
also bears an S-configuration at position 8.  
7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine-8-carboxylic acid (16 and 17). The 
same procedure for ring opening was applied. After evaporating the ammonia water was added and the 
obtained solution was carefully treated with 1N HCl, till the target amino acid precipitated as a creamy white 
solid (pH 6), which was filtered off and dried.  White solid. Yield 60-67%; m.p. chars without melting at 220°C 
(analytical data see SI). 
[(8R)-7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-8-yl]methanol  (24). Purified by 
column chromatography dichloromethane/methanol (11:1). Yellowish white solid. Yield 67%, m.p. 83-85 °C 
(analytical data see SI).  
[(8S)-7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-8-yl]methanol (25). Purified by 
column chromatography dichloromethane/methanol (11:1). Yellowish white solid. Yield 62.6%, m.p. 83-85 °C 
(analytical data see SI). 
General procedure for the reduction of the ester function: To a suspension of lithium aluminium hydride 
(2 mmol) in dry THF was added a solution of respective ester (1 mmol) in dry THF and the reaction mixture 
was stirred at room temperature for 90 min (heated under reflux for 3 hrs for compounds 18 and 19). Excess 
lithium aluminium hydride was quenched with methanol, the reaction mixture was filtered off and the filtrate 
was evaporated under reduced pressure. 
[(8RS)-7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-8-yl]methanol (18 and 19). 
Purified by column chromatography dichloromethane/methanol (11:1). Creamy white solid. Yield 42%, m.p. 
100-103°C. 1H NMR: 300 MHz (CDCl3): δ 2.24 (s, 3H, N-CH3), 2.78-2.90 (m, 5H, aliphatic), 3.02-3.11 (m, 
1H, aliphatic), 3.18-3.22 (m, 1H, aliphatic), 3.66-3.72 (m, 1H, CH2OH), 3.76-3.81 (m, 1H, CH2OH), 4.11-4.16 
(d, J=15, 1H, H-15), 4.33-4.38 (d, J=15, 1H, H-15), 7.07-7.28 (m, 6H, aromatic), 7.34-7.35 (d, J=7, 1H, 
aromatic), 7.49-7.51 (d, J=8, 1H, aromatic), 7.98 (s, 1H, indole-NH). (Column: Teicoplanin T (150 x 4.6 mm 
i.d.); eluent: methanol-glacial acetic acid-triethylamine, (100:0.50:0.025); flow rate: 1.0 mL/min; UV detector 
λ= 282 nm). (Column: Teicoplanin T (150 x 4.6 mm i.d.); eluent: methanol-glacial acetic acid-triethylamine, 





(8R)-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinolin-8-ylmethanol (20). Crystallized 
from acetone/hexane giving yellowish crystals. Yield 82.6%, m.p. 198-200°C (analytical data see SI). 
 (8S)-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinolin-8-ylmethanol (21). Crystallized 
from acetone/hexane giving yellowish crystals. Yield 79.3%, m.p. 197-199°C (analytical data see SI). 
8-Carboxy-7-methyl-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinolin-7-ium iodide 
(14 and 15). To an ice cold-suspension of 12 or 13 (4.4 mmol) in 80 mL methanol was slowly added 27 mL 1N 
NaOH. The reaction mixture was stirred at 0 °C for 2 hours and then acidified with 1N HCl.  Methanol was 
removed under reduced pressure and the remaining aqueous suspension was cooled in an ice bath for 30 
minutes. The obtained pale yellow precipitate was filtered off and dried. Yield 71-77%; m.p.: chars without 
melting at 235°C. 1H NMR: 250 MHz (DMSO-d6): δ 2.99-3.59 (m, 4H, aliphatic), 3.44 (s, 3H, N+-CH3), 3.85-
3.59 and 4.17-4.31 (m, 2H, aliphatic), 4.7 and 4.17-4.31 (m, 1H, H-8), 6.50-6.53 (2s, 1H, H-14b), 7.03-7.17 (m, 
2H, aromatic), 7.35-7.62 (m, 6H, aromatic), 10.41 and 11.81 (2s, 1H, indole-NH).  
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I. Experimental synthetic procedures: 
General methods: Melting points are uncorrected and were measured in open capillary tubes, using a 
Gallenkamp melting point apparatus. 1H- and 13C-NMR spectral data were obtained from a Bruker 
Advance 250 spectrometer (250 MHz) and Advance 400 spectrometer (400 MHz). Elemental analyses 
were performed on a Hereaus Vario EL apparatus. TLC was performed on silica gel F254 plates 
(Merck). MS data were determined by GC/MS, using a Hewlett Packard GCD-Plus (G1800C) apparatus 
(HP-5MS column; J&W Scientific).  
α-Methyltryptamine (2). prepared following the procedure described previously described in the 
literature1. A solution of indole-3-carboxaldehyde (4.35 g, 30 mmol) and ammonium acetate (1.2 g, 15 
mmol) in a mixture of  nitroethane (70 mL) and acetic acid (30ml) was heated at 110 °C for 8 h. The 
reaction mixture was cooled down to rt, whereupon an orange brown solid separated out. This was 
filtered off and the filterate was concentrated to half its volume to precipitate the rest of nitropropenyl 
derivative. Collective yield: 3.66 g (65%); mp. 185-186 °C, reported 190-192 °C. 1H NMR: 250 MHz 
(DMSO-d6): δ 2.48-2.50 under DMSO (mc, 3H, CH3), 7.12- 7.27 (m, 2H, aromatic), 7.48-7.51 (d, J= 7, 
1H, aromatic), 7.81-7.84 (d, J=7, 1H, aromatic), 7.99 (s, 1H, aromatic), 8.45 (s, 1H, C=CH), 12.19 8s, 
1H, indole-NH).  
The nitopropenyl derivative (3.85 g, 19 mmol) was subsequently dissolved in dry THF (25 mL) and 
the solution was slowly added to a suspension of lithium aluminium hydride (3 g, 80 mmol) in dry THF 
(100 mL). The reaction mixture was heated under reflux for 6 h, cooled down to rt and then quenched 
with a saturated solution of potassium sodium tartarate. It was filtered off, and the filtrate was 
evaporated under vaccum leaving a yellowish oil, which solidified on standing. Yield 5.9 g (89%),  mp. 
90-82 °C, reported 97-100 °C. 1H NMR: 400 MHz (CDCl3): δ 1.19-1.21 (d, J=6, 3H, CH3), 1.56 (s, br, 
2H, NH2), 2.66-2.72 (dd, J=14,8, 1H, CH2), 2.89-2.93 (dd, J=14,4, 1H, CH2), 3.30-3.33 (m, 1H, CH), 
7.05 (s, 1H, aromatic), 7.12-7.15 (t, J=7, 1H, aromatic), 7.20-7.23 (t, J=7, 1H, aromatic), 7.37-7.39 (d, 
J=8, 1H, aromatic), 7.63-7.65 (d, J=8, 1H, aromatic), 8.27 (s, 1H, indole-NH). 
Methyl D- and L- tryptophanate (8 and 9). Esterification of D- and L-tryptophan was carried out 
using MeOH/SOCl22. D- or L-tryptophan (5 g, 24.5 mmol) was added to a solution of thionyl chloride 
(4.25 mL, 58 mmol) in methanol (50 mL) and the resulting solution was heated under reflux for 18 h. 
After evaporation of the solvent, a white residue of hydrochloride salt was obtained, which was 
neutralized by a sodium carbonate solution and the ester was extracted with ethyl acetate (200 mL). The 
organic layer was dried over MgSO4 and evaporated under reduced pressure yielding a colourless oil, 
which solidified upon standing to a white solid. Yield: 4.9 g (92%), mp: 90-91 °C, reported 89 °C. 1H 
NMR: 250 MHz (CDCl3): δ 1.63 (s, 2H, NH2), 3.02-3.11 (dd, J=14,8, 1H, CH2), 3.26-3.43 (dd, J=14,5, 
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1H, CH2), 3.72 (s, 3H, COOCH3), 3.82-3.87 (m, 1H, CH), 7.04-7.05 (d, J=, 1H, aromatic), 7.12-7.26 
(m, 2H, aromatic), 7.33-7.37 (d, J=8, 1H, aromatic), 7.61-7.64 (d, J=8, 1H, aromatic), 8.28 (s, 1H, 
indole-NH). 
Methyl (8R)-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinoline-8-carboxylate 
(10). 1H NMR: 250 MHz (CDCl3): δ 2.67-2.77 (m, 1H, aliphatic), 2.94-3.38 (m, 5H, aliphatic), 3.76 (s, 
2H) and 3.89 (s, 1H) (COOCH3), 4.13-4.18 (dd, J=6, 1.5, ⅔H) and 4.22 -4.29 (dd, J=11, 6, ⅓H) (H -8), 
5.47 (s, ⅓H) and 5.62 (s, ⅔H) (H-14b), 7.07-7.42 (m, 7H, aromatic), 7.50-7.55 (m, 1H, aromatic), 7.73 
(s, br, 1H, indole-NH). Anal. calcd. for C21H20N2O2 x 0.75 H2O: C 72.92%, H 6.26%, N 8.10%; found C 
73.24%, H 6.31%, N 8.10%. 
Methyl (8S)-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquinoline-8-carboxylate 
(11). As expected, the 1H NMR spectrum showed two sets of signals, corresponding to the two formed 
diastereomers. One of the diastereomers was obtained in a significantly higher amount (almost twofold 
excess) than the other. 1H NMR: 250 MHz (CDCl3): δ 2.67-2.77 (m, 1H, aliphatic), 2.95-3.39 (m, 5H, 
aliphatic), 3.77 (s, 2H) and 3.89 (s, 1H) (COOCH3), 4.15-4.18 (dd, J=6, 2, ⅔H) and 4.23-4.30 (dd, J=11, 
6, ⅓H) (H-8), 5.48 (s, ⅓H) and 5.65 (s, ⅔H) (H -14b), 7.07-7.42 (m, 7H, aromatic), 7.50-7.55 (m, 1H, 
aromatic), 7.71 and 7.76 (2s, 1H, indole-NH). Anal. calcd. for C21H20N2O2: C 75.88%, H 6.06%, N 
8.43%; found C 75.70%, H 5.89%, N 8.29%. 
8R-(Methoxycarbonyl)-7-methyl-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquino-
lin-7-ium iodide (12). 1H NMR: 250 MHz (DMSO-d6): δ 3.03-3.12 (m, 1H, aliphatic), 3.24-3.62 (m, 
3H, aliphatic), 3.39 (s, 3H, N+-CH3), 3.84 (s, 3H, COOCH3), 3.84-4.04 (m, 1H, aliphatic), 4.10-4.12 
(m, 1H, aliphatic), 5.15-5.20 (m, 1H, H-8), 6.33 and 6.36 (2s,  1H, 14b), 7.02-7.19 (m, 2H, aromatic), 
7.36-7.39 (m, 2H, aromatic), 7.51-7.63 (m, 4H, aromatic), 10.35 (s, 1H, indole-NH). Anal. calcd. for 
C22H23IN2O2: C 55.71%, H 4.89%, N 5.91%; found C 55.56%, H 4.87%, N 5.60%. 
8R-(Methoxycarbonyl)-7-methyl-5,6,8,9,14,14b-hexahydroindolo[2’,3’:3,4]pyrido[2,1-a]isoquin-
olin-7-ium iodide (13). 1H NMR: 250 MHz (DMSO-d6): δ 3.04-3.12 m, 1H, aliphatic), 3.21-3.62 (m, 
3H, aliphatic), 3.39 (s, 3H, N+-CH3), 3.84 (s, 3H, COOCH3), 3.84-4.04 (m, 1H, aliphatic), 4.10-4.12 
(m, 1H, aliphatic), 5.15-5.20 (m, 1H, H-8), 6.33 and 6.36  (2s,  1H, 14b), 7.02-7.19 (m, 2H, aromatic), 
7.36-7.39 (m, 2H, aromatic), 7.51-7.63 (m, 4H, aromatic), 10.35 (s, 1H, indole-NH). 
7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine-8-carboxylic acid (16 and 17). 
1H NMR: 250 MHz (DMSO-d6): δ 2.29 (s, 3H, N-CH3), 2.61-3.03 (m, 6H, aliphatic), 3.27-3.31 (m, 1H, 
H-8), 4.17 (s, 2H, H-15), 6.88-7.01 (m, 2H, aromatic), 7.11-7.15 (mc, 3H, aromatic), 7.24-7.27 (d, J=8, 
1H, aromatic), 7.36-7.44 (m, 2H, aromatic), 10.88 (s, 1H, indole-NH). HRMS 357.159 (calcd. for 
C21H22N2O2: 357.158). 13C NMR: 250 MHz (DMSO-d6): δ 25.8 (5), 31.25 (9), 33.13 (15), 43.90 (N-
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CH3), 53.55 (6), 68.41 (8), 108.51 and 108.54 (13), 110.95 and 111.00 (9a), 117.70 (10), 118.69 (11), 
120.67 (12), 126.68 (3), 126.82 (1), 128.69 (9b), 130.68 (2), 130.85 (4), 135.31 and 135.47 (14a), 
136.39 and 136.53 (13a), 138.51 (4a), 139.59 (15a), 173.63 (C=O). HRMS: 357.159 (calcd. 
C21H22NaN2O2 357.158). 
 (8R)-8-(Hydroxymethyl)-7-methyl-5,6,8,9,14,14b-hexahydroindolo[2',3':3,4]pyrido[2,1-a]isoquin-
olin-7-ium iodide (22). 1H-NMR: 250 MHz (DMSO-d6): δ 3.00-3.18 (m, 1H, aliphatic), 3.23 and 3.27 
(2s, 3H, N+-CH3), 5.56-5.60 and 5.64-5.68 (2t, J=5, 5H, H-8), 6.11 and 6.27 (2s, 1H, H-14b), 7.00-7.62 
(m, 8H, aromatic), 10.23 and 11.55 (2s, 1H, indole-NH). 
[(8R)-7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-8-yl]methanol  (24). 
 = -158.4° (c 1.26, CHCl3). 1H-NMR: 400 MHz (CDCl3): δ 2.27 (s, 3H, N-CH3), 2.80-2.95 (m, 
5H, aliphatic), 3.00-3.11 (m, 1H, aliphatic), 3.16-3.23 (m, 1H, aliphatic), 3.68-3.72 (m, 1H, CH2OH), 
3.77-3.81 (m, 1H, CH2OH), 4.14-4.18 (d, J=15, 1H, H-15), 4.35-4.38 (d, J=15, 1H, H-15), 7.07-7.28 
(m, 6H, aromatic), 7.34-7.36 (d, J=7, 1H, aromatic), 7.48-7.50 (d, J=8, 1H, aromatic), 7.91 (s, 1H, 
indole-NH). HPLC retention time:  min (%) and  min (%). (Column: Teicoplanin T (150 x 4.6 mm i.d.); 
eluent: methanol-glacial acetic acid-triethylamine, (100:0.50:0.025); flow rate: 1.0 mL/min; UV detector 
λ= 282 nm). 
 [(8S)-7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-8-yl]methanol  (25). 
= 161° (c 1.25, CHCl3).1H-NMR: 400 MHz (CDCl3): δ 2.28 (s, 3H, N-CH3), 2.79-2.94 (m, 5H, 
aliphatic), 3.00-3.11 (m, 1H, aliphatic), 3.16-3.24 (m, 1H, aliphatic), 3.69-3.73 (m, 1H, CH2OH), 3.78-
3.82 (m, 1H, CH2OH), 4.14-4.17 (d, J=15, 1H, H-15), 4.35-4.38 (d, J=15, 1H, H-15), 7.07-7.28 (m, 6H, 
aromatic), 7.34-7.36 (d, J=7, 1H, aromatic), 7.48-7.50 (d, J=8, 1H, aromatic), 7.88 (s, 1H, indole-NH). 
13C-NMR: 400 MHz (CDCl3): δ 25.86 (5), 32.18 (9), 33.00 (15), 40.98 (N-CH3), 53.71 (6), 63.28 
(CH2OH), 64.18 (8), 110.43 (13), 110.63 (9a), 118.23 (10), 119.30 (11), 121.51 (12), 126.69 (3), 127.17 
(1), 128.54 (9b), 130.26 (2), 130.69 (4), 133.39 (14a), 135.61(13a), 136.93 (4a), 140.07 (15a). HPLC 
retention time:  min (%) and  min (%). (Column: Teicoplanin T (150 x 4.6 mm i.d.); eluent: methanol-
glacial acetic acid-triethylamine, (100:0.50:0.025); flow rate: 1.0 mL/min; UV detector λ= 282 nm). 
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Dibenzazecines are a novel class of dopamine receptor antagonists, characterized by their high 
affinities as well as their tendency for D1-selectivity.  Hitherto, the most active dibenzazecines were 
phenolic in nature; a 3-hydroxyl substituent was found to result in the highest affinities. However, the 
phenolic nature of these compounds mostly renders them unsuitable for in vivo application, due to the 
poor pharmacokinetic profile, imparted by the phenolic group. A novel dibenzazecine derivative was 
prepared, bearing a methylenedioxy moiety at the 2,3-position instead of the 3-hydroxyl group. The 
newly synthesized derivative 3 showed high affinities similar to the lead LE404, displaying nanomolar 
affinities for all dopamine receptor subtypes. Its dibrominated derivative 4, though exhibiting almost a 
fivefold decrease in affinities, still displayed nanomolar ones for all dopamine receptors, except for D4. 
In a functional Ca2+ assay both compounds 3 and 4 were found to possess antagonistic properties at the 
dopamine receptors. 
Introduction: Dopamine is a regulator of numerous physiological functions in the CNS and the 
periphery. Dysfunctions of the dopaminergic system have been implicated in the pathogenesis of 
several neurological disorders, including schizophrenia, Parkinson’s disease, depression, attention-
deficit hyperactivity disorder (ADHD) as well as drug and alcohol dependence. [1;2]  
Dibenz[d,g]azecines are a novel class of dopamine receptor antagonists, which are distinguished by 
their new chemical structure as well as their high affinities for dopamine receptors, predominantly for 
the D1 family. [3;4] SAR studies on this new class of compounds revealed that derivatives 
encompassing a dibenz[d,g]azecine moiety as the backbone structure  and bearing a hydroxyl 
substituent at position 3 (e.g. compound 1; LE404), display the highest affinities, specifically for 
human D1 and D5 receptors. [3-5] Changing the position of the hydroxyl group or replacing it by a 
methoxy function both led to decreased affinities. [4] Surprisingly, a 2,3-dihydroxy substitution 
pattern (compound 2; LE403), which bears the most structural resemblance to dopamine, the natural 
ligand, showed ca. 100-1000 fold lower affinities than the monohydroxylated LE404). [3]   
However, the high affinities of these dopamine antagonists are coupled with drawbacks. Phenols and 
especially dihydroxylated compounds tend to be chemically unstable. Due to their phenolic nature, 
these compounds are predisposed to poor pharmacokinetics (low bioavailability), which would restrict 
their utility for in vivo experiments and render them unsuitable for clinical development. Accordingly, 
our preliminary in vivo evaluations have shown that compound 1 (LE404) has a low oral 
bioavailability when administered to rats. (Schulze et al., J. Pharmacol. Exp. Therapeutics submitted)  
Studies on other classes of phenolic dopamine antagonists, in particular SCH23390 and SCH39166, 
have revealed similar results. [6;7] Both compounds showed very low bioavailability besides a short 
duration of action. The latter fact has been attributed to the fast biotransformation of these phenolic 
compounds, occurring mainly by glucuronidation at the phenolic function. [6;7] Analogues lacking 
1
this phenolic group have indeed been found to exhibit better pharmacokinetics and longer duration of 
action, which is more advantageous for in vivo application. [8] 
 
 
Figure 1. The 3-hydroxybenzazecine derivative LE404, the inactive 2,3-dihydroxy analogue LE403, and the 
target methylenedioxy analogues 3 and 4 
Goal of the present study was to prepare a dibenz[d,g]azecine where positions 2 and 3 are connected 
through a methylenedioxy moiety. This was appealing for the following reasons. 
• Our previous studies have shown that the nature, number and position of the substituents at the 
benzene ring significantly affect the binding affinities. It was hence interesting to investigate the 
influence of this spatially rather confined group on the affinities. A methylenedioxy moiety, shares 
similar electronic properties with the 2,3-dihydroxy and -dimethoxy substituents, but is spatially 
distinct from all previously examined substitution patterns. 
• Compared with the previously synthesized phenolic dibenzazecines the target compound 3 is 
presumably chemically more stable and conceivably of better pharmacokinetics. 
Results: 
Chemistry: As outlined in Scheme 1, the target dibenzazecine 3 was obtained through its pentacyclic 
precursor quinolizine 7. Our previously established procedure, where the amine was reacted with 2-(2-
bromoethyl)benzaldehyde in the presence of trifluoroacetic acid, [9] only yielded the intermediary 
isoquinolinium salt 6 and not the expected quinolizine 7. Trials to cyclise the obtained isoquinolinium 
salt by Pictet Spengler cyclization using 6N HCl were unsuccessful. The quinolizine 7 was thus 
achieved through the reaction of the precursor amine 5 with 2-(chloroethyl)benzoyl chloride, and the 
obtained intermediate was directly cyclised using Bischler-Napieralski conditions and subsequently 
reduced. Conversion of the quinolizine 7 to the target dibenzazecine 3 was similarly knotty. 
Conventionally at that step, the quinolizine derivative (7) was quaternized with methyl iodide and the 
obtained quaternary salt was cleaved under Birch conditions to the corresponding azecine. In this case, 
reduction of the quaternary salt 8 with sodium in liquid ammonia gave a 1:1 mixture of two different 
compounds having the same molecular weight. These substances were identified by means of GCMS 
as the phenolic azecines 1 (LE404) and 9, which was confirmed by spiking the GCMS with reference 
samples of 1 and 9, both available in our lab from previous work. The phenomenon of the cleavage of 
the methylenedioxy moiety under various reductive conditions has been formerly described. [10;11] 
For instance, reduction under Birch conditions (sodium and liquid ammonia) was found to result in the 
cleavage of methylenedioxy derivatives, yielding the respective p-phenolic compounds. [10] It has 
2
been suggested that the nature of the substituent positioned opposite to the methylenedioxy moiety 
directs the site of cleavage, which leads to the formation of either the m- or p-phenolic compound.  In 
our case, however, cleavage of the methylenedioxy group occurred at two different positions and not 
at only one position, as observed with reported methylenedioxy derivatives. [10] This of course may 
be attributed to the fact that both substituents lying across the methylenedioxy group exert equal 
effects.  
Scheme 1. 
Reagents and conditions: (a) TFA, dioxane, reflux, 12 h; (b) 6N HCl, reflux, 10 h; (c) NEt3, CH2Cl2, rt, 90 min; (d) 
POCl3/MeCN (1:2), reflux, 36h; NaBH4, MeOH, reflux, 2h;  (e) MeI, acetone; (f) Na0, liq. NH3, -40⁰C, 10min; (g) ClCOOEt, 
dry THF, -65⁰C, 4h, then NaCNBH4, -65⁰C to rt; (h) LiAlH4, dry THF, reflux, 2h; (i) Br2, AlCl3, CH2Cl2, rt, 10h. 
To accomplish ring opening and avoid degradation of the methylenedioxy function, the quinolizine 7 
was first converted to the carbamate 10 according to literature [12], which was subsequently reduced 
with LAH to give the target compound 3. This azecine was further dibrominated, to examine the 
impact of the additional bromine atoms on the affinities. Unfortunately, the monobrominated 
derivatives could not be obtained, even when equimolar amounts of bromine were used.    
Pharmacology:  
The target compounds 3 and 4 as well as the precursor quinolizine 7 were screened for their affinities 
for the human cloned dopamine receptor subtypes D1, D2L, D3, D4.4, and D5. These receptors were 
stably expressed in HEK293 or CHO cells; [3H]SCH23390 and [3H]spiperone were used as 
radioligands at the D1-like and D2-like receptors, respectively. Ki values are given in nanomolar units 
(Table 1). In addition, the compounds were tested in an intracellular Ca2+ assay, to determine their 
functionality at the D1 and D2 receptors. For this purpose, HEK293 cells, stably expressing the 
respective D-receptor were loaded with a fluorescent dye, and after preincubation with rising 
concentrations of the test compound, an agonist (SKF 38393 for D1 and quinpirole for D2) was 
injected and the Ca2+-induced fluorescence was measured with a microplate reader. The ability of the 
test compound to suppress the agonist-induced Ca2+ influx is an indication of antagonistic or inverse 
agonistic properties at the receptor. Both the radioligand binding assay and the Ca2+ assay have been 






Table 1. Affinities (Ki, nM) For Human D1-D5 Receptors, Determined by Radioligand Binding Experiments  














341±41a >5000a n.d. 165±12a 1078±42a 
 
3 3.6±1* 5.5±1.2* 20.6±5.5* 46.0±9.9* 0.5±0.01* 
 
4 35.0±14.5* 30.0±19.6* 38.9±1.1* 2760 ± 552* 4.7±1.9* 
 
7 >10000 >10000 >10000 >10000 >10000 
 
11 28.5±9.7b 13.0±9.00b 75.7±7.30b 43.4±13.3c 54.0±20c 
 
12 8.9±0.8b 36.9±27.8b 296±60.0b 913±79.0 8.92±0.82 
 
13 82.0±30b 62.0±5.00b 151±57.5b 5987±675 14.4±8.5 
 
14 8.70±2.00b 84.1±2.75b 215±94b 202±73.5 8.6±3.9 
 
15 7.6±1.5 b 164±12 b 1833±292 b 390±160 10.5±2.8 
 
16 509±51 >5000 n.d. 2514±101 2610±120 






















































The newly synthesized dibenzazecine derivative 3 proved to be a highly active dopamine antagonist 
(functional Ca2+ assay), showing comparatively high affinities at the different dopamine receptors as 
the lead compound 1 (LE404), all lying in the nanomolar range. The D1 selectivity profile, 
encountered with most members of this class of dopamine antagonists, was however lost. Compound 3 
displayed equal affinities for the D1 and D2 subtypes and showed the highest selectivity for the D5 
receptor (D1/D5≈7). With respect to the affinities, compound 3 is superior to previously synthesized 1- 
and 2-monohydroxylated derivatives (14 and 12) and the 1-, 2- and 3-monomethoxylated 
dibenzazecine derivatives (15, 13 and 11) and similarly active to the 3-hydroxylated compound 1. 
Compared with the 2,3-dihydroxy (2) and the -dimethoxy derivative (16) it showed a tremendous 
improvement in affinities; almost 100 fold increase in the affinity for D1 and 1000 fold for D2 and D5 
was observed. The dibromo derivative 4 displayed the highest affinity for the D5 receptor , for the D1, 
D2 and D3 it showed similar but somewhat lower affinities while the D4 affinities were strongly 
decreased.  
Previous SAR studies have already indicated that a hydroxyl group at position 3 of the dibenzazecine 
ring is crucial for high affinities. It presumably interacts through H-bond formation with a serine 
residue (Ser 5.46 or Ser 5.50) in the receptor binding pocket, as already observed with other dopamine 
antagonists at the D2 receptor. [13]  
Derivatives bearing a methoxy substituent especially at position 2 or 3 showed significantly decreased 
affinities.This could be attributed to the fact that a methoxy group, which rotates freely, is spatially too 
bulky for the receptor binding site. A 2,3-dimethoxy substitution pattern requires much more space 
due the free internal rotation of both methoxy groups, hence resulted in a pronounced decrease in 
affinities. Conversely, a methylenedioxy substituent, which requires less space due to its restricted 
rotation, showed similarly high affinities as the highly active 3-hydroxy derivative 1. From our 
observations it can be drawn that the phenolic compounds rather act as H-acceptor than as H-donor.  
Taken together, a methylenedioxy moiety placed at the 2,3-position of the dibenzazecine ring is not 
only favoured in terms of chemical stability and pharmacokinetics but also in regards to the binding 
affinities to dopamine receptors.  
Experimental: 
General methods. Melting points are uncorrected and were measured in open capillary tubes, using a 
Gallenkamp melting point apparatus. 1H- and 13C-NMR spectral data were obtained from a Bruker 
Advance 250 spectrometer (250 MHz) and Advance 400 spectrometer (400 MHz). TLC was 
performed on silica gel F254 plates (Merck). MS data were determined by GC/MS, using a Hewlett 
Packard GCD-Plus (G1800C) apparatus (HP-5MS column; J&W Scientific). Purities of the 
compounds were determined by elemental analysis, performed on a Hereaus Vario EL apparatus. All 
values for C, H and N were found to be within ± 0.4. All compounds showed >95% purity. 
2-[2-(1,3-Benzodioxol-5-yl)ethyl]-3,4-dihydroisoquinolinium trifluoacetate (6) 
A solution of 2-(1,3-benzodioxol-5-yl)ethylamine (5) (1.65 g, 10 mmol), 2-(2-
bromoethyl)benzaldehyde [15] (3.2 g, 15 mmol) and trifluoroacetic acid (1.7 g, 15 mmol) in dioxane 
(40 ml) was heated under reflux for 12 hours. The isoquinolinium salt, and not the expected 
quinolizinium salt, separated as a yellow solid. This was filtered off, washed with dioxane, then 
diethylether and dried (1.2 g, 36%). M.p. 214-216°C. 1H-NMR: 250 MHz (MeOD-d4): δ 3.16-3.22 (t, 
J = 7, 2H, 4), 3.25-3.31 (t, J = 8, 2H, ethylene-2), 4.10-4.16 (t, J = 8, 2H, ethylene-1), 4.24-4.30 (t, J = 
7, 2H, 3), 5.93 (s, 2H, OCH2O), 6.74-6.81 (mc, 2H, aromatic), 6.89 (s, 1H, aromatic), 7.48-7.56 (m, 
2H, aromatic), 7.73-7.83 (m, 2H, aromatic), 8.91 (s, 1H, N+=CH). 
5
5,8,9,14b-Tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[1,2-a]isoquinoline (7) 
To an ice-cooled solution of 2-(1,3-benzodioxol-5-yl)ethylamine (5) (2.97 g, 18 mmol) in 
dichloromethane (30 ml) was added triethylamine (5.45 g, 54 mmol) followed by a solution of 2-
(chloroethyl)benzoylchloride (4.02 g, 19.8 mmol) in dichloromethane (10 ml). The reaction mixture 
was stirred at room temperature for 90 min, subsequently washed with 10% HCl (2x30 ml) followed 
by brine (30 ml). The organic layer was dried over Na2SO4 and evaporated under reduced pressure 
yielding a brown oil. This crude amide was dissolved in a mixture of POCl3/acetonitrile (15 ml/30 ml) 
and the reaction mixture was heated under reflux for 36 h. The solvents were then removed under 
reduced pressure and the remaining POCl3 was removed by washing with petroleum ether (40-60) 
followed by diethylether. The residue was dissolved in methanol (150 ml) without prior purification, 
then NaBH4 (4 g) was carefully added to the ice-cooled solution. The reaction mixture was heated 
under reflux for 2 h, the solvent was subsequently removed under reduced pressure and the residue 
treated with water (100 ml) and extracted with diethylether (2x100ml). The collected organic layers 
were dried over Na2SO4 and evaporated under reduced pressure. The obtained oil was purified by 
column chromatography (EtOAc/MeOH, 9:1) yielding a yellowish white oil (0.52 g, 10%) which 
solidified on standing. M.p. 122-123°C. 1H-NMR: 250 MHz (CDCl3): δ 2.74-2.94 and 3.04-3.26 (2m, 
8H, 5, 6, 8 and 9), 5.00 (s, 1H, 14b), 5.89 and 5.91 (2s, 2H, 12), 6.61 (s, 1H, 10), 6.69 (s, 1H, 14), 
7.11-7.26 (m, 4H, 1-4). GC-MS: m/z: 278 (100%), 250 (25%), 191 (8%), 178 814%), 165 (16%), 148 
(11%), 130 (11%), 115 (24%), 103 (19%), 89 (23%), 77 (39%), 63 (30%). Anal. calcd. for C18H17NO2 
x 0.1 EtOAc: C 76.79%, H 6.23%, N 4.86%. Found: C 76.73%, H 6.19%, N 4.94%. 
Ethyl 5,8,9,15-tetrahydrobenzo[d][1,3]benzodioxolo[5,6-g]azecine-7-carboxylate (10) 
A stirred solution of the quinolizine 7 (0.78 g, 2.7 mmol) in dry THF (50 ml) was cooled in 
methanol/dry ice at -65°C. While keeping the reaction mixture under nitrogen, ethyl chloroformate 
(1.63 g, 15 mmol) was added and stirring was continued for 4 h. Then a solution of sodium 
cyanoborohydride (0.59 g; 9.4 mmol) in dry THF (10 ml) was slowly added at -65°C and the reaction 
mixture was stirred overnight while allowing it to reach room temperature. It was subsequently treated 
with 2N NaOH (120 ml), the THF layer was separated, washed with brine, and finally the organic 
layer was evaporated under reduced pressure to give a yellow waxy solid. The obtained product was 
purified using column chromatography (EtOAc/n-hexane, 1:2) yielding a white solid (0.65 g, 69%). 
M.p. 110°C 1H-NMR: 400 MHz (CDCl3): δ 0.74-0.80 and 0.94-1.00 (2t, J = 11, 3H, OCH2CH3), 2.33-
2.37 and 2.46-2.50 (2t, J = 9, 2H, 5), 2.86-2.94 (m, 2H, 9), 3.40-3.57 (m, 4H, 6,8), 3.79-3.78 and 3.82-
3.90 (2q, J = 11, 2H, OCH2CH3), 3.98 (s, 2H, 15), 5.89 (s, 2H, 12), 6.57, 6.61, 6.64 and 6.74 (4s, 2H, 
10, 14), 7.03-7.26 (m, 4H, 1-4). 13C-NMR: 400 MHz (CDCl3): δ 14.35 and 14.33 (OCH2CH3), 32.63 
and 33.09 (5), 33.82 and 34.17 (9), 37.94 and 38.44 (15), 51.74 and 51.86 (6), 52.85 and 53.69 (8), 
60.80 and 60.90 (OCH2CH3), 100.78 (12), 126.23, 126.47, 126.68 and 126.75 (2, 3), 129.97 and 
130.92 (1), 131.06 and 132.08 (4), 132.39 and 132.77 (9a), 133.46 and 133.67 (14a), 139.53 and 
139.60 (4a), 140.00 and 140.34 (15a), 146.07, 146.26 and 146.56 (10a, 13a), 156.38 (C=O). 
GC-MS: m/z: 353 (28%), 280 (9%), 248 (31%), 237 (16%), 220 (72%), 207 (12%), 191 (17%), 178 
(70%), 165 (100%), 152 (47%), 139 (19%), 128 (30%), 115 (64%), 104 (70%), 91 (41%), 77 (55%), 
65 (41%). Anal. calcd. for C21H23NO4: C 71.37%, H 6.56%, N 3.96%. Found: C 71.17%, H 6.58%, N 
3.87%. 
7-Methyl-5,6,7,8,9,15-hexahydrobenzo[d][1,3]benzodioxolo[5,6-g]azecine (3) 
A solution of compound 10 (0.8 g, 2.3 mmol) in dry THF (20 ml) was slowly added to an ice-cooled, 
stirred suspension of lithium aluminium hydride (0.25 mg, 9 mmol) in dry THF (75 ml) while keeping 
the reaction under nitrogen. After the addition was completed, the reaction mixture was heated under 
reflux for 2 h. It was then cooled in an ice bath, and the excess of unreacted lithium aluminium 
hydride was quenched by careful addition of saturated potassium sodium tartarate solution until no 
further H2 evolved. The resulting suspension was then filtered off and the filtrate evaporated under 
6
reduced pressure, to give a white waxy solid a (0.65 g, 97%). The obtained product was purified by 
column chromatography (EtOAc/MeOH, 9:1). M.p. 70-71°C. 1H-NMR: 250 MHz (CDCl3): δ 2.26 (s, 
3H, N-Me), 2.64-2.71 (mc, 8H, 5, 6, 8, 9), 4.35 (s, 2H, 15), 5.88 (s, 2H, 12), 6.56 (s, 1H, 10), 6.75 (s, 
1H, 14), 7.04-7.33 (m, 4H, 1-4). 13C-NMR: 250 MHz (CDCl3): δ 34.46 and 34.48 (5, 9), 38.06 (15), 
46.92 (N-Me), 60.70 and 60.74 (6, 8), 100.66 (12), 109.99 (10, 14), 126.10 and 126.29 (2, 3), 130.52 
and 130.89 (1, 4), 133.63 and 133.88 (9a, 14a), 141.02 and 141.09 (4a, 15a), 145.78 and 145.84 (10a, 
13a). GC-MS: m/z: 295 (12%), 237 (30%), 223 (38%), 207 (10%), 190 (32%), 178 (60%), 165 
(100%), 152 (39%), 139 (16%), 128 (21%), 115 (55%), 103 (33%), 89 (43%), 71 (60%), 63 (41%). 
Anal. calcd. for C19H21NO2 x 0.1 EtOAc: C 76.60%, H 7.22%, N 4.60%. Found: C 76.78%, H 7.28%, 
N 4.57%. 
10,14-Dibromo-7-methyl-5,6,7,8,9,15-hexahydrobenzo[d][1,3]benzodioxolo[5,6-g]azecine (4) 
To a suspension of compound 3 (0.15 g, 0.5 mmol) and anhydrous AlCl3 (0.03 g, 0.23 mmol) in 
dichloromethane (4 ml) was slowly added a solution of bromine (0.4 g, 2.5 mmol) in dichloromethane 
(2 ml). After 10 h of stirring at room temperature, the reaction mixture was poured onto a saturated 
solution of sodium metabisulfite (50 ml) and extracted twice with dichloromethane (2x15 ml). It was 
washed with saturated NaHCO3 solution (2x50 ml) and twice with water (2x50 ml). The organic layer 
was dried over Na2SO4 and evaporated under reduced pressure, leaving a brownish solid, which was 
crystallized from methanol giving yellow crystals. (0.15 g, 67.6%). M.p. 135-136°C. 1H-NMR: 250 
MHz (CDCl3): 2.35 (s, 3H, N-Me), 2.65-2.78 (m, 8H, 5, 6, 8, 9), 4.86 (s, 2H, 15), 6.09 (s, 2H, 12), 
7.03-7.26 (m, 4H, 1-4). 13C-NMR: 250 MHz (CDCl3): δ 32.71 (5), 34.88 ( 9), 37.95 (15), 46.54 (N-
Me), 58.89 (6), and 60.79 (8), 101.26 (12), 104.23 and 104.43 (10, 14), 126.24 (2), 126.43 (3), 130.15 
(4), 130.79 (1), 135.17 (9a), 135.59 (14a), 139.31 (4a), 141.35 (15a), 144.20 and 144.27 (10a, 13a). 
Anal. calcd. for C19H19Br2NO2: C 50.36%, H 4.23%, Br 35.26%, N 3.09%. Found: C 50.20%, H 
4.29%, Br 35.08%, N 2.96%. 
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4. Unpublished results 
4.1. Trials to synthesize the [4,3-ef][2]benzazecine and indolo[4,3-de][2]benz-
azonine derivatives 3 and 4 
The indolo[4,3-ef][3]benzazecine and indolo[4,3-fg][3]benzazaundecene derivatives 1 and 2 
showed a strong discrepancy in activities (paper 1). Compound 1 containing a ten-
membered central ring displayed no notable affinities for the dopamine receptors, while 2 
encompassing an eleven-membered central ring was similarly active to the lead compound 
LE300. Therefore, it was interesting to examine the affinities of other ring size-reduced 

























Figure 4.1: Ring size-reduced analogues of the active indolo[4,3-fg]benzazaundecene and the inactive 
indolo[4,3-ef]benzazecine derivatives. 
To obtain the target derivatives 3 and 4, the precursor lactams 5 and 6 were prepared 
following a previously reported procedure used for the synthesis of analogous lactams106. For 
this purpose, the respective amines (4-aminoethyl- and 4-aminomethylindole) were reacted 
with 2-formylbenzoic acid in a mixture of ethanol and water in the presence of sulfuric acid. 
(Figure 4.2) Diverse trials to reduce the obtained lactams to the corresponding quinolizine 
and indolizine derivatives 7 and 8 were all in vain; the unreacted lactams were ultimately 
1 2 
3 4 
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recovered. These trials included reduction with lithium aluminum hydride, alane (a mixture of 






















Figure 4.2: Synthetic route for the synthesis of indolo[4,3-ef][2]benzazecine and indolo[4,3-de][2]benzazonine. 
4.2. LE300 substituted at the methylene bridge 
Small substituents (methyl and ethyl) at the indole nitrogen of LE300 have been found to be 
either advantageous or well tolerated with regard to the biological activity (paper 2). It was 
thus interesting to similarly substitute the neighboring methylene group connecting both 
aromatic moieties in order to test the effect of small substituents placed near the indole 
nitrogen. We have already reported on the 15-methylated derivative 9112 (table 4.1), here it 
was planned to further derivatize that position with an ethyl and a methoxy group. 



















Figure 4.3: Scheme for the synthesis of an LE300 derivative substituted at the methylene bridge. 
The target 15-ethylated LE300 (10) was obtained in a four-step-procedure. First the 
quinolizine 11 was oxidized by iodine to the imminium salt 12, which was treated by the 
Gringard reagent from Mg and ethyl iodide to give the 14b-ethylated quinolizine 13. The latter 
was quaternized with methyl iodide and acetone and subsequently reduced under Birch 
conditions to afford the desired benzindoloazecine derivative 10. (Figure 4.3)  
11 12 13  10 
5, 6 7, 8 3, 4 
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4.2.2. Trials to synthesize an LE300 derivative bearing a methoxy group at the 
methylene bridge 
First, the 7-cyano-15-methoxybenzindoloazecine derivative 14 was prepared by reaction of 
the quinolizine 11 with cyanogen bromide and methanol according to a procedure described 



















Figure 4.4: Synthetic approach for the synthesis of an LE300 derivative substituted with a methoxy group at the 
methylene bridge. 
Applying the reported procedure for the conversion of the cyano- (14) to the corresponding 
methylazecine 15, namely by reduction with lithium aluminum hydride113, unexpectedly led to 






















Figure 4.5: Speculated mechanism for the conversion of the cyanoazecine 14 into the starting quinolizine 11 after 
reduction with lithium aluminum hydride. 
This presumably took place through the formation of the intermediary carbamic acid 
derivative, which dissociates by elimination of carbon dioxide. The formed intermediate, 
bearing negatively charged nitrogen, is unstable and thus directly eliminates a methoxide 
moiety to give the unsubstituted quinolizine derivative 11. (Figure 4.5) It is however 
incomprehensible why this elimination took place in case of the cyanobenzindoloazecine 
derivative and not as reported113 with related benzothiophene and thiophene derivatives. 
11 14 15 
11 
14 
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4.2.3. Affinities for the dopamine receptors 
Results of the radioligand binding experiments (table 4.1) revealed that substitution at 
position 15 of the benzindoloazecine scaffold is not well tolerated; both ethyl and methyl 
substitution led to a decrease in affinities, most pronouncedly for the D3-receptor.  
The cyanoazecine derivative 14 was found to be devoid of affinities for all dopamine 
receptors (Ki >10000 nM), most likely due to the decreased (or nonexistent) basicity of the 
central nitrogen. (For Ki values see Table 4.1) 
Table 4.1: Affinities (Ki, nM) of derivatives substituted at the methylene bridge. 
  Ki (nM), (Radioligand binding experiments) 





















>10000 >10000 n.d. >10000 >10000 
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4.3. 8-Substituted benzindoloazecines  
 
4.3.1. Racemized benzindoloazecines derived from D- and L-tryptophan 
In our attempts to synthesize LE300 derivatives substituted at position 8, we set to prepare 
benzindoloazecines starting from D- and L-tryptophan and to further derivatize them. Goal 
was not only to prepare derivatives bearing different functional groups in order to study the 
effect of the various substituents at that position, but also to obtain them in an 
enantiomerically pure form with the purpose of examining the influence of the 
stereochemistry on the affinities for the dopamine receptors. As described in paper 4 
enantiopure azecines substituted at position 8 with methyl and hydroxymethyl groups were 
obtained, and the affinities of the R- and S-enantiomers were found to be markedly different. 
Several other azecines substituted at position 8 with various functional groups, including 
carboxy (paper 4), acyl, amide and amine functions, were successfully prepared. (Figure 
4.6) Although enantiopure starting materials were used, various findings indicated that the 
obtained products were racemized and not enantiopure as expected. In the following part, 
the synthesis and binding affinities of these racemized products will be discussed.  
4.3.1.1. Synthetic route 
As described in paper 4, the quinolizine derivatives starting respectively from methyl D- and 
L-tryptophanate were prepared. These quinolizine were converted to the corresponding 
quaternary salts 16 and 17, which were subsequently hydrolyzed in an alkaline medium at 
0 °C to afford the carboxylic acid derivatives 18 and 19, as described in paper 4. Subsequent 
reduction under Birch conditions yielded the amino acid derivatives 20 and 21. (Paper 4) 
These were reduced into the hydroxymethyl derivatives 22 and 23 (paper 4), which were in 
turn acylated by benzoyl and acetyl chloride. In addition, the amino acid derivatives 20 and 
21 were converted to the diethylamide 26 and 27 and successively into the 
diethylaminomethyl derivatives 28 and 29. (Figure 4.6) 
However, our investigations (optical rotation and chiral HPLC analysis in co-operation with 
Dr. Hefnawy, King Saud University) indicated that the precursory azecines 20, 21, 22 and 23 
were not enantiomerically pure (paper 4), and conclusively all the subsequently obtained 
target azecines.  
Racemization evidently took place at a step prior to the hydroxymethyl derivatives 22 and 23. 
Reduction of the carboxylic to the hydroxymethyl group using lithium aluminum hydride 
clearly does not result in racemization; the same reaction conditions were applied elsewhere 
(paper 4), and the enantiopurity of the compounds was maintained.  
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Reagents and conditions: (a) 1N NaOH, MeOH, 0 °C, 2 h; (b) Na°, liq. NH3, -40 °C, 10 min;  (c) LiAlH4, dry 
THF, reflux, 5 h; (d) RCOCl, pyridine, 0 °C - rt, 3h; (e) HN(Et)2, EDCxHCl, DMAP, CH2Cl2, DMF, 40 °C, 24 h. 
Figure 4.6:  Scheme for the synthesis of various azecines derived from D- and L-tryptophan.  
Hence, finding the “culprit”, i.e. the reaction that resulted in racemization, is not difficult. Into 
consideration comes primarily the step where the ester function of the quaternary salts 16 
and 17 was hydrolyzed to the corresponding carboxylic acids 18 and 19.  Amino acids are 
generally known to be labile to racemization in alkaline medium. Although the conditions 
applied for the hydrolysis of 16 and 17 were mild (reaction was carried out at 0 °C), and 
similar conditions have been conventionally used for the hydrolysis of optically active methyl 
ester derivatives114;115, the quaternary amino acid salts (18 and 19) seem to be even more 
labile to racemization in alkaline medium than conventional amino acid derivatives. The most 
reasonable explanation is that the α-hydrogen in the quaternary salts 16 and 17 as well as 18 
and 19 is more acidic due to the additional neighboring positively charged ammonium 
function.   
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26, 27 28, 29 
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4.3.1.2. Affinities for the dopamine receptors 
The affinities of the obtained compounds for the dopamine receptors were assessed in a 
radioligand binding assay. (Table 4.2) In view of the fact that the obtained compounds are 
not enantiopure and that analogous enantiopure compounds showed a great difference in 
the affinities of the enantiomers (cf. paper 4), little can be deduced from the herein measured 
affinities.  
Table 4.2: Affinities (Ki, nM) of racemized 8-substituted LE300 derivatives.  
  Ki (nM), (Radioligand binding experiments) 
 Compounds D1 D2 D3 D4 D5 
20* 
 
>10000 >10000 >10000 >10000 657 ± 163 
21* 
 
>10000 >10000 n.d. >10000 1020 ± 368 
22* 
 
44.8 ± 29.6 200.7 ± 89.4 >10000 512 ± 274 93.2 
23* 
 
31.8 ± 13 566 ± 266 n.d. n.d. 23.1 ± 3.1 
24 
 
17.2 ± 6 430.5 ± 219.5 2214 ± 540 32.8 ± 11.5 16.6 ± 9.2 
25 
 
26.7 ± 2.5 244 ± 27 n.d. n.d. 12.0 ± 3.8 
27 
 
692.8 ± 279 2300 ± 1158 n.d. >10000 489.3 ± 35.8 
28 
 
12.8 946 ± 2 n.d. n.d. 11.4 ± 1.9 
29 
 
29.05 ± 4.9 648.3 ± 145.4 201.00 n.d. 20.9 ± 6.0 
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Indeed, the obtained Ki values may serve as additional evidence that partial racemization 
occurred, since no significant difference in the affinities of the ‘supposed’ R- and S- 
enantiomers could be observed. (Cf. compounds 22 and 23 as well as 28 and 29). 
Determination of the full affinity profile of the derivatives was hence not further pursued. 
Nevertheless, some deductions can be made from the determined affinity results when 
bearing in mind that these target compounds were obtained in an almost completely 
racemized form. (Table 4.2) No significant difference was observed between the racemized 
hydroxymethyl azecines 22 and 23 and the acylated ones 28 and 29, indicating that 
introduction of an acetyl group or even a bulkier benzoyl group might still be well tolerated at 
the receptor binding site. A diethylaminomethyl residue (compounds 28 and 29) seems to be 
similarly well tolerated, whereas its amide counterpart (compounds 26 and 27) showed a 
pronounced decrease in affinities. The most significant decrease in affinities was observed 
with the carboxylic acid residue (compounds 20 and 21). This was however highly 
remarkable, since they lacked affinities for all dopamine receptors, except for D5. (Paper 4)  
4.3.2. Enantiopure 8R- and 8S-methyl benzindoloazecine: Understanding the 
reason behind the discrepancy in their affinities 
As mentioned in paper 4  the S-enantiomer of the 8-methylated LE300 showed almost no 
difference in affinities to the lead LE300 while the R-enantiomer was at least 100-fold less 
active, showing micromolar affinities for the D1-like receptors and practically no affinities for 
D2-like receptors (Ki  >10000 nM). The vast difference in the affinities of the R- and S-
enantiomers could only be attributed to their different spatial arrangement, which in turn 
affects their binding to the receptor binding pocket. In order to picture these derivatives in 
space (no crystal structure could be obtained for the separated enantiomers), the X-ray 
structure (CCDC-198889) of the parent compound LE300 served as starting point.  
As depicted in figure 4.7, LE300 HCl has a folded structure (cage-like structure), where the 
central azecine ring is present in the form of a cage with both aromatic moieties at each side 
and the N-methyl group pointing into this “cage-like” structure. Interestingly, two energetically 
equivalent structures, that are mirror images to each others, were found in the X-ray 
structure. If the perspective is fixed so that the structure is bent forward, it becomes obvious 
that in one structure the indole ring is on the left side (A) and in the other on the right (B). 
This could be perceived as a kind of axial isomerism, originating at the methylene bridge 
connecting both aromatic rings.  
 









Figure 4.7: X-ray structure of LE300 HCl; two ‘enantiomers’ (mirror images; energetically equivalent) are found in 
a 1:1 ratio.  
To visualize the spatial arrangement of the obtained (8S)- and (8R)-methylated 
indolobenzazecines, one of the H-atoms in each of the aforementioned “mirror images” of 
LE300 HCl (figure 4.7,  A and B) was replaced by a methyl group, so that it bears an S- or 
an R-configuration. (Figure 4.8: S-A and S-B; and figure 4.9: R-A and R-B, respectively).  
The following observations can be made from figures 4.8 and 4.9:  
• Unlike LE300 (figure 4.7), the structures of both possible axial isomers obtained for 
the S-enantiomer (figure 4.8) are not mirror images and thus energetically 
nonequivalent. The same applies for the R-enantiomer.  
• The position of the additional methyl group (in red) is highly different in both axial 
isomers (compare S-A and S-B). In one structure the methyl group points into the 
bend azecine ring (S-B) and in the other outwards (S-A). 
• S-A and R-B are mirror images to each other and energetically equivalent, the same 
goes for S-B and R-A.   
A B 








Figure 4.8: Insertion of an (8S)-methyl group (in red) at position 8 of both ’enantiomers’ found in the X-ray of 









Figure 4.9: Insertion of an (8R)-methyl group (in red) at position 8 of both ‘enantiomers’ found in the X-ray of 
LE300 HCl.   
In conclusion, either S-A and R-B or S-B and R-A could exist as the possible conformers of 
the S- and R-enantiomers, respectively. This depends on the position of the 8-methyl group 
(pointing inwards or outwards the cage-like structure) which is energetically more favored. 
This means that the additional methyl group at position 8 would most probably force the ring 
into only one of the axial isomeric forms unlike LE300. 
• Consequently, a major difference between the S- and R-enantiomer would lie in the 
position of the indole and benzene ring with respect to the curved central azecine 
structure, in addition to the position of the 8-methyl group (left or right).  
R-A R-B 
S-A S-B 
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• This implies that the reason behind the activity of the S-enantiomer and the inactivity 
of the R-enantiomer might result from the spatial orientation of the axial isomer 
(indole to the left or to the right of the bent structure).  
• Unraveling the energetically more favored structure will not only help decipher the 
reason behind the high discrepancy in the affinity of the S- and R-enantiomer, but 
also reveal which of the axial isomers of LE300 is more active at the receptor binding 
site. 
As a preliminary step, the potential energy of the four different forms (S-A, S-B, R-A and 
R-B) in addition to both forms A and B of LE300 HCl was calculated. For this purpose, the 
Dreiding energy (as a parameter of the potential energy) was calculated using Chemaxon 
5.3.0. The results obtained are given in table 4.3. 


























Based on the calculated energy results, the conformations where the 8-methyl group points 
outwards, i.e. S-A and R-B,  are energetically markedly more favored than those where the 
8-methyl group points into the cage-like structure (S-B and R-A). Nevertheless, the 
determination of the lowest energy conformer by crystal structure or molecular dynamics is 
still needed to ascertain these findings.  
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Assuming that the S- and R- enantiomer exist in the S-A and R-B conformation, respectively, 
two reasons might lie behind the discrepancy in their affinities. First, the position of the indole 
ring with respect to the bend structure (left in S-, right in the R-enantiomer). This might 
indicate that the indole ring to the left side is more favored at the receptor binding pocket; 
which would also be applicable for unsubstituted benzindoloazecines such as the lead 
compound LE300.  
Second, the position of the 8-methyl group might also be of influence; to the left there could 
be enough space (S-enantiomer) while to the right it might present a steric hindrance at the 
binding pocket (R-enantiomer).  
More calculations and modelling approaches will be necessary to confirm these 
assumptions.  
4.4. Substitution of the alicyclic N with longer and functionalized side chains 
4.4.1. Synthesis of N-hydroxyhexyl LE300 
Previous studies have shown that a methyl substituent at the central aliyclic nitrogen is most 
favored, while longer substituents resulted in decreased affinities. Nevertheless, it remains of 
interest to examine how longer substituents bearing a functional group would affect the 
activities towards the dopamine receptors and whether a selectivity towards one of the 
receptor subtypes could be achieved. For this purpose, the N7-(6-
hydroxyhexyl)benzindoloazecine derivative 31 was prepared, and its affinities for the 














Figure 4.10: Synthesis of an LE300 derivative bearing a hydroxyhexyl chain at the alicyclic nitrogen. 
The target azecine was prepared in two steps. First the quinolizine 11 was treated with two-
molar excess of 6-bromohexanol - only very poor results were achieved with equimolar 6-
bromohexanol - and the resulting quaternary salt 30 was then reduced under Birch 




11 30 31 
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Table 4.4: Affinities (Ki; nM) of N7-(6-hydroxyhexyl)benzindoloazecine derivative 31. 
  Ki (nM), (Radioligand binding experiments) 






208 ± 28  315 70.1 
  
Trials to further derivatize the hydroxyl group into a diethylamine function through the 
tosylated derivative 32 failed. (Figure 4.11) The product obtained from the tosylation reaction 




















Figure 4.11: Trial to convert the hydroxyl to a diethylamine function.  
Another possible way of obtaining the N,N-diethylated derivative 33 is through selective 
quaternization of the quinolizine by dibromoalkane to the bromoalkyl quinolizinium salt 34. 
For this purpose the dibromoalkane should be used in excess to avoid the formation of the 
bivalent derivative 35. The formed quaternary salt 34 could then be derivatized by 
diethylamine then reduced under Birch conditions to obtain the desired azecine derivative. 
(Figure 4.12) Advantages of this method would be that different dibromoalkanes with varying 
chain length (which are easier to obtain and relatively inexpensive compared to 
bromoalcohol derivatives) could be used and derivatization of the obtained quaternary salts 
could be achieved by various amines. This would secure a wide variety of products enabling 
































Figure 4.12: Alternative route for the synthesis of LE300 derivatives with long functionalized chains at the alicyclic 
nitrogen.  
First trials to follow this route were promising. The bromohexyl quaternary salt 34 was 
obtained in a relatively pure form; 1H-NMR showed mainly the target quaternary salt 34 







4. Unpublished Results       47 
 
4.5. Synthetic procedures, spectral and analytical data 
4,5,11b,13-Tetrahydro-7H-isoindolo[2',1':1,2]azepino[3,4,5-cd]indol-7-one (5): To a 
solution of 4-aminoethylindole (3.38 g, 24 mmol) and 2-formylbenzoic acid (3.59 g, 24 mmol) 
in a mixture of 120 ml ethanol and 120 ml water was added 24 ml 2N H2SO4  and the 
reaction mixture was heated under reflux for 48 h. The product separated out as a black solid 
which was filtered off, washed with a mixture of water and ethanol (1:1) and dried. Yield 71%; 
m.p. 226-228 °C.  1H-NMR: 250 MHz (MeOD-d4): δ 3.30-3.59 (m, 2H, aliphatic), 3.82-3.93 
(m, 1H, aliphatic), 3.20-3.30 (m, 1H, aliphatic), 6.20 (s, 1H,  indole-CH-benzene), 6.82-6.84 
(d, J=7, 1H, aromatic), 6.99-7.02 (t, J=7, 1H, aromatic), 7.12-7.22 (d, J=8, 1H, aromatic), 
7.31 (s, 1H, aromatic), 7.51-7.54 (t, J=7, 1H, aromatic), 7.66-7.79 (m, 2H, aromatic), 7.92-
7.95 (d, J=8, 1H, aromatic).  
2,12b-Dihydroisoindolo[2,1-b]pyrrolo[4,3,2-de]isoquinolin-8(6H)-one (6): Starting from 4-
aminomethylindole (2.34 g, 16 mmol) and 2-formylbenzoic acid (2.4 g, 16 mmol) in a mixture 
of 80 ml ethanol, 80 ml water and 16 ml 2N H2SO4 the same procedure applied for the 
synthesis of compound 5 was adopted. A yellowish white solid was obtained. Yield 66%; 
m.p. 214 °C. 1H-NMR: 250 MHz (DMSO-d6): δ 4.55-4.61 (d, J=16, 1H, 6), 5.47-5.54 (d, J=16, 
1H, 6), 6.07 (s, 1H, indole-CH-benzene), 6.93-6.96 (d, J=7, 1H, aromatic), 7.06-7.12 (t, J=7, 
1H, aromatic), 7.20-7.23 (d, J=8, 1H, aromatic), 7.46-7.55 (m, 2H, aromatic), 7.67-7.73 (m, 
2H, aromatic), 8.08-8.11 (d, J=8, 1H, aromatic), 11.05 (s, 1H, indole-NH).  
14b-Ethyl-5,6,8,9,14,14b-hexahydroindolo[2',3':3,4]pyrido[2,1-a]isoquinoline (13): A 
solution of quinolizine 11 (274 mg, 1 mmol) and iodine (1.02 g, 4 mmol) in 70 ml ethanol was 
refluxed under nitrogen for 3.5 h. The solvent was removed under vacuum and then a 
saturated solution of sodium thiosulfate was added until the color of the mixture faded to 
yellow. The product was extracted with chloroform, the solvent removed under reduced 
pressure, leaving the imminium salt as a yellow solid.  
To a suspension of Mg-turnings (100 mmol) in dry diethyl ether was added ethyl iodide 
(5 mmol) and the suspension was warmed to 45 °C for 30 min. The reaction mixture was 
subsequently cooled in an ice-bath and a solution of the obtained imminium salt 12 (400 mg, 
1 mmol) in dry THF was slowly added. The ice bath was removed and the mixture refluxed 
for 5 h under nitrogen. The reaction was quenched by dropwise addition of water, and the 
product was extracted with diethyl ether. The organic solvent was dried over MgSO4 
evaporated under reduced pressure leaving a creamy white solid, which was column 
chromatographed using dichloromethane/methanol (75:2) as eluent. Yield 66%; m.p. 109 °C. 
1H-NMR 250 MHz (CDCl3): δ 0.73-0.79 (t, J=7, 3H, CH3CH2), 2.26-2.34 (q, J=7, 2H, 
CH3CH2), 2.67-2.91, 2.94-3.21, 3.48-3.64 (mc, 8H, 5, 6, 8, 9), 7.05-7.35 (m, 6H, aromatic), 
7.48-7.50 (d, J=7, 1H, aromatic), 7.57-7.60 (d, J=8, 1H, aromatic), 7.82 (s, 1H, indole-NH).  
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Anal. calcd. for C21H22N2 x 0.4 CH2Cl2: C 79.72%, H 7.07%, N 8.77%; found C 79.80%, H 
7.05%, N 8.55%.  
15-Ethyl-7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine (10): The 
quinolizine 13 was quaternized with methyl iodide and the obtained salt was reduced under 
Birch conditions following previously described procedures.105 White waxy solid. Yield 66%; 
m.p. 106 °C. 1H-NMR 250 MHz (CDCl3): δ 0.92-0.98 (t, J=7, 3H, CH3-CH2), 2.04-2.21 (m, 2H, 
CH3CH2), 3.22 (s, 3H, N-CH3), 2.52-3.54 (m, 8H, 5, 6, 8, 9),  4.85-4.91 (t, J=8, 1H, 15), 7.05-
7.28 (m, 6H, aromatic), 7.43-7.46 (m, J=7, 2H, aromatic), 7.88 (s, 1H, indole-NH). Anal. 
calcd. for C22H26N2 x H2O: C 78.53%, H 8.39%, N 8.33%; found C 78.76%, H 8.68%, N 
8.11%. 
15-Methoxy-5,6,8,9,14,15-hexahydro-7H-indolo[3,2-f][3]benzazecine-7-carbonitrile (14): 
To a solution of the quinolizine 11  (356 mg, 1.3 mmol) in dry THF and dry methanol (4:1) 
was added magnesium oxide (312 mg, 7.2 mmol) and cyanogen bromide (234 mg, 2.21 
mmol). The reaction mixture was stirred at room temperature for 2 h, filtered off to get rid of 
magnesium oxide, and the filtrate was removed under reduced pressure. The residue was 
suspended in water and the product extracted with dichloromethane. The organic layer was 
dried over MgSO4 and evaporated under reduced pressure leaving a white solid. Yield 93%; 
m.p. 213-214 °C 1H-NMR: 250 MHz (CDCl3): δ 2.26-2.66, 2.89-3.01, 3.05-3.08, 3.18-3.32 
and 3.88-3.90 (m, 8H, 5, 6, 8 and 9), 3.37 (s, 3H, OCH3), 5.96 (s, 1H, 15), 7.05-7.11 (t, J=7, 
1H, aromatic), 7.16-7.26 (m, 2H, aromatic), 7.32-7.42 (m, 4H, aromatic), 7.51-7.54 (d, J=7, 
1H, aromatic), 8.92 (s,1H, indole NH). 13C-NMR: 250 MHz (CDCl3): δ 23.76 (5), 32.86 (9), 
55.40 (8), 56.07 (OCH3), 56.28 (6), 74.75 (15), 107.85 (9a), 111.21 (13a), 117.45 (11), 
118.01 (CN), 119.24 (10), 121.99 (12), 128.02 (3), 128.06 (9b), 128.18 (2), 128.92 (1), 
129.55 (4), 134.77 (14a), 136.95 (4a), 138.41 (13a), 138.56 (15a).  
(7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-8-yl)methyl benzoate 
(24) To an ice-cold solution of the methylalcohol derivative 23 (150 mg, 0.47 mmol) in 2 ml 
pyridine was added benzoyl chloride (70 mg, 0.5 mmol), and the reaction mixture was stirred 
at room temperature for three hours. It was then poured onto ice water and extracted with 
dichloromethane. The organic layer was washed with 0.1 N HCl, with water and then with a 
dilute solution of sodium bicarbonate, and finally evaporated under reduced pressure. The 
obtained product was purified by column chromatography using ethyl acetate/hexane (1/1). 
Yield 53.1%; m.p. 70-71 °C. 1H-NMR: 400 MHz (CDCl3): δ 2.41-2.46 (m, 1H, aliphatic), 2.46 
(s, 3H, N-CH3), 2.64-2.69 (m, 1H, aliphatic), 2.83-2.90 (m, 3H, aliphatic), 2.99-3.04 (m, 1H, 
aliphatic), 3.12-3.18 (m, 1H, aliphatic), 4.25-4.28 (d, J=15, 1H, 15), 4.37-4.54 (m, 3H, 15 and 
CH2OH), 7.06-7.10 (t, J=7, 1H, aromatic), 7.13-7.22 (m, 4H, aromatic), 7.28-7.32 (m, 2H, 
aromatic), 7.46-7.53 (m, 3H, aromatic), 7.57-7.64 (m, 1H, aromatic), 7.98 (s, 1H, indole-NH), 
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8.09-8.14 (m, 2H, aromatic). Anal. calcd. for C28H28N2O2 x ⅓EtOAc: C 77.62%, H 6.81%, N 
6.17%; found C 77.34%, H 6.59%, N 5.80%. 
(7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-8-yl)methyl acetate 
(25) The methylalcohol derivative 23 (128 mg, 0.4 mmol) was acetylated using acetyl 
chloride (35 mg, 0.44 mmol), following the same acylation procedure described for 
compound 24. The product was chromatographed with dichloromethane/MeOH (19:1). Yield 
35%; m.p. 69-70 °C. 1H-NMR: 250 MHz (CDCl3): δ 2.13 (s, 3H, COCH3), 2.32-2.42 (m, 1H, 
aliphatic), 2.38 (s, 3H, N-CH3), 2.58-3.01 (m, 6H, aliphatic), 4.04-4.30 (m, 3H, H-15 and 
CH2OH), 4.36-4.42 (d, J=15, 1H, 15), 7.06-7.30 (m, 7H, aromatic), 7.46-7.48 (d, J=7, 1H, 
aromatic), 7.96 (s, 1H, indole-NH). Anal. calcd. for C23H26N2O2 x 0.5 MeOH: C 74.57%, H 
7.46%, N 7.40%; found C 74.64%, H 7.44%, N 7.19%. 
N,N-Diethyl-7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine-8-carbox-
amide (26 and 27): To an ice-cold suspension of the respective amino acid derivative 20 or 
21 (1 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) hydrochloride (1.1 mmol) 
and dimethylaminopyridine (DMAP) (1 mmol) in diochloromethane and dimethylformamide 
(8:1) was added diethylamine (1.05 mmol). The reaction mixture was stirred at 40°C for 24 h, 
and subsequently washed with a diluted solution of sodium bicarbonate then with water. The 
organic layer was evaporated under reduced pressure and the obtained brownish oil was 
purified by column chromatography using a mixture of dichloromethane/MeOH (25/1) as 
eluent giving a creamy white solid. Yield 32-40%; m.p. 104-106 °C. 1H-NMR: 400 MHz 
(CDCl3): δ 1.15-1.19 (t, J=7, 3H, CH3CH2N), 1.19-1.23 (t, J = 7, 3H, CH3CH2N),  2.14 (s, 3H, 
CH3), 2.68-2.83 (m, 2H, aliphatic), 2.89-2.97 (m, 2H, aliphatic),   3.06-3.13 (m, 1H, aliphatic), 
3.32-3.65 (m, 5H, aliphatic), 3.80-3.83 (dd, J=10, 2, 1H, 8), 4.18-4.22 (d, J=15, 1H, 15), 4.37-
4.41 (d, J=15, 1H, 15), 7.07-7.19 (m, 5H, aromatic), 7.28-7.31 (m, 2H, aromatic), 7.47-7.49 
(d, J=7, 1H, aromatic), 8.15 (s, 1H, indole-NH). 13C-NMR: 400 MHz (CDCl3): δ 13.26 
(CH3CH2N), 14.71 (CH3CH2N), 26.41 (5), 31.85 (9), 34.65 (15), 40.17 (CH3CH2N),  41.75 
(CH3CH2N),  42.18 (N-CH3), 53.14 (6), 64.46 (8), 110.43 (9a), 110.50 (13), 117.91 (10), 
119.19 (11), 121.21 (12), 126.39 (3), 126.85 (1), 128.76 (9b), 130.22 (2), 130.74 (4), 134.92 
(14a), 135.34 (13a),  137.21 (4a), 140.16 (15a), 172.38 (C=O). Anal. calcd. for C25H31N3O x 
0.25 H2O: C 76.20%, H 8.06%, N 10.66%; found C 76.23%, H 8.11%, N 10.44%. 
N,N-Diethyl-N-[(7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecin-8-yl)-
methyl]amine (28 and 29): The respective amide (26, 27) was reduced using two molar 
excess of lithium aluminum hydride in tetrahydrofuran. A creamy white solid was obtained 
after purification by column chromatography (dichloromethane/methanol 20:1). Yield 80-81%; 
m.p. 75-76 °C. 1H-NMR: 250 MHz (CDCl3):  δ 1.03-1.09 (t, J=7, 6H, CH3CH2N),  2.18-2.31 
(m, 2H, aliphatic), 2.36 (s, 3H, CH3), 2.43-3.05 (m, 11H, aliphatic), 4.21-4.27 (d, J=15, 1H, H-
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15), 4.40-4.46 (d, J=15, 1H, H-15), 7.05-7.30 (m, 7H, aromatic), 7.61-7.65 (d, J=8, 1H, 
aromatic), 7.85 (s, 1H, indole-NH). 13C-NMR: 250 MHz (CDCl3): δ 12.04 (CH3CH2N), 26.88 
(5), 32.73 (9), 34.54 (15), 41.53 (N-CH3), 47.34 (CH3CH2N),  53.53 (6), 45.25 (CH2N(Et)2), 
63.33 (8), 110.43 (13), 110.63 (9a), 118.23 (10), 119.30 (11), 121.51 (12), 126.69 (3), 127.17 
(1), 128.54 (9b), 130.26 (2), 130.69 (4), 133.39 (14a), 135.61(13a),  136.93 (4a), 140.07 
(15a). Anal. calcd. for C25H33N3 x 0.8 H2O: C 77.00%, H 8.94%, N 10.78%; found C 76.69%, 
H 8.69%, N 10.46%. 
7-(6-Hydroxyhexyl)-5,6,8,9,14,14b-hexahydroindolo[2',3':3,4]pyrido[2,1-a]isoquinolin-7-
ium bromide (30):  A solution of the quinolizine 11 (493 mg, 1.8 mmol) and 6-bromohexanol 
(391 mg, 3.24 mmol) in toluene was heated under reflux for 24 h. The separated yellow solid 
was filtered off and dried. Yield 48.9%; m.p. 270-271 °C. 1H-NMR: 250 MHz (DMSO-d6): δ 
1.26-1.38 (m, 6H, aliphatic), 1.91 (mc, 2H, aliphatic), 3.12-3.45 (m, 7H, aliphatic), 3.89-3.98 
(m, 4H, aliphatic), 4.32-4.36 (m, 1H, aliphatic), 6.20 (s, 1H, 14b), 7.01-7.07 (t, J=7, 1H, 
aromatic), 7.11-7.17 (t, J=7, 1H, aromatic), 7.36-7.53 (m, 6H, aromatic), 10.82 (s, 1H, indole-
NH). 
7-(6-Hydroxyhexyl)-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine (31): The 
quaternary salt 30 was reduced under Birch conditions following the conventional procedure. 
The obtained yellowish oil was converted to the HCl salt and triturated with hexane, leaving a 
yellowish white solid, which was reconverted to the base and extracted with 
dichloromethane. Yield 72.6%; m.p. 80-81 °C. 1H-NMR: 400 MHz (DMSO-d6): δ 1.25-1.34 
(m, 4H, aliphatic), 1.39-1.45 (m, 2H, aliphatic), 1.73-1.77 (m, 2H, aliphatic), 3.01-3.67 (m, 
12H, aliphatic), 4.03-4.06 (d, J=15, 1H, 15), 4. 30-4.34 (d, J=15, 1H, 15), 6.95-6.99 (t, J=7, 
1H, aromatic), 7.02-7.06 (t, J=7, 1H, aromatic), 7.19-7.20 (m, 2H, aromatic), 7.26-7.31 (m, 
2H, aromatic), 7.43-7.45 (d, J=7, 1H, aromatic), 7.72-7.74 (d, J=7, 1H, aromatic),  10.62 (s, 
1H, N+-H), 10.85 (s, 1H, indole-NH). HRMS: 377.259 (calcd. C25H33N2O 377.259) 
7-(6-Bromohexyl)-5,6,8,9,14,14b-hexahydroindolo[2',3':3,4]pyrido[2,1-a]isoquinolin-7-
ium bromide (34): To a solution of quinolizine 11 (0.82 g, 3 mmol) in 30 ml acetone was 
added a solution of 1,6-dibromohexane (5.83 g, 24 mmol) in 20 ml acetone. The solution was 
concentrated to 10 ml and warmed to 40°C for 24 h. The formed yellow solid was filtered off 
and dried. Yield 51.6%; m.p. >300 °C. 1H-NMR: 250 MHz (DMSO-d6): δ 1.05-1.10 (m, 4H, 
aliphatic), 1.26-1.45 (m, 4H, aliphatic), 1.72-1.92 (m, 4H, aliphatic), 3.31-3.20 (m, 4H, 
aliphatic), 3.38-3.42 (m, 4H, aliphatic), 6.21 (s, 1H, 14b), 7.01- 7.07 (t, J=7, 1H, aromatic), 
7.11-7.17 (t, J=7, 1H, aromatic), 7.39-7.59 (m, 6H, aromatic), 10.83 (s, 1H, indole-NH).  
 




With the discovery of the benzindoloazecine derivative LE300 and its dibenzazecine 
counterpart LE404 a novel class of potent dopamine receptor antagonists has been 
established, which is characterized by high affinities as well as a general tendency for D1 
selectivity105;106;109;116. Modifications of the structure of both lead compounds by changing 
either the backbone scaffold or the nature or pattern of substitution has usually been 
accompanied by altered affinities and/or selectivity profile106-109. Taking together previous 
findings with respect to SAR studies within this class of dopamine ligands, it can be deduced 
that some structural features, which are shared by most highly affine derivatives, are crucial 
for optimum activity.  
• An optimal backbone scaffold is made up of a two aromatic ring system surrounding a 
central aza-alicycle (preferably a 10-membered ring). Both aromatic rings should be 
separated by a methylene group. Moreover a certain degree of conformational 
flexibility is required; rigid structures like the precursory pentacyclic quinolizines are 
devoid of activity.  
• Regarding the nature of the substituent, an N-methyl substitution of the central 
alicycle of both benzindoloazecines and dibenzazecines was most favored, longer 
chains or no substituents both led to decreased affinities106;117. Within the 
dibenzazecine series, a 3-hydroxyl substitution was found to be an essential feature 
for high affinities109.  
In the present work, these main established structural features were mostly retained and the 
structures of LE300 and LE404 were otherwise modified.  
Modification of LE300 has been accomplished by either changing the annulation pattern of 
the backbone skeleton (paper 1) or by introducing different substituents at various positions, 
including position 14 (indole-N) (paper 2), position 15 (the methylene group separating both 
aromatic rings) (chapter 4.2) and position 8 (central ring) (paper 4 and chapter 4.3). LE404 
has been modified by replacing the 3-hydroxyl substituent by a methylenedioxy moiety to 
connect positions 2 and 3. (paper 5).  
Goal behind these modifications was to try to optimize the structures of both leads to attain 
higher affinities and/or enhanced selectivity. Moreover, this would help verify and further 
develop existing SAR studies in order to get better insights into the structural properties, 
which are determinant for high affinities as well as subtype selectivity. The various structural 
modifications accomplished in this work are depicted in figure 5.1.  
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All prepared azecines together with some of the precursory compounds were screened for 
their affinities for the human cloned dopamine receptor subtypes (D1-D5). The functionality of 
the compounds was tested by an intracellular calcium assay, where compounds with 
agonistic properties are characterized by their ability to increase intracellular Ca2+ levels, 
whereas antagonists suppress the Ca2+ influx induced by a standard agonist. A detailed 
description of the experimental procedures is given in paper 1.  
The affinities of all prepared derivatives, together with those of some lead and previously 
prepared compounds for comparison purposes, are given in table 5.1. In the calcium assay; 


































R = CH3, C2H5, CH2CH2F, n-C3H7,  
      CH2CH=CH2, CH2C    CH, 
                    , COCH3, n-C5H11, 
      n-C8H15, CH2CH2CH2-C6H5,
* R, S, RS
R = CH3, COOH, 
      CH2OH, CH2OCOCH3,    
      CH2OCOC6H5,  CON(Et)2, 





























Figure 5.1: The different structural modifications of both lead compounds LE300 and LE404, which have been 
accomplished in this work.   
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5.1. Synthesis of the different quinolizine derivatives as important precursors 
for the target azecines 
Quinolizine derivatives, though themselves usually devoid of dopamine activity, are of value 
as the sole precursors for the target benzindolo- and dibenzazecines. Hitherto, these 
quinolizines have been prepared by reacting the respective aralkylamines with either 1-
isochromanone118 or 2-(2-chloroethyl)benzoyl chloride108. The resulting hydroxymethyl-
benzamides were then cyclized under Bischler-Napieralski conditions and the quinolizines 
were finally obtained after reduction with NaBH4. An example of these synthetic procedures 
































Figure 5.2: Previously applied synthetic procedures for the synthesis of quinolizine derivatives. 
However, these laborious multistep procedures often resulted in relatively low yields 
sometimes even failed to produce the desired quinolizines, as is the case with quinolizines 
starting from 4-aminomethyl- or 4-aminoethylindole. Either no reaction took place, the 
hydroxyethylbenzamide was formed in very low yields or obtained in a highly impure form. 
Alternatively, it has been described that analogous quinolizine derivatives (e.g. 
benzothienoethylamine and thienoethylamine) could be prepared by reacting the 
aralkylamine derivative with 2-(2-bromoethyl)benzaldehyde followed by cyclization of the 












Figure 5.3: Synthesis of a quinolizine derived from benzothienoethylamine as described by Browne113. 
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However, some of the aralkylamines, namely tryptamine, indole-2- and -4-ethylamine, failed 
to produce the intermediary isoquinolinium salt when the described reaction conditions were 
applied. Hence, the reaction conditions were modified and the amine derivatives were 
refluxed in the presence of trifluoroacetic acid with 2-(2-bromoethyl)benzaldehyde to directly 
afford the desired quinolizines. This new established one-pot synthetic procedure for the 
synthesis of quinolizines could be regarded as an easily applicable route, which in contrast to 
the previously applied ones, is less laborious and time-consuming and yields the target 
compounds in relatively good yields. The described procedure has been used to prepare 
quinolizine derivatives of indol-4-ethylamine, -2-ethylamine (paper 1), α-methyltryptamine, as 
well as D- and L- tryptophan (paper 4). Moreover, the quinolizine precursor of the lead 
compound LE300 was alternatively prepared using this method (paper 2), which is simpler 






























Reagents and conditions: 
R = (RS)-CH3,
       (R)-COOH, 
       (S)-COOH
 
Figure 5.4: Different quinolizines prepared starting from the respective indolethylamines and 2-(2-
bromoethyl)benzaldehyde. 
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5.2. Modulation of the annulation pattern of LE300 
Previous investigations have shown that changing the annulation pattern of LE300 from an 
indolo[3,2-f][3]benzazecine to an indolo[2,1-b][3,6]benzodiazecine scaffold (compound 37, 
figure 5.5) results in an inversion of the selectivity profile; the latter derivative displaying 100-








indolo[3,2-f][3]benzazecine scaffold indolo[2,1-b][3,6]benzodiazecine scaffold  
Figure 5.5: LE300 and its analogue 37 with an altered scaffold119.  
In paper 1 the annulation pattern of LE300 was further modified in order to assess how the 
different backbone structures affect the selectivity and affinity for the dopamine receptors. 
Three LE300 analogues 1, 2 and 38 and their pentacyclic precursors 39-41 (figure 5.6), all 
of a novel heterocyclic ring structure, were prepared and tested for their affinities for the 
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Results of the radioligand binding experiments (cf. table 5.1) revealed that changing the 
annulation pattern of LE300 did not lead to pronounced changes, in contrast to what was 
previously observed with the indolo[2,1-b][3,6]benzodiazecine derivative 37119. Analogue 2 
showed comparable affinities with LE300, whereas 38 displayed a noticeable decrease in 
affinities; however they were still in the nanomolar range. Regarding the selectivity profile, a 
slight change could be observed; the affinities of compounds 2 and 38 for the D2 with respect 
to D1 receptors increased and thus the D1 selectivity, common to other azecine-type 
dopamine receptor antagonists, has been lost.  
It seems, however, that decreasing the distance between the alicyclic nitrogen and the indole 
ring with the accompanied decrease in conformational flexibility can result in a complete loss 
of affinities. This is evident when comparing the affinities of both homologues 1 and 2. The 
more rigid analogue 1, where the alicyclic nitrogen is connected through a methylene group 
to the indole ring, displayed no significant affinities (Ki >10000 nM), whereas the ring 
expanded and hence more flexible analogue 2 showed similar affinities to the lead LE300. 
This discrepancy in affinities could be explained by the fact that compound 1, though 
containing an central azecine moiety like LE300, is much more constrained as a 
consequence of its annulation pattern. Moreover, the distance between the central nitrogen 
and the indole ring, both important pharmacophores, is reduced. In contrast, compound 2 
with the ring expanded structure shows higher flexibility as well as similar distances between 
the pharmacophoric groups as in LE300.  
In line with our previous findings, the rigid pentacyclic precursor compounds 39-41, had 
generally weak to no affinities. The quinolizine 39 displayed no affinities (Ki >10000 nM) for 
all dopamine receptors, its homologue 40 showed micromolar affinities for the D1, D2, and D5 
subtypes and the quinolizine 41 showed micromolar ones for the D1 and D2 subtypes. (Table 
5.1)   
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5.3. Substitution of LE300 at different positions 
A major part of this work has focused on preparing LE300 derivatives, substituted at different 
positions, mainly position 14 (indole-NH), position 15 (methylene bridge) and position 8. (The 




















Figure 5.7: Positions of LE300 (in red), which have been modified in this work. 
5.3.1. N14-substituted LE300 derivatives 
A series of eleven LE300 derivatives (42-52) (figure 5.8) substituted at the indole-NH with 
different residues, ranging from saturated to unsaturated chains of different length, bulk and 
electronic properties, has been prepared and tested for the affinities at the D1-D5 receptors. 
(Paper 2) Both the affinity and selectivity profile of the derivatives were found to be 






R = CH3, C2H5, CH2CH2F, n-C3H7, CH2      , CH2-CH=CH2,  
CH2-C≡CH, COCH3, CH2CH2CH2-C6H5, n-C5H11, n-C8H17 
Figure 5.8: Indole-NH substituted LE300 analogues. 
All derivatives bearing an alkyl chain at the indole-NH retained more or less the D1-selectivity 
profile; except for the N-methylated derivative 42. Compared with LE300, compound 42 
showed a 5-15 fold increase in affinities for all dopamine receptors, except for D1 where it 
was equally active as LE300. Increasing the chain length led to a decrease in affinities; the 
ethyl derivative 43 displayed weaker affinities than the methylated one but was still as active 
as LE300 itself. The most pronounced decrease was perceived with the octyl derivative 52, 
which exhibited one of the lowest affinities among all tested compounds. An interesting 
finding was that the indole-N-pentyl derivative 51, though generally possessing higher 
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showed the highest D1/D5 selectivity among the indole-N alkylated derivatives. This may be 
an indication that longer chains are better tolerated at the D1 than at the D5 receptors.  
Modification of the alkyl chains, did not lead to substantial alterations in the affinities, as 
could be observed with the derivatives bearing fluoroethyl 44 or cyclopropylmethyl 46 
moieties.  
A general increase in the affinities for the D4 with respect to D1 receptor could be observed. 
While LE300 has almost a 60-fold D1 over D4 selectivity, all indole-N substituted derivatives 
showed a D1/D4 ratio ranging from 0.4- to 20-fold. This was most remarkable with the 
allylated derivative 47, which displayed the highest affinity for D4, even higher than that for D1 
and equally high to that for D5. 
5.3.2. LE300 bearing substituents between the aromatic rings 
Two benzindoloazecine derivatives substituted with methyl112 or ethyl groups at the 
methylene moiety (figure 5.9), connecting both aromatic rings, were prepared and tested for 
their affinities. In contrast to indole-N-methyl and -ethyl derivatives (42 and 43), these 
compounds (9 and 10) displayed a marked decrease in affinities, most pronounced was the 
decrease in the activity for the D3 receptor (Ki >10000 nM). No significant difference in the 
affinities of the methylated and ethylated derivatives (9 and 10) was observed.  
In brief, a substituent at the methylene bridge seems to be disadvantageous to the activity of 
benzindoloazecines. However, it should be kept in mind that the compounds were obtained 
as a mixture of two different enantiomers, and it could be contemplated that the separate 
enantiomers would display different affinities.  
A 7-methylbenzindoloazecine, substituted at C-15 with a methoxy group. could not be 
obtained; reduction of the precursory cyano derivative 14 failed to produce the desired 











Figure 5.9: LE300 derivatives substituted at the methylene bridge.  
The cyano derivative was also tested for its affinities for the dopamine receptors, where it 
was completely inactive. This could be anticipated, since the basicity of the alicyclic nitrogen 
9, 10 
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R = COOH, CH2OH, CH2OCOC6H5, 
CH2OCOCH3, CON(Et)2, COCH2N(Et)2 
is completely demolished; and hence a crucial pharmacophoric group, namely the protonated 
central nitrogen interacting with Asp 3.32 in the receptor binding pocket, is lost.  
5.3.3. LE300 substituted at position 8 
The structure of LE300 was further modified by preparing derivatives substituted at position 8 
with various groups. One of the main goals was to obtain the (8R)- and (8S)- enantiomers 
separately to study the effect of the stereochemistry on the affinities for the dopamine 
receptors. Many of the obtained derivatives were however found to be enantiomerically 
impure and only a few could be obtained in an enantiopure form. In the following, the 
obtained derivatives will be discussed separately according to their enantiopurity. 
5.3.3.1. Extensively racemized 8-substituted LE300 derivatives  
As described in chapter 4.3 and paper 4, the indolobenzazecines depicted in figure 5.10 
were all obtained in an almost completely racemized form, although the synthetic route was 
started from L- and D-tryptophan separately. Evidence thereof was gathered by determining 
the optical rotation and investigating the enantiomeric purity of some derivatives by chiral 
HPLC using Teicoplanin T as chiral stationary phase (conducted by Dr. Hefnawy, King Saud 
University). Conclusive was also the comparison of both the optical activity and the 
measured affinities (Ki values) of the herein obtained 8-hydroxymethyl derivatives and of 
those obtained through an alternative synthetic route (paper 4). While the former displayed 
almost no difference in the affinities between the “alleged” R- and S-enantiomers, a 
remarkable difference was observed between the affinities determined for the “confirmed” R- 





Figure 5.10: Racemized 8-substituted LE300 derivatives. (Cf. chapter 4.3.1)  
Since the prepared compounds have been proved to be a mixture of two enantiomers, little 
could be deduced regarding the effect of the nature of the substituents on the affinities for the 
dopamine receptors. One highly interesting finding was however that the partially racemized 
amino acid derivative (20 and 21) showed a substantial D5/D1 selectivity. This is highly 
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R = CH3  (56),  
CH2OH (53) 
R = CH3  ( 57),  
CH2OH (54) 
two receptor subtypes, a fact which has impeded the pharmacological investigation of the 
roles of both receptors120.  














Figure 5.11: Enantiopure 8-methyl and 8-hydroxymethyl LE300 derivatives.  
Starting from D- and L-tryptophan as well as from racemic α-methyltryptamine, 
enantiomerically pure (8R)- and (8S)-hydroxymethyl- in addition to (8R)- and (8S)-methyl 
LE300 were successfully obtained (paper 4). (Figure 5.11)  
First for clarification reasons, it has to be mentioned that the assignment of the configuration 
differs from the hydroxymethyl to the methyl derivatives. This is due to the change in the 
priorities of the groups involved at the chiral centre; a hydroxymethyl group has a different 
priority than a methyl group. For instance, in the compounds where the 8-substituent points 
behind the plane (dashed bond, figure 5.11) the methylated derivative 57 is assigned an S-
configuration while the hydroxymethyl one 54 has an R-configuration.  
The results obtained from the radioligand binding experiments were quite interesting; the 
separate enantiomers showed completely different affinities at the dopamine receptors.  
The S-enantiomer of 8-methylated LE300 (compound 57, table 5.1), was almost as affine as 
the lead LE300, indicating that a methyl group at that position is well tolerated. Meanwhile, 
the R-enantiomer (compound 56, table 5.1) was at least 100-fold less active than the S-
enantiomer and was practically inactive at the D2-like receptors (Ki >10000 nM).  
A similar but less pronounced difference was observed between the R- and S- enantiomers 
of 8-hydroxymethyl LE300 (table 5.1, compounds 54 and 53, respectively). The R-
enantiomer was more active than the S-enantiomer, however only a tenfold difference in 
affinities was found. While the R- enantiomer of 8-hydroxymethyl LE300 was relatively less 
active than its 8-methylated counterpart (the S-enantiomer), the (8S)-hydroxymethyl 
derivative was more active than the (8R)-methylated one.  
In an attempt to explain the discrepancy in the affinities of the S- and R- enantiomers of 8-
methyl LE300, preliminary modelling studies were carried out. (Chapter 4.3.2) In the crystal 
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structure of LE300 HCl, two different ‘enantiomers’ were previously found, which has been 
attributed to a sort of axial isomerism, originating at the methylene group connecting both 
aromatic moieties. The benzindoloazecine scaffold exists in a cage-like structure, in one 
isomer the indole ring is on the right side of the bend structure and in the other on the left 
one. Which of the isomers is more active at the receptor binding site has not yet been 
discerned.  
Introduction of a methyl group at position 8 most likely forces the structure into one of the 
axial isomeric forms. (Cf. chapter 4.3.2) Based on internal energy calculation, it could be 
assumed that in the S-enantiomer the indole ring (and the 8-methyl group) is on the left side 
of the bend azecine ring, and vice versa in the R-enantiomer. Consequently, the decreased 
affinities of the R-enantiomer could have two possible explanations: First, the position of the 
indole ring in the R-enantiomer with respect to the cage-like structure is less active at the 
receptor binding site. Second, the additional methyl group in the R-enantiomer is sterically 









Figure 5.12: According to calculations of potential energy, the S- and R-enantiomers would adopt the herein 
depicted axial isomeric forms (or a slightly deviated one). 
While trying to understand the reason behind the discrepancy in the affinities of the 
enantiomers, focus was mainly set on the 8-methylbenzindoloazecines. The 8-hydroxymethyl 
derivatives showed similar results, the R-enantiomer 54 (congener of the active (8S)-methyl 
derivative 57) was more active than the S-enantiomer 53. That the hydroxymethyl group also 
forces the scaffold into one of the axial isomeric forms could well be expected. The higher 
affinity of the 8S-hydroxymethyl derivative with respect to its 8-methyl congener (the R-
enantiomer), might be attributed to an additional interaction of the hydroxyl group at that 
position with the receptor, which is not possible in case of a methyl substituent. 
S R 
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5.4. Methylenedioxydibenzazecine derivative  
Thus far, all highly affine dibenzazecines were phenolic in nature109. Most of the previously 
prepared dibenzazecines bear either a hydroxyl or methoxy group at the benzene ring, 
where a 3-hydroxyl substituent was most favored in terms of affinities. 2,3-Dihydroxy- 
(LE403) or 2,3-dimethoxydibenzazecine (LE400) showed a strongly attenuated activity106, 
which was unexpected particularly with the 2,3-dihydroxy derivative, as it bears the highest 




















Figure 5.13: Novel dibenzazecine derivative bearing a methylenedioxy moiety instead of the conventional 
hydroxyl or methoxy group. 
The high affinities of the phenolic dibenzazecines are however coupled with some 
drawbacks; LE404 for instance was found to have a low oral bioavailability (paper 3) 
presumably due to the fast biotransformation of the phenolic group.  
To further assess the effect of the substitution pattern on the affinities of the compounds and 
simultaneously evade another phenolic substituent, a dibenzazecine derivative bearing a 
methylenedioxy substituent at the 2,3-position (figure 5.13) was prepared and examined for 
its affinities for the dopamine receptor subtypes D1-D5. This azecine was further dibrominated 
to examine the impact of the additional bromine atoms on the affinities. 
The dibenzazecine derivative 58 was found to be a highly active dopamine receptor 
antagonist, showing nanomolar affinities comparable with those of the lead LE404. 
Moreover, it was superior to previously synthesized 1- and 2-monohydroxylated and the 1-, 
2- and 3-monomethoxylated dibenzazecine derivatives in terms of affinities. Compared with 
2,3-dihydroxy-(LE403) and the 2,3-dimethoxydibenzazecine (LE400) it displayed a 100 to 
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methylenedioxy moiety is restrained and thus it occupies less space than that required for 
dimethoxy or even methoxy substituents.  
The dibrominated derivative 59 generally exhibited lower affinities than the unbrominated 
one, however the affinities were still considerably high and lied in the nanomolar range, with 
the exception of the D4 receptors where the affinities were significantly attenuated.  
5.5. Antipsychotic potential 
Since the indole-N methylated LE300 derivative 42 displayed remarkably high affinities for all 
dopamine receptors together with a low cytotoxicity (paper 2), it was selected among other 
compounds to test its antipsychotic potential in vivo. For this purpose, the ability of the 
compound to inhibit conditioned avoidance response (CAR) in a pole jump model was tested 
as a measure for its effectiveness against positive symptoms. Moreover, the tendency to 
induce catalepsy (bar and cross leg models) was studied as an indication for its potential to 
cause EPS.  
Results showed that the indole-N methylated LE300 (42) has a high potential to inhibit CAR 
(ED50 = 0.7 mg/kg) comparable with that of the antipsychotic drug risperidone. In addition, a 
low tendency to induce catalepsy was observed; cataleptic behavior occurred only at doses 
much higher than those required for effective inhibition of CAR. It can be concluded that 
compound 42 has a high therapeutic range; the CAT/CAR ratio ranged between 8.7 and 
11.7, which is better than that found for the antipsychotics haloperidol and risperidone. 
Among the tested azecine derivatives, it showed the second best results after the 
dibenzazecine LE404. Meanwhile it was superior to LE404 in the preliminary oral 
bioavailability assessment. These results render the indole-N methylated LE300 derivative 
42 attractive as potential antipsychotic. (Paper 3)   
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Table 5.1: Affinities (Ki, nM) of some relevant lead compounds and the new azecines for the 
dopamine receptors, determined by radioligand binding experiments. 
Compounds 
Ki, (nM) 
D1 D2L D3 D4.4 D5 





















509 ± 51 >5000 n.d. 2514 ± 101 2610 ± 120 
Modulation of the annulation  




210e 13.2e n.d. n.d. n.d. 
1 
 
>10000 >10000 >10000 >10000 >10000 
2 
 
4.2 ± 0.5 4.0 ± 0.5 42.9 ± 8.5 39.1 ± 9.6 2.5 ± 0.7 
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D1 D2L D3 D4.4 D5 
39 
 
>10000 >10000 >10000 >10000 >10000 
40 
 
1836 ± 658 4458 ± 1192 >10000 >10000 1525 ± 206 
41 
 
2101 ± 703 1476 ± 28.5 >10000 >10000 >10000 




2.0 ± 0.5 8.2 ± 5.8 7.2 ± 2.8 13.2 ± 3 0.5 ± 0.1 
43 
 
3.2 ± 0.8 51.7 ± 12.4 181 ± 66 65.5 ± 28.9 7.5 ± 1.5 
44 
 
12.6 ± 3.6 54 ± 5 119 ± 24 11.9 3.8 ± 0.8 
45 
 
22.3 ± 7.3 197 ± 5.5 307 ± 15 84 ± 11 9.8 ± 2.6 
46 
 
14.3 ± 0.2 241 ± 17 305 ± 68 39 ± 24 57 ± 40 
47 
 
27 ± 15 28.9 ± 9.3 99.3 ± 15 9.1 ± 3.6 5.5 ± 2 
48 
 
6.9 ± 0.2 128 ±  45 411 ± 81 36.5 1.2 ± 0.3 
49 
 
























































D1 D2L D3 D4.4 D5 
50 
 
116 ± 30 356 ± 16 810 ± 169 1327 ± 535 25.6 ± 5.3 
51 
 
23.2 ± 12 773 ± 160 390 ± 67.5 455 ± 8.0 261 ± 65 
52 
 
184 ± 60 3383 ± 694 1760 ± 532 1414 ± 531 77.3 ± 3 
LE300 bearing substituents  




49 ± 7 200 ± 32 >10000 533 ± 45 64 ± 28 
10 
 
116 ± 66 725 ± 102 >10000 298 21.7 ± 3 
14 
 
>10000 >10000 n.d. >10000 >10000 
8- substituted LE300   
20 
 
>10000 >10000 >10000 >10000 657 ± 163 
53 
 
114 ± 9 2923 ± 442 4676 ± 1593 4861 ± 803 91.4 ± 8.5 
54 
 
























































D1 D2L D3 D4.4 D5 
55 
 
32.4 ± 13.3 526 ± 69 385 ± 3.5  16.9 ± 6.5 
56 
 










3.6 ± 1 5.5 ± 1.2 20.6 ± 5.5 46.0 ± 9.9 0.5 ± 0.01 
59 
 
35.0 ± 14.5 30.0 ± 19.6 38.9 ± 1.1 2760 ± 552 4.7 ± 1.9 
* Previously reported. a Values taken from referecence108. b Values taken from reference106. c Values taken 



































Benzindoloazecines and dibenzazecines compose a new class of dopamine receptor 
antagonists, which has attracted attention due to its structural novelty, their high affinities for 
dopamine receptors and their selectivity for the D1-like receptors. Extensive SAR studies 
have been conducted on these azecine-type dopamine receptor antagonists by manipulating 
the structure of both lead compounds, the benzindoloazecine LE300 and the dibenzazecine 
LE404. Focal point of the presented work was to further modify the structure of both leads 
while basically maintaining these structural features, previously established to be imperative 
for high activity. Work has mainly focused on modifying the structure of LE300 by changing 
its annulation pattern or introducing substituents at various positions of its tetracyclic ring 
system. For this purpose, a novel modified synthetic procedure was applied for a more 
efficient synthesis of several precursory quinolizines. Moreover, the structure of the lead 
dibenzazecine derivative LE404 was modified by replacing the 3-hydroxyl group by a 
methylenedioxy moiety.  
The goal was to further develop SAR studies on this novel class of dopamine receptor 
antagonist with the aspiration of attaining compounds with improved affinities, higher subtype 
selectivity or better pharmacokinetics. A total of 29 novel azecine derivatives have been 
prepared, their affinities at the dopamine receptors were tested by radioligand ligand binding 
assay and their functionality by an established Ca2+ assay. 
Based on the results obtained in this work, the following conclusions can be made: 
• The herein introduced alterations in the annulation pattern of LE300, namely by 
converting its indolo[3,2-f][3]benzazecine scaffold to an indolo[4,3-
fg][3]benzazacycloundecene and indolo[2,3-f][3]benzazecine one, did not lead to 
pronounced effects on the affinities, suggesting that the distances between the different 
pharmacophores and the flexibility of this ring system rather than its annulation pattern 
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This is supported by the lack of activity of the more rigid indolo[4,3-ef][3]benzazecine 
derivative, which encompasses shorter distances between the pharmacophoric 
groups, specifically between the indole ring and the central nitrogen. 
• Substitution of the indole-NH by various residues led to varying alterations in the 
affinities and selectivity profile. A methyl group increased the affinities for all dopamine 
receptors, except for D1. An ethyl residue was well tolerated and did not significantly 
affect the affinities when compared with the lead LE300, while longer and bulkier 
residues mostly led to a proportionate decrease in affinities. The relative affinities for 
the D4 receptor were generally increased; this was most remarkable with the allylated 






Worth mentioning is that the indole-N methylated LE300 showed a promising 
antipsychotic effect in vivo, with a low potential to cause EPS. Moreover, primary 
results infer that it possesses a good oral bioavailability, better than the lead compound 
LE404.   
• Small substituents (methyl and ethyl) at the methylene bridge connecting both aromatic 
moieties were much less tolerated, especially at the D3 receptor. A clear-cut conclusion 
on the effect of the substituents at that position on the affinities could however not be 
made, since the derivatives were obtained as racemates; the effect of the configuration 







• The effect of the substituent at the 8-position of the benzindoloazecine ring depended 
on the nature of the substituent and more pronouncedly on its configuration. Both 
enantiopure derivatives, where the substituents points below the plane, namely (8S)-
methyl and (8R)-hydroxymethyl LE300, showed similar or slightly decreased affinities 
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* R and S 
R = CH3, CH2OH 
than LE300. The derivatives bearing the opposite configuration, i.e. (8R)-methyl and 
(8S)-hydroxymethyl LE300, exhibited a substantial decrease in affinities; almost a 100-
fold decrease for the methyl- and a 10-fold for the hydroxymethyl derivative. The D1-
selectivity profile was retained with all derivatives.  
Preliminary investigations indicate that the additional substituent at the 8-postion forces 
the structure into only one of the axial isomers, compared to the two isomers 
‘enantiomers’  found in LE300. Hence, the difference in the affinity of the enantiomers 
could arise either from the spatial orientation of the 8-methyl group or the orientation of 
the existing axial isomer (indole to the right or to the left of the bent azecine structure).  
The effect of other substituents at position 8 could not be accurately assessed, since 
the various derivatives were obtained in an enantiomerically impure form. However, a 
highly attractive derivative was obtained, namely that bearing a carboxylic acid group at 
position 8, as it showed practically no affinities for all dopamine receptors, expect for D5 






• The first highly active nonphenolic analogue of LE404 was prepared, namely by 
substitution of the 2,3-position with a methylenedioxy moiety. This derivative showed 
nanomolar affinities for all dopamine receptors, the selectivity for the D1-like receptors 
was however lost. This indicates that the rather pharmacokinetically unflavored 
phenolic group is not imperative for high affinities, and could be replaced with a 
methylenedioxy moiety; which is expected to be of better pharmacokinetics and 
chemical stability than previously prepared highly affine phenolic benzazecines, such 

























Azecine sind eine neuartige Klasse von Dopaminrezeptor-Antagonisten, gekennzeichnet 
durch ihre nanomolare Affinitäten an den Dopaminrezeptoren und vor allem ihre Selektivität 
für die Rezeptoren der D1-Familie. Strukturwirkungsbeziehungen dieser Verbinungsklasse 
wurde umfassend erforscht. Die Strategie der vorliegenden Arbeit war die Strukturen der 
Leitverbindungen LE300 und LE404 so zu modifizieren, dass die erforderlichen strukturellen 
Merkmale weitgehend erhalten werden sollten. Das Benzindoloazecin LE300 wurde vielfältig 
modifiziert; z.B. durch Veränderung des Annellierungsmusters vom Ringgerüst oder 
Einfügen eines Substituents an verschiedenen Stellen. Außerdem wurde die phenolische 
Gruppe der Leitstruktur LE404 vom Dibenzazecin-Typ durch eine Methylendioxygruppe 
ersetzt.  
Das Ziel dieser Arbeit war die Strukturwirkungsbeziehungen dieser neuartigen Klasse von 
Dopaminrezeptor-Antagonisten weiter zu entwickeln, um Derivate mit höheren Affinitäten 
und besser ausgeprägten Subtypselektivität zu erreichen.  
Insgesamt wurden 29 Zielverbindungen synthetisiert und die Affinitäten an den 
verschiedenen Dopaminrezeptoren (human) durch Radioligandbindungsstudien ermittelt. 
Weiterhin wurde die Funktionalität der Verbindungen (Agonisten oder Antagonisten) mit Hilfe 
eines Calcium Assays bestimmt.  
Folgende Strukturwirkungsbeziehungen konnten erkannt werden: 
• Die Änderung des Annellierungsmusters von LE300 hatte keinen signifikanten Einfluss 
auf die Affinitäten; die Indolo[4,3-fg][3]benzazacycloundecen und Indolo[2,3-
f][3]benzazecin Derivate zeigten ähnliche oder etwas niedrigere Affinitäten als die 
Leitverbindung LE300.  Hingegen führte eine Verkürzung der Distanzen zwischen den 
Pharmakophoren, und die damit verbundene Verringerung der Flexibilität, zu einem 
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• Die Substitution des Indol-NH vom Benzindoloazecin LE300 mit verschiedenen 
Gruppen hatte unterschiedliche Auswirkungen auf die Affinitäten. Die Einführung einer 
Methylgruppe am Indol-NH führte zu einer signifikanten Affinitätssteigerung an allen 
Dopaminrezeptoren außer am D1-Rezeptor. Eine Ethylgruppe wurde toleriert, wobei 
längere Ketten verminderte Affinitäten zeigten. Eine Affinitätssteigerung an den D4-







In den Tierversuchen an Ratten zeigte die methylierte LE300 Verbindung eine hohe 
neuroleptische Potenz hinsichtlich der Aufhebung der Positivsymptomatik und zeigten 
dazu eine geringere Tendenz extrapyramidale Nebenwirkungen hervorzurufen. 
Ausserdem konnte bei der Methylverbindung eine gute orale Bioverfügbarkeit 
festgestellt werden.    
• Kleine Substituenten an der Methylengruppe zwischen beiden Aromaten führten im 
Allgemeinen zu Affinitätsverlusten, besonders am D3 Rezeptor. Der Einfluss der 
Substituenten an dieser Stelle konnte aber nicht gründlicher beschrieben werden, da 
die Derivate als Razemate erhalten wurden, und der Einfluß der Konfiguration von 







• Die Einführung verschiedener Substituenten in der 8-Position des Benzindoloazecin-
Ringgerüstes hatte unterschiedliche Auswirkungen, die von der Art und Konfiguration 
des Substituents abhängig waren. Enantiomerenreine Verbindungen, bei dem der 
Substituent nach hinten zeigte, nämlich (8S)-Methyl und (8R)-Hydroxymethyl LE300, 
zeigten ähnliche oder etwas niedrigere Affinitäten als die Leitverbindung LE300. 
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* R and S 
R = CH3, CH2OH 






Der Einfluss anderer Substituenten an dieser Stelle konnte nicht genau bestimmt 
werden, da die Derivate in einer razemisierten Form erhalten wurden. Interessant war 
jedoch, dass Aminosäurederivat (substituiert mit einer Carbonsäure an der 8-Position.), 
praktisch keine Affinitäten an allen Dopaminrezeptoren zeigte außer am D5-rezeptor, 
und damit eine seltene D5-Selektivität darstellt.  
• Eine hochaffine nicht-phenolische Dibenzazecinverbindung wurde erhalten, indem die 
phenolische OH-Gruppe mit einer Methylendioxygruppe an der 2,3-position ersetzt 
wurde. Die neue Verbindung zeigte nanomolare Affinitäten, vergleichbar mit der 
Leitsubstanz LE404, aber auch einen Verlust der D1 Selektivität. Es wird erwartet dass 
die Verbindung eine bessere Pharmakokinetik, unter anderem bessere orale 
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List of Abbreviations 
ADHD Attention deficit hyperactivity disorder 
AMPA α-Amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid 
Asp Aspartic acid 
c-AMP Cyclic adenosine monophosphate 
CAR Conditioned avoidance response 
CAT Catalepsy 
Cf.  Compare, see 
CNS Central nervous system 





EPS Extrapyramidal symptoms 
Et Ethyl 
GABA γ-Aminobutyric acid 
GPCR G-protein coupled receptors 
HPLC High performance liquid chromatography 




NMDA N-Methyl-D-aspartic acid 
NMR Nuclear magnetic resonance 
OMe Methoxide 
PFC Prefrontal cortex 
PKA Protein kinase A 
SAR Structure activity relationship 
Ser Serine 
THF Tetrahydrofuran 
THPB Tetrahydroprotoberberine  
TM Transmembrane domain 
VTA Ventral tegmental area 
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